CHARACTERIZATION AND IMPLEMENTATION OF A DECELLULARIZED PORCINE
VESSEL AS A BIOLOGIC SCAFFOLD FOR A BLOOD VESSEL MIMIC

A Thesis Presented to the Faculty of
California Polytechnic State University, San Luis Obispo

In Partial Fulfillment of the requirements for the Degree
Master of Science in Biomedical Engineering

By
Aubrey Nichole Smith
May 2011

© 2011
Aubrey N. Smith
ALL RIGHTS RESERVED

ii

COMMITTEE MEMBERSHIP

TITLE:

Characterization and
Implementation of a
Decellularized Porcine Vessel as a
Biologic Scaffold for a Blood
Vessel Mimic

AUTHOR:

Aubrey Nichole Smith

DATE SUBMITTED:

May 27, 2011

COMMITTEE CHAIR:

Kristen O'Halloran Cardinal, PhD

COMMITTEE MEMBER:

Trevor Cardinal, PhD

COMMITTEE MEMBER:

Lily Laiho, PhD

iii

Abstract
CHARACTERIZATION AND IMPLEMENTATION OF A DECELLULARIZED PORCINE
VESSEL AS A BIOLOGIC SCAFFOLD FOR A BLOOD VESSEL MIMIC
Aubrey Smith
Every 34 seconds, someone in the United States suffers from a heart attack. Most heart
attacks are caused by atherosclerotic build up in the coronary arteries, occluding normal blood
flow. Balloon angioplasty procedures in combination with a metal stent often result in
successful restoration of normal blood flow. However, bare metal stents often lead to restenosis
and other complications. To compensate for this problem, industry has created drug-eluting
stents to promote healing of the artery wall post stenting. These stents are continually advancing
toward better drug-eluting designs and methods, resulting in a need for fast and reliable preclinical testing modalities. Dr. Kristen Cardinal recently developed a tissue engineered blood
vessel mimic, with the goal of testing intravascular devices. However, the scaffold component
of this model exhibits several physiological limitations that must be addressed to create a truly
biomemtic BVM. The current model uses expanded poly(terafluorethylene) [ePTFE] or
poly(lactic-go-glycolide) [PLGA] as the choice material for the scaffold. EPTFE has several
advantages as it is a widely recognized biomaterial. However, ePTFE is very expensive and
lacks native mechanical properties. PLGA is another polymer that is created in-house to produce
a uniquely tailored scaffold for use in the BVM; resulting in a cheaper alternative scaffold
material. However, PLGA again lacks the necessary native mechanical properties to properly
mimic an in-vivo artery. The creation of a biological scaffold will provide a unique biomimetic
material to most accurately recapitulate the artery in-vitro.
Decellularization is the process of removing all cellular components from a tissue,
leaving an acellular structure of extracellular matrix. Understanding the clinical problem and the
iv

potential of the BVM, the aim of this thesis is to develop the decellularization process for the
creation of a biologic scaffold as a replacement to the non-physiologic polymer scaffolds for the
BVM. The first phase of this thesis was to develop and optimize an acceptable protocol for the
decellularization of porcine arteries. The use of a 0.075% sodium dodecyl sulfate detergent was
sufficient for complete removal of all vascular cell types, without significant degradation to the
scaffold wall. In the second phase of this thesis, the decellularized scaffolds were mechanically
tested to ensure retention of their native properties. The longitudinal and radial properties of the
scaffold were found to be similar to the native artery, indicating the decellularized scaffold
improves several physiologically aspects when compared to a polymer scaffold. These
mechanical attributes improve the testing environment when evaluating sent deployment or new
balloon angioplasty devices; as the decellularized scaffold has an phsyiolgical compliance. The
final phase of this thesis examined the cellular adhesion capacities of the scaffold through
recellularization with human umbilical vein endothelial cells (hUVECS). Fluorescent
microscopy analysis suggests uniform attachment of cells along the length of the scaffold
creating a monolayer. These results indicate this new scaffold type can develop an endothelium
to complete the ideal, most physiologically relevant BVM system. Further optimization of the
decellularization procedures could enhance the ability of the scaffold to be cultured for long-term
interaction with intravascular devices.
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Chapter 1 - Introduction
1.1 Motivation
In 2010 in the United States, the occurrence of cardiovascular disease (CVD) has recently
reached an all time high, affecting more than 81.1 million people per year according to the
American Heart Association (1). Atherosclerotic build up in coronary arteries (known as
coronary artery disease, or CAD) contributes to the majority of heart disease suffers; about 17.6
million people in the U.S. (1). Since 1987 the development of metallic stents has greatly
improved the effectiveness of traditional balloon angioplasty as a treatment for CAD (2). Stent
design is an ever-improving technology. Specific areas of improvement include stent
architecture, drug-eluting designs, deployment methods, and adjuvant drug therapies (3).
Current methodologies for testing stents and other intravascular devices require the use of in-vivo
animal models. The use of animal models requires money, time, and resources. As new stent
designs develop daily, there is an increased need for a fast and reliable form of testing to bridge
these devices to market. One potential solution is to create and implement a living in-vitro test
model that serves as a conduit to represent a simplified human vessel.
The recently developed “blood vessel mimic” (BVM) has been shown to successfully
evaluate the endothelialization of bare metal and coated stents, by using specific tissue
engineering techniques to create a living in-vitro model (4, 5). Although most tissue engineered
blood vessels are created with a goal being a treatment of CAD by creating bypass or
replacement grafting, there is great potential for the use of engineered blood vessels as a
consistent, accurate, and relevant pre-clinical testing modality for intravascular devices. The
implementation of such a testing modality would improve the cost and accuracy of pre-clinical
testing and potentially reduce the number of animal studies.
1

Previously, the BVM system was created using a synthetic polymer scaffold lined with
human microvessel endothelial cells (HMVECs). However, this model has several limitations
with regard to its physiological and mechanical properties. The ‘gold standard’ for the polymer
scaffold material in the BVM has been, and is currently, expanded poly(tetrafluoroethylene),
which is non-degradable and biocompatible. The ePTFE scaffold has been well characterized to
support the development necessary to mimic the native vessel’s endothelium. It is however,
subject to several disadvantages such as high cost, poor mechanical compliance, and inability to
mimic the native extracellular (ECM) microstructure (physically and chemically). Therefore, the
purpose of this thesis was to create a biologic scaffold to serve as an alternative scaffolding
material to improve the BVM model.
The following sections of this Introduction will provide the background and foundation
on which this thesis is based. A summary of coronary artery disease and treatments, including
bypass grafting, angioplasty, and stenting will be provided. A review of tissue engineered
vascular grafts (TEVGs) will be presented, with an emphasis on scaffolding. The Introduction
will also include a review of the decellularization process, including the theory and methodology
specific to TEVG development. The Introduction will conclude with the aims and overall goals
of this thesis.
1.2 Cardiovascular Disease
The leading cause of death in the United States is heart disease, claiming more than 2300
lives per year (1 in every 2.9 American deaths) (1). On average 1 in 3 Americans is affected by
one or more types of cardiovascular diseases (CVD) (1). CVD is an umbrella term for many
specific types of heart and artery problems such as heart attacks, congenital heart defects, heart
failure, stroke, CAD, peripheral artery disease (PAD), and some arrhythmias. High cholesterol,
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poor diet, inactivity, high blood pressure, and obesity contribute to a person’s increased risk for
the occurrence of CVD (1). CAD is one of the most common types of heart disease, claiming
approximately 1 in every 6 CVD patients and costing an average of $11.7 billion per year (1).
CAD occurs when there is plaque build-up in an isolated area of the artery as illustrated in Figure
1.1. When the plaque builds to the extent pictured in Figure 1.1B, a restriction of the blood flow
occurs, which can cause angina, shortness of breath, heart attack, stroke and often death (6).

Figure 1.1. Development of plaque in the coronary artery. This type of blockage leads
to CAD (7).
1.3 Treatment of Coronary Artery Disease
Common approaches and therapies used to treat CAD include changes in life style, drugs,
a stent, or bypass surgery (8). Life style changes include a better diet, increased exercise, and
quit smoking, or drinking. Drugs can be taken to help treat heart disease, by lowering blood
pressure such as, hydrochlorothiazide and atenolol (9). A stent can be inserted into the occluded
artery to re-open the artery to restore normal blood flow. Bypass surgery is performed only in
3

the worst case scenarios to create a new flow path for the blood around the blockage. All of
these therapies can help to treat different severities of the disease. Due to their relevance to this
thesis, bypass surgery and stenting will be reviewed in greater detail in the subsequent sections.
1.3.1 Coronary Artery Bypass Grafting
From 1996 to 2006 the number of cardiovascular operations and procedures increased by
33% annually, according to the American Heart Association’s Heart Disease and Stroke
Statistics in 2010 (1). Over 176,138 coronary artery bypass graft (CABG) surgeries were
performed in 2007 (1). A bypass surgery aims to use an artery from the patient to use as a graft
on the heart to redirect blood flow around the blocked portion of the artery, as illustrated in
Figure 1.2. This procedure is the most common type of open-heart surgery, and is highly
invasive to the patient (10). While CABG is expensive and requires a long recovery time, it has
been successful long term with a lower rate of mortality, angina, and revascularization
procedures than alternative methods (11).
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Figure 1.2. The procedure for bypass grafting. The graft is connected from the aorta to the
distal part of the epicardial coronary arteries to redirect flow around the blocked portion of the
coronary artery (10).
There are three main classifications for a biological bypass graft: autografts, allografts, or
xenografts. Autografts utilize ones own vessels, usually the internal mammary artery or the
greater saphenous vein. Less commonly used are the radial artery and lesser saphenous vein
along with a few others (12). In any of these cases, bypass surgery is performed by isolating the
graft from the host’s leg, arm, or chest. It is then connected proximally and distally to the
blockage in order to reroute the blood flow as shown previously in Figure 1.2. The chance of an
immune response is low since the graft is from the host’s body. Unfortunately only 60% of
patients needing bypass surgery have suitable vessels for grafting (13). In most cases the patient
suffers from a number of pre-existing cardiovascular diseases and therefore may have

5

atherosclerotic build up rendering any possible autologous vessels non-viable for grafting (13).
If this is the case, either allografts or xenografts must be used.
The next most commonly utilized vessel type is an allograft, where the vessel is donated
from an individual of the same species. Although donors are matched with a host, allografts
have an increased risk for immune rejection, and patients will normally be placed on
immunosuppressants to increase the graft’s success (14). This is a suitable alternative for a
native vascular graft, but the number of donors is in short supply. Finally, with the shortage of
donor allografts and viable autologous vessels there has been an increase in exploration into
xenogenic grafting. A xenogenic graft is donated from a different species, usually porcine. Pig
vessels closely mimic the human physiology and size, but will elicit an immune response from
the host (15, 16). This rejection is just as severe as allograft responses and will require the
patient be on immunosuppressants (16, 17). Due to the limitations of xenogenic grafts, along
with other biologic grafts, a synthetic graft is another plausible alternative to be utilized for
CABG.
Synthetic grafts are well characterized for use in peripheral locations in the body and can
be scaled up for high-throughput clinical uses. These types of grafts are commonly used for the
larger diameter bypass procedures, but are currently not viable options for CABG, which
requries a small diameter graft. For over 50 years, synthetic grafts have primarily been made of
poly(ethylene terphalates) [Dacron] and expanded poly(tetrafluoroethylene) [ePTFE] (18). Both
of these materials have been used clinically for peripheral applications and have become well
characterized and clinically tested with successful outcomes for large diameter (>6 mm) vessels
(18). Although a synthetic material is a seemingly suitable choice for an alternative CABG
material, there are several disadvantages regarding the lack of physiological attributes. Synthetic
6

grafts lack the appropriate endothelium, have little to no compliance, and have high thrombosis
rates in small diameter grafts (19). Specifically, the lack of an effective endothelium contributes
to the onset of intimal hyperplasia and thrombus formation, rendering the graft not functional for
use in CABG grafting procedures (20-22). To improve the functionality of the graft, the
development of a surface endothelialization of Dacron and ePTFE has shown a reduction of the
thrombogenic effects normally seen in-vivo (23). There are several other treatments that can be
performed on synthetic grafting material such as chemical modifications, heparization and
protein coatings to improve the functionality of the graft (24). These treatments do help in short
term, in-vivo applications, but still tend to end in a graft failure via hyperplasia or thrombosis
long term evaluation (24, 25). Table 1.1 and 1.2 summarize the potential bypass grafts for
synthetic grafts (Table 1.1) and a comparison of biological grafts (Table 1.2). To summarize, the
use of either a synthetic or natural graft as a CABG material has specific individual limitations,
resulting in a high demand for new materials and/or alternative treatments for CAD.
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Table 1.1. The Most Clinically Used Synthetic Graft (18).

Table 1.2. Comparison of Biologic Grafts (18).

1.3.2 Angioplasty and Stenting
There is one procedure that is commonly performed on CAD patients that does not
require open-heart surgery and can open a partially blocked artery to restore normal blood flow.

8

This procedure is called angioplasty and it is mainly used on CAD patients who have not reached
a life threatening point. It has been performed in over 1,300,000 patients in the United States, in
2006 according to the American Heart Association (1, 26). To perform angioplasty, a balloon
catheter is inserted into the patient’s heart via their femoral artery near the groin. The balloon is
expanded at the blockage area, compressing all the plaque to the outer most diameter of the
vessel, and re-augmenting restoring proper blood flow, as illustrated in Figure 1.3 (27).

Figure 1.3. The angioplasty procedure. A balloon catheter is inserted to the blocked area(A),
expanded to compress the plaque (B), then deflated and removed (C) (27).
Unfortunately, this procedure restores blood flow temporarily, this simple compression
does not maintain long lasting results; and restenosis, narrowing of the artery, commonly occurs.
To augment a longer compression on the plaque, a bare metal support (stent) was developed to
deploy with the help of the balloon during angioplasty (26, 27). When deployed, the metal stent
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expands to its full diameter, it pushes the blockage radially towards the wall of the vessel,
reopening flow through the artery, as illustrated in Figure 1.4 (26). This stent would remain in
place permanently to keep the vessel open. Since 1987 approximately 80% of all angioplasties
incorporated the deployment of a stent, consequently the restenosis rate was reduced by 50 %
(1).

Figure 1.4. Stenting procedure. The balloon catheter with a collapsed stent is placed in the area
of the blockage (A). The balloon is expanded along with the metal stent to deploy the stent, (B).
Then the balloon is deflated and removed while the stent remains in place (C) (27).
While the use of a stent extends the effects of the angioplasty procedure, in-stent
restenosis is an common complication with bare metal stents (26). In-stent restenosis occurs
when plaque starts to re-form near and around the stent, recreating the original blockage
problems (26, 27). This process is illustrated in Figure 1.5, the bare metal stent displaces and
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disrupts the normal layer of plaque and the endothelium of the vessel causing an increase in
inflammation. The inflammation expands the vessel wall and becomes extremely sticky causing
components in the blood stream to attach to the build up and cause further narrowing of the
vessel.

Figure 1.5. Restenosis. The stent remains in place throughout time (A), but the endothelium
becomes inflamed and restenosis occurs (B) (27).
To reduce restenosis, researchers have recently improved the bare metal stent by coating
it with a time-releasing drug, known as a drug-eluting stent (26). The released drugs typically
prevent cell proliferation, thereby inflammation. Through this specific, localized application of
the drugs to the intima of the blood vessel, the responses to stenting have become more
successful. Additionally, researcher’s focused on the characterization and development of the
specific drugs and their elution profiles, as well as the acute and chronic healing responses. To
encourage the continued advancement with the stenting technology, these devices should be
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carried through for FDA approval for use in the clinical setting as quickly as possible. Thus, the
development of a high throughput, consistent in-vitro testing modality could serve as a primary
way to assess the utility of these specific and unique stents in a timely manner.
1.4 Tissue Engineered Blood Vessels
In the past 10 – 15 years there has been extreme progress in cell biology and cell culture,
leading to the creation of the tissue engineering field (28). As tissue engineering is newer
science, many human tissues have recently been researched and developed; to name a few,
TEBV, skin, bladder, heart valves, and cartilage (29). Tissue engineers have focused on these
areas not only because of the large clinical need, but also because they have relatively simple
structures that can be mimicked with synthetic or natural scaffolds. The main goal of tissue
engineering is to recreate functional tissues and organs with cultured human cells for the
production of replacement tissues (28). In the case of a TEBV, the goal is to create an
autologous vascular graft for bypass surgery. However, as previously mentioned, it is also
possible to engineer a blood vessel for use in preclinical device evaluation. Tissue engineering
manipulates material properties to produces a unique configuration to mimic a specific tissue and
help thousands (4).
1.4.1 Highlights of Tissue Engineered Blood Vessels
The development of tissue engineered blood vessels made its debut in published
literature in the 1980’s, with vessels utilizing a synthetic (Dacron) or biologic (collagen) scaffold
(30, 31). As TEBVs have developed, the addition of endothelial cells (ECs), smooth muscle
cells (SMCs), and fibroblasts have modeled a more physiologically relevant scaffold,
representing the various layers of a blood vessel (4, 19, 32). In 1986, Weinberg and Bell were
the first to develop a vessel composed primarily of biological components: bovine aortic ECs
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(BAECs), SMCs, and fibroblasts on a layer of collagen (33). The collagen and SMCs were
jelled together using a casting media in a tubular mold with a centrally located mandrel, to
represent the media of a vessel. Then a Dacron sleeve was placed around the exterior of the
tissue engineered ‘media’ and drip sodded with fibroblasts to enhance mechanical properties of
vessel and mimic the adventia. After one week of culture, the central mandrel was removed to
present a lumen to be pressure sodded with BAECs. The mechanical strengths along with the
scaffold structure of this vessel mimicked the mammary muscular artery, representing the first
TEBV with increased physiological relevance and durability (31).
Soon after Weinberg and Bell’s biologic scaffold, Foxhall et al. experimented with the
application of endothelial cells on Dacron grafts (30). In attempts to simplify the development of
a TEBV, Foxhall et al. worked with different coatings to promote endothelization. Collagen and
fibronectin were coated on the luminal surfaces of Dacron resulting with a surface that
significantly increased the proliferation of endothelial cells (30). This synthetic scaffold was
thought to have a greater potential for use as a small diameter vascular graft (30). Results
indicated that the scaffold had similar in-vitro properties as a mammalian muscular artery and
could be used to study the cellular interactions with a vascular ECM.
In 1998 L’Heureux et al. developed a construct to improve upon Weinberg and Bell’s
mostly biological scaffold (28). This scaffold utilized a simple collagen sheet which was seeded
with human vascular SMCs and wrapped around a small mandrel, to represent the media of a
vessel. Then a similar sheet seeded with fibroblasts was wrapped around the exterior of the
SMCs, to mimic the adventia, as seen in Figure 1.6. Finally, the mandrel was removed and the
lumen was seeded with ECs (28). The L’Heureux et al. vessel was completely biologic and had
the potential for natural remodeling and reduced foreign body reactions. Unfortunately, this
model had limited mechanical strength and tears would occur when used on its own (28). The
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development of these and several other scaffold types created the ground work for future
TEBVs. These scaffolds have many basic qualities, such as the proper cell type, natural shape,
and a microstructure that increased the scaffold’s physiological relevance (34). With these
strong foundations, many researchers branched out to create countless types of tissue engineered
grafts with the goal of transitioning these models into clinical applications for CABG.

Figure 1.6. Completely biological vessel (28).
Through the development of TEBV, several qualities have been identified tto be
extremely important to the graft function. The development of the microstructure is one of the
most important aspects to be taken into consideration during the scaffold selection process. To
create a comfortable ‘living environment’ for cells, the microstructure of a TEBV scaffold
should have small fibers that are randomly interconnected to create a unique porous scaffold.
Having the proper structure onto which the cells can anchor will encourage strong cell adhesion,
and contribute to the ability of the cells to proliferate and express normal endothelial cell
markers, to communicate with the surrounding tissues for potential remodeling, thus increasing
the scaffolds overall physiological relevance (18). These are achieved by having a
microstructure that closely mimics the native ECM (18). The ECM for native blood vessels is
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constructed of nanofibers about 100 nm that are layered in random orientation, eventually
producing a porous wall (29, 35-37). Blood vessel ECM consists of mostly collagen, fibronectin,
gylcoaminoglycans, elastin, and laminin (29). These components will interact with the ECs to
aid in cell adhesion, integration with neighboring tissues as well hemodynamic interactions (35).
To create a TEBV, the graft which best represents the native microstructure and components will
be the most advantageous for a successful vessel.
1.4.2 Synthetic Scaffolds for TEBV
Synthetic scaffolds have been most frequently used in recent history for clinical and
investigational applications of a TEBV(18). The material properties for synthetic scaffolds are
generally well characterized with reproducible and consistent results when tested for the ability
to physically function as a graft (28). Synthetic scaffolds have a high but acceptable burst
strength, positive surgical handling, and is usually biocompatible (28). Non-degradable
synthetic polymers which are most often utilized in a TEBV are poly(ethylene terphalates)
[Dacron] and ePTFE (4, 18, 28). Dacron and ePTFE are both a highly crystalline and
hydrophobic materials, that reduce the overall elusion of particles (contributing to the overall
biocompatibility) and structural integrity (18, 32). The widespread use of synthetic scaffolds
occurs because the material characteristics have widely accepted microstructure, reproducibility,
and biocompatibility (32). Scaffold properties can be changed by specifically manipulating
given components of the polymer makeup, thus changing the microstructure (32). For example,
ePTFE can be manufactured to have varying intermodal distances by knitting the basic polymers
together (32). This manipulation will contribute to the way the cells interact with the scaffold;
knitting the polymers will produce a microstructure with a large surface area increasing the
ability for coatings and cells to anchor to the material (32). The knitted construction of the
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scaffold increases the intermodal distance from the well characterized 30μm to and experimental
60μm (32). Although cells adhere better to these more porous surface, the mechanical properties
are weakened, causing the scaffold to undesirably kink (32). Even though these materials are
well characterized, many researchers are trying to improve upon the basic design to create new
scaffolding material.
In addition to the non-degradable scaffolds summarized above, there are also other
degradable synthetic scaffolds, such as polyglycolic acid (PGA) (32), which have quickly
become more prevalent than non-degradable materials for TEBV. PGA along with other
degradable scaffolds can be manufactured to have unique microstructures. Scaffold
microstructure alterations may include increased porosity for better cell adhesion, a variety of
degradation profiles for drug delivery or integration with the host, as well as specific mechanical
properties for improved surgical handling or overall strength improvement (32, 38). These are
only a few select examples of scaffold properties that may be manipulated to tailor the
capabilities of a particular scaffold. The properties of synthetic scaffolds have encouraged their
wide spread acceptance as a tissue engineering material and will continue to be used for TEBV.
While synthetic scaffolds are extremely controllable, predictable, and reproducible, there
are still downfalls in their fundamental construction. For example, ePTFE does not contain a
media or adventitia layer, which contributes greatly to the scaffold’s ability to mimic an artery.
This downfall limits the physiological relevance of the scaffold, because it has an inability to
remodel and react to signals sent by the endothelium (4, 32, 39). The inability to have a
communication with the cells on the scaffold will limit the abilities of the scaffold to naturally
heal and change with the environment, if used in a CABG procedure (39). The lack of
communication may lead to an increase in the foreign body response and chronic inflammation
(28). Low performance as a physiological scaffold will increase the rate at which an in-vivo
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vessel will have thrombogenic occurrences (40). Some of these downfalls of a synthetic material
can be improved by conditioning or coating the scaffold with native proteins (such as collagen or
fibronectin) or molecules (such as nitric oxide or adhesion molecules) to improve cellular
interaction with the material (32). To address the limitations of synthetic materials biologic
materials have been explored and developed for TEBV.
The production of a combination scaffold aims to combine the best of a synthetic and
biologic material. These scaffolds are fabricated by combining a synthetic material with a
biologic component (usually collagen) to produce a tubular vascular scaffold. There are several
different manufacturing processes to create different mechanical properties of the material and
can be a highly controlled process. This control will directly influence the mechanical
properties, as well as the cellular interface with the biologic components (32). These
improvements help to improve the physiological relevance of the scaffold. The production of
these types of scaffolds relies heavily on creating a unique, intricate, porous scaffold as a
structural foundation. One way researchers have been able to create these types of scaffolds is
through a process termed electrospinning (32). Electrospinning is the process of charging a
solution as it is pushed out of a syringe towards a spinning mandrel, which is grounded as a
collector for the polymer/biologic solution (32). This process creates a tubular scaffold that can
have micro to nano-sized fiber diameter with randomly orientated porous walls (32). While the
composition and core development of the scaffold is more ideal than other synthetic materials,
there are ways to improve the basic structure to better mimic the ECM. In the case of
electrospinning, altering the voltage charge on the syringe or the distance between the source and
the collected will alter the fiber diameter of the scaffold (41). Electrospinning has produced
nanofibers that have enhanced mechanical properties while maintaining biocompatibility (41).
However, the process for determining the right combination and concentration of the blend is
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difficult, time consuming, and can become quite costly. If the electrospun scaffold has the
proper fiber size, porosity, and mechanical strength, the fibers may still have limited cell
adhesion, migration, proliferation, and differentiation properties due to the unique material made
up of the scaffold (41). Continued research with the various combinations of parameters may
produce a better scaffold. While the combination of biologic and synthetic materials produces a
scaffold with more physiological attributes, the more biologic components that are incorporated
can only improve the capabilities of the scaffold. The biological components are derived from
natural growth factors and proteins, which mimic the ECM and should be maximized for the
most physiologically relevant scaffold.
As will be described in more detail in the next section, there are several methods to create
a biological scaffold or manipulate a synthetic scaffold. However, the most efficient and
pertinent construction of a scaffold will depend on the desired properties and applications of the
scaffold. To narrow the choices down, many properties of the scaffold should be considered
including mechanical strength, biocompatibility, porosity, and cellular interaction to better
classify the material. Identification of the properties that are crucial to the functionality of the
scaffold’s final application is imperative to select the most appropriate scaffolding material. To
better understand the information previously described, Table 1.3 represents a summary of the
essential differences between a biologic scaffold and a synthetic scaffold. Once a scaffold
material is selected, it can be used for many different applications, all leading towards improving
knowledge and treatments for CVD.
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Table 1.3. The Comparison of the Biologic Verses the Synthetic Scaffolds.
Characteristics

Mechanical
Properties

Ability For
Structural
Manipulation

Compliance

Synthetic

Strong

Strong

Weak

Biologic

Weak

Weak

Strong

Immune
Response

Small
Diameter
Potential

Repair and
Remodeling
Potential

Consis
-tency

Weak

Weak

Weak

Weak

Strong

Strong

Strong

Strong

Strong

Weak

Protein
Interactions

1.5 Biologic Scaffolds for TEBVs
Although synthetic scaffolds have certainly demonstrated significant progress and
success for use in TEBV research, another significant scaffold choice for a TEBV is the use of
biologic material. A biologic scaffold, is commonly composed of materials naturally found in
the ECM of vessels or arteries, such as collagen or fibrin (32, 42, 43). These scaffolds can be
composed of the entire ECM by decellularizing a native vessel, or contain a combination of a
polymer and biologic components as discussed earlier (32). Once again the desired properties of
the scaffold will determine which of these methods may best be utilized for the proper result.
The following is a brief overview of the development of various biologic scaffolds.
As discussed previously in the history of TEBV, Weinberg and Bell along with Foxall in
1986 were among the first to develop a TEBV composed of biological components using ECs,
SMCs, and fibroblasts mixed with collagen (30, 33). This ground work provided a solid
foundation for other researchers such as Yuan et al. in 1994 and L’Heureux et al. in 1998 to
develop similar constructs (28, 33). While these scaffolds improved the biological interfaces
compared to synthetic materials, the man-made completely biologic vessel lacked the mechanical
strength to be used in-vivo (28). In attempts to increase the mechanical strength and overall
construction of a biologic vessel, researchers looked into isolating the primary tissue source and
removing all of its cellular components (40). This cellular removal process is known as
decellularization and has been utilized to develop a scaffold that maintains its structural integrity,
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while retaining its native biological components (40). The use of primary tissues as a scaffold
was first developed in the 1960’s when researchers thought that by cross-linking the tissue, the
immunogenic effects would be reduced enough to create a viable scaffold source (44). The
lowered immune response occurred through crosslinking, but mechanical properties were lost
and cell death occurred (44). Laka et al. in 1989 decided to use a detergent to break cellular
bonds from the ECM, leaving an acellular, biological graft (44, 45). This chemical
decellularization process provided more desirable mechanical results without the detrimental
effects of fixation (45). From this original paper, many other researchers further developed the
decellularization process (44). There are many applications for which decellularization may be
utilized; essentially any tissue that can be isolated can be decellularized. The major benefit of
decellularization is not only the potential to create scaffold with ideal microstructure and
mechanical properties, but also its reduction to the basic biological components that are seen
throughout the animal kingdom, thus limiting immunogenic effects of a graft while increasing
the potential tissue sources (45, 46).
1.5.1 The Use of a Decellularized Biological Scaffold
Utilizing a decellularized scaffold may improve the current issues with ‘man-made’
TEBV. As described in the previous section, decellularization is the systematic removal of all
cellular and nuclear components from tissues to leave the complex mixture of functional and
structural proteins that form the native ECM (47). The removal process is gentle enough to
minimize its effects on the composition, biological activity, and mechanical integrity of the
remaining ECM (47). When the cellular components are removed from the native ECM, most of
the protein material that remains is conserved among species (47). Having a native structure that
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is tolerable across many species opens a huge field for the potential to use xenogeneic and
allogeneic grafts, which makes scaffold sources easily and widely available (47).
The process of decellularization usually entails physical agitation and a chemical
treatment. Trypsin, ionic solutions, or detergents can be utilized to disrupt cellular membranes
and their bonds to the ECM (47). Physical agitation is usually performed via sonication,
mechanical pressure, or a freezing and thawing cycles in order to pull cells away from the
scaffold once the cellular bonds are broken (47). Once all of the cells are removed the
extracellular matrix of the original tissue is all that remains. Through this relatively simple
process, a scaffold with the native microstructure and protein make-up can potentially serve as
an ideal scaffold to engineer new tissues.
To elaborate on the widespread used of decellularization in the creation of tissue
engineered materials, the following will briefly describe a few applications of this process. Ott
et al. have worked to decellularize an intact rat heart. Perfusing a sodium dodecyl sulfate (SDS)
solution, a common detergent, through dissected rat hearts produced an enacted acellular rat
heart (48). After numerous rinses to remove excess SDS, the heart scaffold was recellularized
with neonatal cardiac cells, and contractions occurred with an electrical stimulus (48). This work
effectively showed how the decellularization process can be utilized to create tissues with the
most accurate native architecture, encouraging this process’s continued used. The development
of a decellularized vessel can be seen through Schanner et al.’s work in 2004 (49). The protocol
used SDS to break cellular bonds from a porcine carotid blood vessel to produce a natural
scaffold, composed only of blood vessel ECM. Another example of decellularization for tissue
engineering can be seen with decellularized bladders, where the native viscoelastic behavior of
the scaffold is vital to the overall function of the bladder (50). Through decllularization, the
architecture of the scaffold remains intact and thus enables the bladder to maintain the
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mechanical strength needed for contraction and relaxation (50). Though these are only a few
specific examples of decellularized tissues, the overarching idea behind decellularizing tissues is
to keep the essential properties of that tissue intact to produce the most physiologically relevant
scaffold.
Although the potential attributes are numerous, there are some disadvantages to using the
decellualrization process. The production of the scaffold tends to be a more laborious process
while not consistently showing improvement over many synthetic scaffolds (40, 47). The
decellularization process is a time consuming treatment to perform on a tissue, but is similar to
the time needed to specifically manipulate synthetic grafts which encompass similar
microstructural properties. There may also be trace amounts of the decellularization chemicals
on the scaffold, potentially affecting the scaffolds ability to house cells. While these are some
potential limitations of a decellularized scaffold, the advantages of proper mechanical properties
and essential biologic components typically out-weigh the risks and make it a highly desirable
material for TEBV
After decellularization, several components of the ECM remain in the scaffold (51). A
decellularized blood vessel has the tissue specific components and the unique capacity to interact
with intravascular devices, such as a drug-eluting stents, the cellular monolayer, enabling the
material to mimic an artery. This scaffold type also maintains a native microstructure throughout
various treatments, making it the well-suited to house cells and to culture an effective
endothelium. Additionally, a decellularized scaffold has a unique composition that is unmatched
by other scaffolding material. It innately houses all the layers of an artery and can be used to
study the inflammation pathway found during restenosis. Together these properties encourage
the use of a decellularized scaffold in the BVM because it’s a simplistic way to mimic a native
blood vessel.
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1.6 Purpose of a Blood Vessel Mimic
As summarized previously, researchers have developed several different kinds of stents,
including bare metal and drug eluting stents, and degradable stents, which are currently
emerging. With new devices being developed at a rapid rate, there is a need for improved
methods of testing. Currently, there are two main modes for evaluating the functionality of
stents. Testing can be done either in a highly controlled, usually two-dimensional, in-vitro
environment or in the environment of in-vivo animal models. In-vitro environments and animal
models can both potentially provide highly effective and reliable methods for evaluating key
properties of stents and other intravascular devices. Tests that are conducted within in-vitro
environments typically lack physiologic conditions, and tend to focus on one aspect of the
material properties such as, toxicity, proper expansion, and mechanical strength (52, 53). In-vivo
animal testing provides vital information about the device’s interactions and integration with the
body; focusing on biocompatibility, healing responses, biodegradation, inflammatory responses,
and elusion profiles (54, 55). To create a bridge between the in-vitro and in-vivo testing Dr.
Kristen O’Halloran Cardinal has developed an in-vitro ‘blood vessel mimic’ (BVM) for the
purpose of testing intravascular devices (4, 5).
The purpose of the BVM is to create a living model of a blood vessel with the goal of creating a
more physiologic in-vitro preclinical testing system (4, 5). The BVM enables a platform for high
throughput analysis of newly developed intravascular devices, intravascular imaging modalities,
and drug delivery systems, (4, 5). The model consists of a cylindrical scaffold with an intimal
endothelial cell lining housed in a biochamber, and luminal perfusion with media via a peristaltic
pump (Figure 1.7) (4). The intimal cell lining acts as a living human tissue for physiologic
interaction with a device (4). This interaction allows for the potential assessment of various
coatings and configurations of intravascular devices, providing more data for the identification of
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the best candidates to proceed to further evaluation (4). Thus, this methodology has the
capabilities to improve the traditional methods of preclinical testing (4).

Figure 1.7. The BVM system. The solidworks model of the current BVM system (Left). The
actual set up of the BVM in an incubator (Right).
1.6.1 The BVM Scaffold
To create a physiologically relevant bioreactor system several aspects of the scaffolding
must be considered, such as size, orientation, material, microstructure, and biocompatibility. The
BVM design allows for variations to the overall composition of the scaffold and bioreactor
system. A scaffold’s size can be varied from 3 mm to 4 mm inner diameter, and from 3 cm to 5
cm in length via exchangeable lure lock fittings. Also, through some configuration alterations,
the bioreactor can house scaffolds with more natural curvatures, such as 90 degree or 180 degree
bends and bifurcations for more native orientations. Changes in orientation of a scaffold may
increase the physiological aspects of the BVM, while presenting more realistic geometries to
evaluate newly developed intravascular devices. These versatile components make the BVM
design a promising preclinical testing method. The scaffold plays a critical roles in the over
function and physiological relevance of the BVM system.

24

The physical orientation of the scaffold is an important attribute of the BVM, but the
scaffold choice is a key aspect as well. As previously described, there are several types of
scaffold materials that can be utilized in a TEBV. Currently in Dr. Cardinal’s research, ePTFE
has been the gold standard for use in the BVM. The synthetic scaffold is well known and
characterized for its use as a TEBV, and will continue to be a consistent choice for countless
testing applications. Although the properties of ePFTE are not ideal, lacking in radial
compliance and native porosity, ePFTE has the ability to support the development of an
endothelium. The question remains if the scaffold can be made better? A scaffold that has a
native porosity, essential proteins of the ECM, native mechanical properties, and the potential to
grow and develop would be a more physiologically relevant option for the BVM. Based on
current work in the TEBV field, as summarized previously, decellularized scaffolds present a
potential option that has not been previously explored for the BVM. Through the
decellularization of porcine arteries, all of these properties are possible.
1.7 Overview and Aims of the Thesis
This Introduction has described the background for which this thesis is based. The
clinical problem of CVD is prevalent in the United States, where CAD is one of the most
commonly treated disorders. As described previously, the development of a metallic stent device
has been widely used to treat CAD, by effectively re-opening the blood flow through the vessel.
New stents are being developed constantly to greatly improve the long-term results of stenting.
To enable the most promising new devices make it to clinical applications, new methods for
preclinical, informative evaluation are required. Thus, a highly specialized testing modality, the
BVM, has been created to provide preliminary endothelialization data in an in-vitro setting.
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As stated, the purpose of the BVM is to create a simplified physiological representative
model of a human blood vessel with the intention of testing intravascular devices. In the current
BVM model, the scaffold must primarily be able to support a functional endothelium. Thus, the
specific characteristic of supporting an endothelium is vital to fulfilling the BVMs main goal. To
achieve this, the scaffold must support cell adherence, proliferation, and phenotypic expression.
The scaffold’s ability to maintain the endothelium will improve the BVM’s capabilities (46).
Once the development of a strong endothelium is ensured, the mechanical properties of the
scaffold become the next characteristic for consideration. Mechanical properties of the scaffold
will determine its capacity to withstand the stent deployment (29). The radial compliance is a
major aspect to investigate when choosing a scaffold material (20, 46). A scaffold with little to
no compliance may prevent the stent from deploying properly, or if it’s too compliant the stent
may not interact with the wall in an ideal manner. Currently, the ePTFE scaffold lacks
physiologic compliance and a new scaffold may have the potential to improve these limitations.
In addition to the mechanical relevance of a decellularized scaffold, integral for stent
deployment, it can be used to improve knowledge of sent interactions with the smooth muscle
cells of an artery to develop knowledge regarding the common problem of restenosis. Further
more, a decellularized scaffold may help to develop novel imaging modalities, as it is a unique
composition and light can penetrate through the material.
Based on published use of decellularized tissues as biologic scaffolds, and specific
successes in the use of decellularized vessels for TEBVs, this thesis explored the development of
decellularized porcine vessels for use as a scaffold in Dr. Cardinal’s BVM. To investigate the
potential use of this scaffold in the BVM, there were three main aspects of this thesis:
establishment of a decellularization protocol, mechanical characterization of the decellularized
scaffold, and finally re-cellularization of the scaffold. These experiments characterized the
26

decellularized scaffold’s potential to be used in the BVM system. The mechanical properties and
the ability to support an endothelium will provide the basic proof of concepts needed to support
further investigation into the consistent use of decellularized blood vessels.
The following is a summary of the specific aims pursued in this thesis.
 Aim 1: Establish a decellularization protocol for the complete decellularization of
porcine arteries and evaluate the success of the decellularization protocol using
histology.
 Aim 2: Determine the ability of the decellularized scaffold to maintain the native
mechanical properties by assessing Young’s Modulus and Critical Yield via tensile
testing. Evaluate burst pressure for the radial compliance of the treated vessel.
 Aim 3: Create a protocol for sodding the vessel with cells and evaluate the recellularized scaffold.
In conclusion, this thesis will provide documentation of the previously mentioned
experiments to support the potential for a decellularized porcine scaffold to be utilized as a
specific scaffold testing modality for the BVM.
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Chapter 2 - Development and Evaluation of Decellularization Protocol
2.1 Introduction
As described in Chapter 1, a range of synthetic polymeric materials exist for various
biomedical applications. One of the widely used polymers previously mentioned, ePTFE, is a
readily used biomaterial for several in-vitro and in-vivo applications. Polytetrafluoroethylene
(PTFE), commonly known as Teflon, was discovered in 1937. Teflon is an inert material and is
considered to be one of the most ideal electrical insulating materials currently on the market (56).
The polymer is composed of highly crystalline and hydrophobic molecules. This particular
combination of molecules prevents hydrolysis from occurring to keep the polymer as an intact
structure (56). One of the first medical uses of PTFE was in the early 1960’s as an implanted
heart valve (56). In 1969, a company called Gore patented an expanded version of the polymer
(ePTFE), which became known as Gore-tex (56).
To create ePTFE, the polymer is manufactured differently than just PTFE. The polymer
is put through a series of stretching and extruding processes, in a heated environment to produce
a microporous, non-woven material (56). Through this manufacturing process along with the
biostable molecules and electronegative surface, ePTFE is capable of supporting tissue adhesion
(Figure 2.1) (56). The tubular ePTFE grafts are manufactured via stretching the material over a
solid polymer shaft. This stretching causes the non-woven material to crack, creating the
micropores (56). This manufacturing process is well defined leading to a predictable
microstructure; there will be node-fibril structures running parallel on the length of the tube
(Figure 2.1) (56). The node-fibrils are approximately 30μm apart with interconnecting fine
fibrils (Figure 2.1) (56).
EPTFE was manufactured to be used for vascular grafting, because once created the
resulting combination of the molecules and expanded micro-porous structure closely mimics the
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native structure of a blood vessel. This material has been used during vascular surgeries for
large diameter bypasses such as aneurysms and aortoiliac occlusive disease, (57). There is a 5year lifetime of this scaffold, which is a large improvement compared to the widely used Dacron
and even the Gelatin coated Dacron grafts (57). Today, ePTFE is the gold standard for large
diameter vascular prostheses in clinical practice. However, when ePTFE is used for small
diameter vascular prostheses, thrombosis occurs within a few months due to the low polymer
compliance (56, 58).

Figure 2.1. Scanning Electron Microscope (SEM) image of ePTFE. The microporous structure,
with nodes running horizontally, parallel to the tubing length and the internodal fibers run
vertically (59).
Also as described in Chapter 1, ePTFE has also found use in the BVM as the primary
scaffold material. The goal of the BVM model is to create a pre-clinical testing system to
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evaluate intravascular devices. This in-vitro model aims to be high-throughput, cost effective,
reliable, and physiologically relevant to simulate an in-vivo environment. The use of ePTFE in
the BVM model has many advantages. Some of these include the extensive existing pre-clinical
and clinical data on the endothelialization on ePFTE, the ability to be autoclaved or gas
sterilized, good biocompatibility, non-biodegradability, proper EC orientation encouraged via the
unique microstructure, and it’s availability in several different dimensions. The fabrication
methods of ePTFE produce a consistent scaffold and hence more consistent results. Although
this is an appropriate material for the development of a high throughput system, ePTFE is costly,
dependent on the suppliers, and has non-native mechanical or physical properties. Simply, the
ePTFE is a limited material that cannot be easily tailored to incorporate specific properties to
further advance the BVM model. The production of a new scaffold which is created in house
scaffold could improve the cost effectiveness and the physiological relevance of the BVM
model. One such scaffold that, which is the focus of this thesis is created through
decellularization of a native tissue.
The production of a decellularized scaffold could potentially result in the production of a
more physiologically relevant scaffold, improving the ePTFE scaffold. In 2004, Schaner et al.
produced a completely decellularized vessel that maintained its native structural properties (49).
This work became the basis for the development of the biologic scaffold for the BVM, using the
decellularization on porcine vessels (49).
The decellularization of arteries for tissue engineering has been used for over two
decades and was first utilized by Malone et al. in 1984 where autologous small diameter carotid
arteries were decellularized and then implanted in dogs (60). These scaffolds were found to
function properly 80% of the time. Since this first experiment, the process of decellularization
has grown exponentially and is now recognized as a legitimate method for the creation of
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scaffolds for uses both in-vivo and in-vitro (61). This thesis intends to further investigate the use
of decellularized scaffolds for in-vitro use specifically. The development of a decellularization
protocol will aid in determining the potential utility of a decellularized biologic scaffold for use
in the BVM.
2.2 Methods for Decellularization
2.2.1 Protocol Development
All vessels were harvested from pigs at the Cal Poly swine unit or at Creston Valley
Meats. Pigs about 2-6 months old were sacrificed and vessels were harvested within one hour of
death. The jugular vein, carotid artery, arteries from the brachiocephalic trunk, subclavian vein
and artery, femoral artery and vein, as well as other superficial arteries throughout the body were
the choice vessels during harvesting. The locations of these vessels are relatively well known,
but the differences between an artery or vein, and the precise locations were not always clear.
Harvested vessels were taken to the lab for cleaning, or the removal of all the connective tissue
using a scalpel, razor blade, and scissors. Extra attention was focused on removing only the
connective tissue, not the adventia of the vessel wall. Care was also taken to ensure the vessel
was not ‘nicked’ by the cutting instrument. Vessels were then cataloged based on their outer
diameter; smaller than 2 mm were recorded as small, from 2-5 cm were recorded as medium, and
larger than 5 cm were recorded as large vessels. Vessels were then stored in a -20°C freezer
within 8 hours of harvesting and remained usable for up to two years. In preparation for
decellularization, vessels were thawed in a 37°C water bath until the structure was malleable. At
this time the vessel was able to be used for any experimentation.
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2.2.1.1 Static Decellularization Methods
The preliminary decellularization parameters were based on the work of Schaner et al.,
including the duration of decellularization and concentration of SDS (49). Primary experiments
focused on determining the ideal concentration of SDS, as was done in Schaner et al’s. work
(49). To optimize the decellularization protocol, different concentrations of SDS, ranging from
0% to 0.125%, were evaluated on the ability to remove all cells from the tissue without altering
the native properties of the vascular wall ECM. A high concentration of SDS, it results in the
degradation of the vessel wall structure. Conversely, a low concentration of SDS will leave all
of the existing cells on the vessel may not be removed. The other experimental parameters were
taken directly from Schaner et al.; the decellularization process took place for 15 hours on a
Daigger orbital shake table (model SH 06050597). The experimental procedure is provided in
Appendix B: B.1, which describes the detailed steps for decellularization. The first test
evaluated concentrations of 0%, 0.075%, 0.1%, and 0.125% SDS to elucidate the optimal
concentration for complete decellularization. The ideal concentration from this experiment
optimized the static decellularization protocol. For these studies, small and medium sized
vessels were utilized.
2.2.1.2 Perfusion Decellularization Methods
Once the vessels were found to be decellularized, further experimentation was required to
evaluate the potential for use as a scaffold in the BVM. The lumen of the vessel needed to
remain open in order to perform these additional experiments. However, during static
decellularization, the vessel became swollen and the lumen was lost in the remaining connective
tissue and adventia. Therefore, to ensure the lumen remained accessible, it was essential to keep
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the lumen open during the decellularization process. A male luer lock barb was inserted into the
lumen. The lure lock barbs were sutured onto either ends of the vessel just after thawing or
during the “clean-up” portion of the harvesting (Figure 2.2). The protocol was further altered by
adding a Thermo Fisher Scientific Masterflex L/S 3 roller peristaltic pump (model 7519-05), to
perfuse the lumen during the decellularization process, rather than the orbital shake table for
mechanical agitation. The change in mechanical agitation is to keep the lumen open was the
only modification to the static decellularization protocol (0.075% SDS for 15 hours). This
modified profusion protocol is in Appendix B: B.2. The SDS solution perfused the lumen at 140
rpm for 15 hours.

Figure 2.2. Luer lock barbs sutured to the scaffold. Sutured during cleaning (right) and
during decellularization (left),
The consequent experiments to improve the perfusion decellularization, the flow rate of
SDS through the lumen was optimized. The perfusion rate through the vessel with SDS was
lowered to 20 rpm. Also, the use of a shake table was reinstated to improve decellularization by
providing two types of agitation to the vessel wall. The final protocol used a 3-roller peristaltic
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pump at 20 rpm for 20 hours on a shake table rotating at 30 rpm (see Appendix B: B.3). The
final set-up with the shake table and peristaltic pump, is pictured in Figure 2.3.

Scaffold
Peristaltic Pump

Shake Table

Figure 2.3. Peristaltic pump and orbital shake table utilized for decellularization.
2.2.2 Protocol Assessment
For both static and perfusion decellularization, histology was used to evaluate the
decellularization process. Samples were fixed in histochoice overnight to ensure the proteins in
the sample were crosslinked. Samples were then processed using a Thermo Scientific, Shandon
Excelsior ES tissue processor and then embedded in paraffin wax via a Thermo Scientific EC350
embedding center. Samples were embedded with a cross sectional orientation to view the
scaffold lumen. Sections approximately 6μm thick were cut from the block, using a Lyca RM
2255 microtome. Samples were stained with hematoxylin, a purple nucleic dye, and eosin, a
pink cytoplasmic and collagen dye (hematoxylin from Fisher Scientific 7211 and eosin from
Fisher Scientific 7111). This staining process is called H&E staining and the full protocol is in
Appendix B: B.4 Histology Staining. Stained and cover slipped slides were imaged using white
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light on an Olympus BX41 Microscope at 10x magnification. The primary evaluation to assess
decellularization consisted of nuclei identification within the image. Secondly, the status of the
tissue was evaluated for any noticeable degradation from the SDS solution. Degradation was
evaluated based on a visual evaluation of the vessel wall structure.
The evaluation of the decellularization was based on the classification of the histological
pictures. There were three classifications of the vessel status: not decellularized, decellularized,
and degraded. A not decellularized scaffold had similar nuclei and wall structure as the control.
A decellularized scaffold had similar wall structure as the control but no nuclei are present.
Finally, a degraded scaffold had no nuclei and an altered structure from the control. With these
classes, all of the images from each sample concentration were evaluated.
2.3 Results
2.3.1 Static Decellularization Results
In Figure 2.4, two images from each concentration of SDS are compiled together. All
sections were stained with H&E and imaged at 10x magnification (higher magnification pictures
are in Appendix C: C.1). Table 2.1 summarizes the classifications given to each sample. A
concentration of 0.075% SDS was considered to be the optimal concentration for
decellularization without degrading the vessel wall.
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Control

0.0% SDS

0.075% SDS

0.01% SDS

0.0125% SDS

Figure 2.4. Images of static decellularized porcine arteries at various concentrations of SDS.
Higher magnification images in Appendix C.1.
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Table 2.1. Summary of Classifications for Each Concentration Sample.
Sample
A
B
C
D
E

SDS
Control
0% SDS
0.075% SDS
0.1% SDS
0.125%SDS

Classification
Not decellularized
Not decellularized
Decellularized
Decellularized, Degraded
Degraded

2.3.2 Perfusion Decellularization Results
To optimize the decellularized scaffold for use in the BVM (or for any use requiring
access to the lumen) the protocol was altered to keep the lumen of the vessel open. The protocol
alteration included the addition of a luer lock barb, which is easily integrated into a simple 50mL
conical bioreactor. The conical bioreactor enables decellularization via luminal perfusion. The
static shaking method focuses on decellularizing from the outside of the vessel into the lumen;
where as perfusion methods have a particular focus on decellularization in the reverse direction,
from the lumen to the outside of the vessel. Using this theory, mechanical agitation by an orbital
shake table from the static protocol was changed in the perfusion protocol. This experiment used
a 0.075% solution of SDS to perfuse the lumen at 140 rpm for 15 hours. Figure 2.5 are the
images from the resulting histological analysis from the perfusion procedure. The vessels were
again scored with the same three classifications: not decellularized, decellularized, and degraded.
Overall, the perfused vessel was scored as ‘not decellularized.’ The flow rate was too high for
the given application and considered to be the main problem with the protocol since it was the
only altered from the working static protocol.
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Figure 2.5. Perfusion decellularization. Perfusion decellularization scaffold (left) and
control vessel (right).
Investigations into the literature revealed that a lower flow rate, for a longer duration
would allow the SDS to better interact with the scaffold, and improve the decellularization of
tissue. Also, a combination of the rotary shake table and perfusion methods was determined to
be the ideal mode of mechanical agitation for complete decellularization. Therefore, the final
decellularization protocol perfused the lumen of the vessel at 20 rpm for 20 hours while on an
orbital shake table (Appendix B: B.3 Final Perfusion Decellularization). Figure 2.6, is the
histological results from this new method compared to a native control and a statically
decellularized vessel. This final protocol was successful for the complete decellularization of a
porcine artery and vascular wall, while maintaining the opening of the lumen. Further verifying
the efficiency of this protocol, the same protocol was repeated over ten times with a similar
result. It is important to note, that with the addition of the luer lock barb the whole tissue was
not decellularized. Through H and E analysis, the portion of the scaffold which was sutured to
the barb was not completely decellularized and the scaffold was always cut from the barb before
further processing.
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Figure 2.6. Successful perfusion decellularization. Static decellularized scaffold (right),
perfusion decellularized scaffold (center), and native control vessel (right).
2.4 Discussion
Several groups have done static decellularization using similar methodologies; where
various methods of agitation were applied to the tissue, helping to remove all the cellular debris.
Singelyn et al. utilized a stir bar to continuously move the tissue in an SDS solution for several
days for full decellularization (51). Licthenburg et al. suspended tissue in an Erlenmeyer flask
with a stir bar to move the solution of SDS continuously around the tissue. The decellularized
scaffold was then re-suspended in a similar manner to for all other in-vitro testing (62). The
methodology from Shanner et al. is the bases for the static protocol used in this experimentation,
where scaffolds were physically submerged repeated times into a SDS solution as the main form
of agitation for cellular removal. This method worked well for decellularization, but all other invitro tests preformed by this group did not require access to the lumen (49). These groups and
others have demonstrated that static decellularization is possible with simple agitation methods,
but the ultimate goal of the research will tailor what methodology works best. In some
applications the structure of the scaffold may remain intact, while for other applications, the
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structure can be lost. Thus, the most vital parameters of any decellularization protocol include
only the concentration of the SDS and some means of agitation to the tissue.
Static decellularization was found to successfully remove all cellular components at a
concentration of 0.075% SDS. It could be debated whether the concentration was best at 0.075%
or at 0.1% SDS, because both were fully decellularized with little damage to the vessel wall. By
looking at several other sections of the different concentrations, 0.1% SDS had more apparent
degradation of the adventia layer of the vessel wall. Also, limiting the amount of SDS present in
the process would be ideal if this scaffold is to be used in biologic experiments. Thus, the lower
and most successful concentration of 0.075% SDS was chosen to be part of the optimal static
decellularization protocol. The other variables of the protocol had been determined through the
literature and were repeated in this experiment. Thus, there was no reason to perform additional
experimentation for the optimization of these parameters.
After successfully establishing a static protocol for decellularization, using 0.075% SDS
and an orbital shake table to agitation, the next phases of in-vitro testing needed to be evaluated.
These alternative in-vitro tests required access to the luminal space. Specifically, to
mechanically evaluate the scaffold is cut open and laid flat to determine its elastic modulus. In
addition when then scaffold is used in the BVM the scaffold to be sutured into the system and
luminally pressure sodded with cells. Therefore, it would be ideal to alter the decellularization
techniques to provide luminal access for down stream testing.
During static decellularization, the vessel became swollen and structures were
unidentifiable from one another thereby rendering the lumen inaccessible. By adding lure locks
and perfusion step to the decellularization process, the vessel lumen could remain open for future
experimentation. By inserting the male lure lock barb into the vessel lumen of a frozen or fresh
vessel, the lumen would remain opened throughout storage and decellularization. The perfusion
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step ensures the lumen is exposed to SDS and with the combination of the shaker have the
mechanical agitation enabled complete cellular debris removal.
Perfusion methods have been used in literature to decellularize scaffolds where keeping
an intact the macrostructure is imperative. Ott et al. was the first group in 2008 to decellularize
an intact rat heart using the perfusion methods. The rat hearts were carefully dissected from the
animals, then the chambers of the heart were perfused (flowing the path of blood flow) with PBS
and SDS for several days (48). Using the perfusion method, most of the macrostructures
remained intact, including: ventricles, atriums, coronary arteries, purjinke fibers, atrioventricular,
and semilunar valves (48). Keeping these macrostructures intact was important for whole heart
decellularization because the scaffold maintains it complexity and intricacy, which is currently
impossible for any man-made scaffold. The end goal for a whole heart decellularization is to
reach the clinic, where it is promised to one day improve the organ transplant process (48). For
this goal, having all of the complexities and intricacy of a normal heart is vital to the usability for
this type of scaffold. Overall, this perfusion method enables the decellularization from the inside
out, without drastically harming the macro- or microstructure. Using a similar perfusion method
to decellularize a single artery, should retain the native macrostructure intact. This has been
preformed in the vascular decellularization literature; produce a physiologically relevant scaffold
(40, 49, 63). Thus in theory and as shown in these experiments, the established perfusion
decellularization protocol maintains the scaffold structure very similar to that of a native artery.
To further evaluate the perfusion decellularization protocol, the reproducibility of the
protocol was evaluated. Reproducibility of a scaffold was designated by efficiently and
repeatedly decellularizing scaffolds of all sizes. Small, medium, and large sized vessels were
decellularized using the final perfusion decellularization protocol (Appendix B: B.3).

Over 50

vessels have been decellularized in this fashion, with continued successful results. To further
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investigate the potential for this procedure transition to a high throughput model, three scaffolds
were successfully decellularized at once time.
In summary, perfusion decellularization did not remove the cells as efficiently as the
static decellularization methodology had done previously. Without changing the concentration
of SDS, the duration of the SDS rinse was extended and the flow rate was decreased in order to
increase the exposure time to the detergent. Finally, a combination method including both
perfusion and rotary agitation was discovered to be ideal at not only for decellularization, but
also for the set-up of future in-vitro testing. Essentially, the final protocol is reproducible,
effective at maintaining an open lumen, efficient at decellularization, and leaves the
microstructure intact. Maintaining the native structure is vital to ensuring the conservation of all
native properties; mechanical for compliance, integral for sent deployment, and biologic
composition, critical for stent-wall evaluations or vascular pathway modeling of disease.
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Chapter 3 - Characterization of Decellularized Vessels
3.1 Introduction
Chapter 2 determined the optimum decellularization protocol for complete removal of
cellular material, without apparent harm to the integrity of the ECM. The goal of the next
investigation was to quantitatively evaluate the condition of decellularized vessels post
decellularization. It was necessary to evaluate the damages sustained to the ECM during the
decellularization treatment, as it may lower the physiological relevance of the vessel scaffold.
Excessive scaffold degradation can prove problematic because the lack of a porous, intact
scaffold wall could hinder endothelium growth and viability in both the short and long term (61).
Currently, one of the key limitations of cell-based tissue engineering is the lack of mechanical
strength within the scaffold wall, resulting in the subsequent reliance on synthetic scaffold
materials (64). The development of a decellularized scaffold promises to bridge the gap between
weak cell-based or biologic scaffolds and synthetic materials. In order for a scaffold to be
incorporated into the BVM, the mechanical, structural, and basic biological properties of the
scaffold should not differ from that of a native vessel. Therefore, the evaluation of the scaffold’s
mechanical properties prior to its use in the BVM is important. The scaffold must effectively
fulfill the goal of the BVM, by maintaining the structural stability necessary to support an
endothelium throughout the course of an intravascular device evaluation.
The structural properties were visually analyzed by Hematoxylin and Eosin staining, as
well as with scanning electron microscopy (SEM). These images were used to examine if the
decellularization treatment had any lasting effects on the wall structure, which is important to the
overall functionality of the scaffold. To evaluate scaffold mechanics, tensile and burst pressure
evaluation were performed on both native and decellularized vessels. The mechanical testing
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methods utilized were modeled from the work done by Montoya et al. in 2009 for the evaluation
of a decellularized scaffold (65).
In addition to structural and mechanical assessment, biological evaluation of the
decellularized scaffold examined its bacterial content post harvesting and post decellularization.
These results provided information regarding the sterility of the harvest and decellularization
process. These experiments characterize and support the ability of the decellularized protocol to
efficiently remove all cellular components from a blood vessel without disrupting its natural
structure, which further demonstrates its potential to be incorporated into the BVM. All
scaffolds used in this investigation were prepared following the final protocol described in
Chapter 2 of this thesis (Appendix B: B.3).
3.2 Methods
3.2.1 Structural Evaluation
3.2.1.1 Hematoxylin and Eosin Staining
Two imaging techniques were utilized to visualize the potential effects of the
decellularization process on the structural integrity of a scaffold. As discussed in Chapter 2,
Hematoxylin and Eosin (H and E) staining can be used to visualize cross-sections of the vessel
wall for specific identification of cell nuclei as well as other macro-structures in the vessel (66).
The H and E staining provides a basic image for comparisons between pre- and postdecellularization; regarding not only the presence of cells as in Chapter 2, but also for the
maintenance of basic structures.
As described in Chapter 2 section 2.2.1.2 (‘Perfusion Decellularization Methods’),
decellularization was performed by perfusing SDS through the lumen while simultaneous
shaking for 20 hours. Once decellularized scaffold sections were fixed in histochoice to fix the
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sample. Then samples were process and embedded in paraffin wax. Sections approximately
6μm tick were taken from each sample and stained with H and E, as discussed in Chapter 2
section 2.2.2 (‘Protocol Assessment’).
The images were again scored based on the amount of degradation present within the
vessel wall. The scoring system for degradation coincides with the decellularization scoring, as
the two evaluations are similar. There were two classifications of the vessel status: not intact or
intact. All of the images evaluated were considered to be properly decellularized. The
classifications are further described as either an intact vessel wall, where the wall of the vessel is
continuously touching and each pink collagen line remains within close proximity to its
neighboring fiber, or not intact, where the pink collagen lines of the vessel do not retain their
close proximity and continual interaction. Examples of “intact” versus “not intact” are provided
in Figure 3.1. The evaluated scaffolds followed the decellularization protocol listed in Appendix
B: B.3.

Figure 3.1. Intact vs. not intact. Decellularized scaffold classified as intact (A). Decellularized
and classified as not intact (B).
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3.2.1.2 Scanning Electron Microscope Imaging
A scanning electron microscope (SEM) provides a micro- or nano- scale view of a
material’s surface topography (67). SEM images produce an image of the material’s surface at
10-20,000 times magnification (67, 68). This high resolution imaging technique reveals
information regarding the material’s porosity, fiber diameter, and composition (67). SEM
images were used to visualize the luminal structure of the decellularized artery; specifically
looking at the fiber topography and possibility of cellular presence. The combination of SEM
and H and E images helped to define the structure of the scaffold pre and post decellularization,
to asses any damage to the scaffold wall from the decellularized treatment.
To obtain an SEM image, the sample was placed in a vacuum, then a high powered
electron beam was directed on the sample. The width of the beam can be altered by the coils to
increase or decrease the magnification (68). The electrons that were not absorbed by the sample
were scattered back towards the walls of the SEM (68). The walls have several detectors to
absorb the backscattered electrons; the angle at which deflected electrons hit the detector and are
computed into topographical image of the sample’s surface (68). Figure 3.2 depicts the
procedure for SEM imaging. The samples were dehydrated prior imaging to ensure quality
images and a functioning SEM. Dehydration is an essential step for SEM images as the electron
beam will heat up any water molecules present in the sample, causing damage to the sample and
potentially to the sensitive instruments within the SEM. The exact dehydration protocol is
provided in Appendix B: B.5. SEM images were acquired using a Hitachi High Technologies’
TM3000 Tabletop Microscope (Figure 3.3)
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Figure 3.2. A diagram for how an SEM operates. Depicting the electron beam, scanning
coils, and backscattered detectors (69).

Figure 3.3. The TM3000 Tabletop Microscope used for imaging.
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3.2.2 Mechanical Evaluation
3.2.2.1 Tensile Testing
The decellularization process requires strong chemical agitation, which may degrade
components of the ECM and weaken the structure. Tensile testing a sample will determine the
elastic modulus and yield strength for a decellularized vessel compared to a control vessel. The
elastic modulus describes the amount of elasticity in a material, while the yield strength
determines the point at which the material begins plastic deformation (70). These results
quantitatively describe how the decellularization treatment affects the mechanical strength of the
vessel wall. All tensile testing was performed on an Instron In-Spec 2200 Portable Tester with
PDA Data Management Software equipped with a 250 N (50 lb) load cell tensile machine for data

collection.
Samples were placed in the tensile testing machine and stretched until failure. The
machine pulls the sample 1 mm every 0.1 seconds and records the resistance of them material
every stem. Equation 3.1 below describes the relationship graphed between extension and load.
The extension of the sample is the distance stretched during the test and the load is the amount of
resistance felt by the machine as it increases the length of the sample. Using the raw data
(extension versus load measurement) and measured specifications (surface area and width) of the
sample, stress and strain was plotted and were then used to calculate the elastic modulus. The
relationship between stress and strain is known as “Hooke’s Law” (seen in Equation 3.2 (70))
and is derived in the following equations (equations 3.3 and 3.4) (70). The elastic modulus (E)
seen in Equation 3.2 is the relationship between stress (σ) and strain (ε) (70). Stress in Equation
3.3 is the load from the raw data divided by the cross-sectional area of the sample
(thickness*width). Strain in Equation 6 is given by the change in length of the sample over the
original length of the sample. Equations 3.1-4 were used to determine the elastic stress and
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strain curve for any given point of the experiment. Young’s Modulus and yield strength were
then calculated for all the raw data points using these stress and strain values. The elastic
modulus was measured by the linear portion of the stress versus strain curve, while the yield
strength was taken where elastic deformation ended and plastic deformation began (just after the
linear portion) (70).
Load ( N )
N

Extension(mm) L
(Pa ) 

Equation 3.1




Equation 3.2 (70)



Load ( N )
N

2
Area(mm ) t * w

Equation 3.3 (70)



Extension(mm)  length(mm) L  Lo

Length(mm)
L0

Equation 3.4 (70)

To tensile test samples, a control group was first cut from each native vessel. Then
samples were decellularized using the protocol from Appendix B: B.3. Samples were cut into
pieces approximately 5cm in length (Figure 3.4). The smaller samples were then cut
longitudinally and laid flat for placement in the tensile tester (Figure 3.5). From Figure 3.5, the
sides indicated by “width” were placed in the clamps of the tensile tester. Once samples were
cut into a flat section, they were oriented longitudinally and edges were placed in the clamps of
the tensile tester. About 1 cm of the sample was aggressively clamped down on either end. The
sample was then stretched until taught; the machine was calibrated at this point to zero for force
and length. The original length (between the two clamps), width, and thickness of the sample
were recorded for later calculations of Young’s Modulus and yield strength. Finally, the tensile
tester was started; samples were pulled 1mm per second, producing a slow and consistent
longitudinal pulling force on the sample, until the sample was broken. For more detailed
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methods see Appendix B: B.6 Tensile Testing Protocol. The stress and strain was calculated
from the raw data using a macro program (full macro program Appendix B. B.7). A two-sample
T test was used to evaluate the statistical significance of the Young’s Modulus for the control
and decellularized scaffolds. Significance is given by a p-value less than 0.05, with six samples
for each group (n=6).
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Figure 3.4. A visual depiction of the cutting preparations for a tensile test. Sections A, B, C,
and D are approximately 5 cm long each.
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Figure 3.5. A representative image of the longitudinal cut made (seen in red on the top images)
to each of the samples for preparation in the tensile tester. The bottom images show the flat
sample of tissue placed in the tensile tester, again red indicates the side of the sample that was
cut. The sides indicated by “width” were placed in clamps to produce a longitudinal tensile
force.
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3.2.2.2 Burst Pressure Evaluation
A burst pressure evaluation was used to further evaluate the mechanical integrity of the
scaffold post decellularization treatment. Burst pressure measures the maximum circumferential
stress that a scaffold can maintain. The scaffold should at minimum be able to withstand normal
physiological pressures from 70 to 150 mmHg (71). Burst pressure was measured via a pressure
transducer. The pressure transducer equipment was controlled using Data Acquisition Software
(ADQ) and AD Instruments (ADI). Samples went through a three-staged process for testing the
maximum burst pressure of the scaffold. Stages included calibration, scaffold set-up, and burst
procedure.
The pressure transducer was calibrated first using the ADI system, a pressure transducer,
blood pressure cuff, and Lab Chart. To calibrate, see Appendix B: B.8 for the detailed steps.
Decellularized and native scaffolds were then connected to the system, one at a time. The distal
end of the sample was capped off and the proximal end was connected to a pressure transducer
(all decellularized scaffolds followed the protocol in Appendix B: B.3). On the transducer side,
extra tubing and a stop cock was attached a water-filled syringe that supplied the pressure into
the scaffold (Figure 3.6). The transducer was also attached to the ADI system to record the
pressure changes throughout the experiment. Finally, the burst pressure was tested by slowly
injecting fluid into the lumen of the decellularized scaffold until it burst open, and the maximum
pressure was recorded. The detailed protocol for this procedure is in Appendix B: B.8.
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Figure 3.6. The complete set up of pressure transducer, syringe, stop cock, cap end, and scaffold
3.2.3 Biological Evaluation
To evaluate the potential contamination of the sample post harvest from the pig and post
decellualrization, a bacterial assay was performed. The harvesting process was not performed in
a sterile environment, thus it is important to assess any level of contamination that may have
occurred. If these scaffolds are to be used in the BVM system and eventually sodded with cells,
thus an aseptic scaffold is ideal. Therefore, determining the amount of biological contamination
was imperative to understanding the scaffold’s potential use in the BVM.
Trypticase soy agar (TSA) plates and lysogeny broth (LB broth) tests were utilized for
this bacterial content assay. The detailed procedures for these tests are provided in Appendix B:
B.9. This assay was conducted with four variables: pre and post decellularization, as well as pre
and post decellularization with 1% penicillin:streptomycin (penstrep). The 1% penstrep is a
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common antibiotic used to prevent bacterial growth. These variables described the condition of
the scaffold post harvesting and post treatment, as well as the potential strength of the antibiotic,
in case there was contamination did occur during the harvesting process. Each of the four
samples were placed on TSA plates and in the LB broth. Evaluation was performed by visual
inspection of the bacterial contamination; if contaminated bacterial colonies will formed on the
TSA plate and the LB broth will become cloudy, if no contamination then both medias will
remain clear.
3.3 Results
3.3.1 Structural Evaluation
3.3.1.1 Hematoxylin and Eosin Imaging
Hemotaoxylin stain was useful for visualizing decellularization (by staining the nuclei),
while the Eosin staining was useful for the structural analysis (by staining the structural
components). The H and E images were then used again to evaluate the changes in the scaffold
wall from the decellularization treatment. Figures 3.7 and 3.8 are images that represent the each
of the classifications (‘Intact’ or ‘Not Intact’); Figure 3.7 were ‘Intact’ scaffolds and Figure 3.8
were ‘Not Intact’ scaffolds. Please note, these images are meant only for comparison purposes;
as these images were taken after further processing and not after the decellularized treatment
alone. Table 3.1 is a summary of the number of scaffolds found to be ‘Intact’ verses ‘Not
Intact’. Interestingly, there was some correlation between the size of the scaffold and the
classification of the scaffold; the larger the scaffold the more likely it was classified as ‘Not
Intact’.
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Figure 3.7. Scaffolds classified as ‘Intact’. The wall of the vessel is continuously touching and
each pink collagen line remains within close proximity to its neighboring fiber.

Figure 3.8. Scaffolds classified as ‘Not Intact’. The pink collagen lines of the vessel do not
retain their close proximity and continual interaction.
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Table 3.1. Summary of Scaffold Classifications.

Intact
Not Intact

Decellualrized
12
6

Diameter
(mm)
2 to 5
<5

3.3.1.2 Scanning Electron Microscope Imaging
In Figure 3.9, the SEM images are the topographical images of the luminal surface of
decellularized vessels at 400x and 1000x magnification. The wavy structure seen in histological
images were two dimensional pictures of the collagen fibers, where are a topographical view
(given by the shade of gray). There is some orientation, in that the fibers flow uniformly
(horizontally in the 400x image on the top and vertically in the 1000x image on the bottom) in
congruence with the orientation of normal blood flow through the vessel. Yet there is random
orientation between the fibers, which is characteristic of a porous scaffold having the capacity to
house cells and encourage cell proliferation and migration (41). These images are devoid of any
cellular structure; where as in Figure 3.10, a native artery has a well defined endothelial cell
lining.
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Figure 3.9. SEM images illustrate decellularized arteries. Top is at 400x magnification.
Bottom is at 1000x magnification. *Note: this SEM image was acquired from a cell-sodded
decellularized vessel, where no cells remained in the lumen (confirmed by H and E).
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Figure 3.10. Images of intact native porcine arteries, with endothelial cell lining. Scale bars, 40
μm (A); 5 μm (B and C) (72).
3.3.2 Mechanical Evaluation
3.3.2.1 Tensile Testing
The tensile tests produced over 1000 raw data points for the force at each length
extension. To summarize this data, a macro program in Excel was created and used (for full
macro, see Appendix B: B.7). From this macro, raw data was used to calculate the stress and
strain of each sample based on equations 3.1-3.4. The stress versus strain was graphed (Figure
3.11, top), to examine total behavior of the sample. The linear portion of the stress strain graph
was re-graphed to show the elastic modulus and is determined by the slope of the equation of the
line (Figure 3.11, bottom). The yield strength was considered to be the highest point of the
elastic modulus, or the last point before plastic deformation. The original parameters for the
example in Figure 3.11 were: original length (Lo) 13.42mm, original width (W) 11.43mm, and
thickness of the sample (T) 0.79mm.
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Figure 3.11. Sample stress versus strain graph (top) and linear component graph (bottom).
Additional data is in Appendix C.2.
Once the raw data for all samples was tabulated using the macro program, the Young’s
Modulus and yield strength was identified for each sample (a summary table of the raw data is
present in Appendix C: C.3). The raw data was summarized to show the average and standard
deviation for each sample group (Table 3.2). A total of 12 scaffolds were tensile tested, 6
decellularized and 6 native. The average Young’s Modulus for the decellularized scaffold was
4.84 ± 1.91 MPa, whereas the average native modulus was 6.15 ± 2.63 MPa. These two groups
were found to be statistically similar, with a p-value of 0.173 (Figure 3.12). The decellularized
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material’s elastic modulus was smaller than that of ePTFE which on the scale of GPa. The yield
strength for decellularized vessels was 1.79 ± 0.786 MPa, versus a native value of 2.69 ± 1.23
MPa. When compared, the yield strength was statistically different between the groups with a pvalue of 0.015 (Figure 3.13).
Table 3.2. Summary of the Average and Standard Deviation of Young’s Modulus and Yield
Strength (n = 6).
Treatment

Avg Young's
(MPa)

Stdev Young's
(MPa)

Avg Yield
Strength (MPa)

Stdev Yield
Strength (MPa)

Native

6.1553

2.6327

2.6901

1.2301

Decellularized

4.8463

1.9158

1.7997

0.78699

Young's Modulus Comparison of Native vs Decellularized Scaffolds
9

Young's Modulus (MPa)

8
7
6
5
4
3
2
Native

Decellularized

Figure 3.12. The Young’s modulus of native and decellularized vessels. Not statistically
different (p = 0.173, n = 6).
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Criticial Yield Comparison of Native vs Decellularized Scaffolds
5

Critical Yeild (Mpa)

4

*

3

2

1
Native

Decellularized

Figure 3.13. Comparison of the critical yield for native and decellularized scaffolds. Found to
be statistically different (p-value = 0.015, n = 6).
3.3.2.2 Burst Pressure Evaluation
The burst pressure for native and decellularized arteries is summarized in Table 3.3. A
total of 2 scaffolds were evaluated, one decellularized and one native. Literature regarding the
burst pressure for native arteries have reported the burst pressure to average 3124 mmHg and the
burst pressure for decellularized vessels at 2338 mmHg (71). Several scaffolds failed to reach
higher pressures because of holes in the graft or poor suturing onto the barbs, and are not
included in the reported data. When the scaffold broke, it appeared to tear longitudinally. The
literature describes an acceptable burst pressure for a decellularized scaffold to be at least 2,000
mmHg (71).
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Table 3.3. Summary of Experimental Burst Pressures.
Treatment

Burst Pressure

Control

2197.38 mmHg

Decellularized

1848.43 mmHg

3.3.3 Biological Evaluation
Figure 3.14, displays the bacterial content of the native and decellularized scaffolds after
12 hours of incubation. Images C and D from Figure 3.14 were the native samples, which have
no bacterial colony growth. The decellularized samples in A and B had significant
contamination, even in the presence of penstrep. Figure 3.15 shows samples that were placed in
the LB broth, where a cloudy liquid indicates a contamination. Tubes 1 and 2 were
decellularized samples and 3 and 4 are native samples; tubes 2 and 4 contained penstrep. The
first 3 tubes were cloudy and contaminated, only the 4th tube was clear (the native with penstrep).
These results indicate harvesting had some contamination, but the penstrep was potent enough to
reduce the spread of bacteria. The contamination in both of the decellularized samples indicated
the decellularization process was not performed sterilely.
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Figure 3.14. The TSA plate bacterial culture. A and B are decellularized tissues, C and D are
native tissues. B and D received penstrep. Dots indicated bacterial colony formation.
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Figure 3.15. Broth culture, from left to right 1 to 3 are contaminated and 4 is not. Tubes 1 and 2
were decellularized samples. Tubes 3 and 4 were native samples. Tube 4 was treated with
penstrep. Cloudiness indicates the presence of bacterial contamination.
3.4 Discussion
3.4.1 Structural Evaluation
As seen in Chapter 2, the SDS treatment for decellularization was successful and did not
have extreme effects on the structure of the scaffold. After H and E evaluation, the
decellularization treatment did not extensively degrade the scaffold. Specifically, the collagen
fibers appeared to remain intact, while the detergent successfully removed all cellular material;
these results coincide with results found in literature (63, 64, 71, 73). The literature indicates
that a change in the thickness of the scaffold is indicative of the decellularization process,
identified by a decrease in the wall thickness of the scaffold after being decellularized (71).
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However, in the decellularization process presented, the wall thickness appeared to increase
rather than decrease. Although the wall thickness was not measured in the data presented, visual
comparisons indicate an increase in overall vessel width. The change in thickness may possibly
occur from the lack of smooth muscle cells (SMCs) in the media of the vessel wall, causing the
structure to be more porous because there are fewer cellular bonds holding it together (73). The
media and adventitia have some separation, having the appearance of slight degradation, but is
considered superficial and caused by the release of fibroblasts from the connective tissue (64).
From the experiments presented, the scaffold remains wavy indicating that collagen fibers
remain in the scaffold (71). Although the increase in the wall thickness shows slight geometry
changes within the scaffold, the gaps are characteristic of SMCs leaving the scaffold and do not
seem to profoundly break-down the scaffold beyond recognition. Thus, the removal of cellular
components from a native scaffold using the protocol presented in Chapter 2, does not present
any drastic morphological complications.
Using the SEM to image the lumen of the scaffold reiterates the lack of drastic changes to
the scaffold wall. The decellularized scaffolds on a micro-scale were not degraded, and showed
no gaps, cells, or odd shapes. These images translate the cross-sectional views of the H and E
images into a longitudinal topographical image. Again the wavy lines indicate the collagen
fibers remaining intact, while the absence of small round cells embedded in the structure
supports the complete decellularization of the scaffold. From the SEM images, the scaffold also
appears to have a porous interconnected structure, which could encourage cellular adhesion if the
scaffold is to be re-cellularized. As a proof of concept, these images along with the visual
classifications of ‘Intact’ were indications that the decellularization treatment did not
significantly deteriorate the scaffold structure.

65

3.4.2 Mechanical Evaluation
3.4.2.1 Tensile Testing
The elastic modulus is useful for describing the elasticity of the scaffold. This
experimentation represents the biomechanical properties of a decellularized scaffold, thus having
implications about the physiological relevance post decellularization (71). Also, with the
construction of any new scaffold it is important to stringently evaluate all the properties to better
understand the scaffold and how it may potentially respond under various stresses (71). The
elastic, or Young’s Modulus, was found to have no statistical difference between the control
vesssl and the decellularized scaffolds. However, the modulus for decellularized scaffolds
showed a trend of being lower than the control. A lower elastic modulus implies the scaffold is
more elastic, most likely due to a lack of cellular bonds that promote a firm structure. This trend
was supported in the literature and is summarized in Table 8 (65, 71, 73, 74). However, it is
difficult to compare all tensile testing methods. There are several apparatuses for tensile testing
and all of them have different clamping and pulling methods. Even the way the sample is cut
and prepared for testing varies between the published literature. While the results do follow
similar trends, direct comparisons should not be made. Also, pig arteries are found to be more
than three times as elastic as human arteries, and as such are not clinically translatable (75).
The yield strength is the measurement of the stiffness of a material. This measurement
occurs at the transition between elastic deformation and plastic deformation (70). The stiffness
was statistically decreased for the decellularized treatments versus the control, indicating the
decellularized sample is stiffer. A stiffer material post decellularization was also suggested
throughout the literature (Table 3.4). Thus, the decellularization treatment has no effect on the
elasticity of the scaffold, but is more likely to reach plastic deformation before a native artery.
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3.4.2.2 Burst Pressure Evaluation
Burst pressure provides information about the radial stress on the scaffold. Radial stress
is related to compliance, which is described by the pressure per cross-sectional area (71). If the
compliance is low in the scaffold, as in ePTFE, the stresses will be harsher because the scaffold
does not have the capacity to dynamically react to the fluid flow (which is very dynamic in a
physiological setting). There was some difficulty testing for burst pressure on decellularized
arteries because during the harvesting and clean up processes, some of the scaffolds were
compromised. Small nicks occurred from the razor blades or scissors when attempting to
remove the sample or connective tissue. These small nicks were exposed when the luminal
pressure was increased and thus the maximum stress was not able to be determined. Once an
uncompromised vessel was tested, the burst pressure was found to be similar to that found in
literature (Table 3.4).
Table 3.4. Summarized Averages Found in Literature (65, 71, 73, 74).

Average

Yield
Strength
(MPa)

Young’s
Modulus
(MPa)

Burst (mmHg)

Contol

0.271

9.16

2338

Decellularization

0.812

7.19

3124

3.4.3 Biological Evaluation
Understanding the bacterial content in a scaffold that is difficult to sterilize is important
for understanding its potential use in cell culture assays or as a tissue engineered construct. The
decellularization process was not done in a sterile environment, and as such resulted in
contamination that could not be ameliorated with simple antibiotics. However, the harvesting
process was considered to be an aseptic procedure; contamination was minimal and a small dose
of penstrep sufficiently decreased the potential for contamination. Thus, by decellularizing the
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scaffold in sterile conditions and using a small dose of penstrep, an aseptic scaffold results for
use in the BVM. Although simple, this biological evaluation provides important information
regarding the scaffold and its potential use in the BVM; the scaffold in combination with a small
dose of penstrep should support cell viability.
In conclusion, the experiments presented in this Chapter examined the structural
integrity, mechanical, and biologic properties of the scaffold post decellularization. The
structural, mechanical, and biological examinations helped to better characterize the scaffold and
examined its physiological potential. All of these experiments suggest that the decellularization
treatment does not negatively harm the scaffold. Images provided visual conformation of the
lack of degradation within the scaffold, specifically compared to the native arteries. Mechanical
tests confirmed that the elasticity and stiffness of the decellularized scaffold were similar to a
native artery, which is important for its physical use. The biological evaluation illustrated the
amount of contamination sustained throughout the harvesting and decellularization process, and
suggested that using aseptic conditions for the decellularization process and a small does of
penstrep the scaffold will produce an aseptic scaffold. Since the scaffold is not affected by the
decellularization treatment, the scaffold remains relatively similar to a native artery; thus, the use
of a decellularized artery in the BVM model presents a relatively physiologic and appropriate
scaffold.
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Chapter 4 - Use of Decellularized Vessels in the Blood Vessel Mimic
4.1 Introduction
Chapters 2 and 3 of this thesis evaluated the potential to decellularize a porcine artery and
the resulting mechanical properties to understand if the scaffold could be implemented in the
BVM system. These experiments characterized several aspects of the scaffold to support the
potential for recellularization. A successful protocol for complete decellularization was
developed, ensuring that the native porcine cellular components were removed from the scaffold.
After decellularization, there was little damage sustained to the structural integrity of the scaffold
wall, where most of the components from the ECM were visually maintained. Furthermore, the
mechanical properties were evaluated to further characterize the remaining ECM components.
Mechanical testing revealed that the decellularization treatment did not change the elastic
modulus or burst pressure of the scaffold. The scaffold was also evaluated for potential
contamination risks; some contaminations were identified, but the addition of 0.1% penstrep was
sufficient to alleviate potential contaminants. The results from these experiments provided
conclusive background to support the use of a decellularized porcine artery as a scaffold in the
BVM. The scaffold was considered similar to a native scaffold with the potential to house cells,
thus supporting the basic requirements needed to fulfill the goals of the BVM system. The next
step of characterization was to recellularize the scaffold and evaluated its ability to have a
monolayer of cells.
The recellularization process entailed the incorporation of cells into a decellularized graft,
thus completing the tissue engineering paradigm. The paradigm describes the combination of a
scaffold with cells to produce a ‘functional’ tissue (76). In this case, the decellularized artery
represented the scaffold by providing the support and essential structure of the tissue, while the
addition of cells provides natural biological cues, creating a ‘functional’ vessel. Cells have the
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capacity to communicate by the exchange of growth factors or through proteins, either expressed
or received, which results in various dynamic responses (77-79). Thus, with the addition of cells
to the scaffold, aids in integration with the body (or simulate a physiologic response in the invitro testing system). The decellularization process stripped the porcine of their native cells;
therefore the addition of new cells was considered a recellularization procedure. There are two
ways to recellularized, either by sodding or seeding. To seed a scaffold a small amount of cells
are placed in the graft and expected to proliferate to cover the scaffold (80). Seeding a scaffold
is typically a static procedure, encourages maximum cell retention within the scaffold. Sodding
is done by introducing an excessive number of cells on the scaffold and expecting a high
percentage to adhere, lowering the amount of proliferation needed (80). With a perfusion system
the stress on the cells can be severe and not conducive for cell adhesion or drastic cell
proliferation. Thus a sodding protocol was ideal for recellularization because the over
compensations of cells necessary to fill the scaffold. Sodding cells within a tubular scaffold was
accomplished by injecting cells into the lumen via pressure sodding.
The creation of an effective sodding protocol was one of the final stages in the
development, characterization, and implementation of a biological scaffold for the BVM. The
sodding protocols followed the work previously investigated by Dr. Kristen Cardinal utilizing
human vascular endothelial cells sodded into the lumen of an ePTFE scaffold to create an
endothelium (4). Once a sodding density was deemed reasonable for short term cultivation, the
scaffold was cultured for longer time points. Equally important to the recellularization process
was the use of a bioreactor, which housed the scaffold and allowed tissue cultivation. A
bioreactor served as a sterile containment device to culture the scaffold; it supplied the external
environment to the scaffold by accounting for the physiologic flow, gaseous exchange, and
culture for the scaffold and cells. For the BVM, the bioreactor consisted of a peristaltic pump, a
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media reservoir, a ‘glad ware’ type vessel chamber, and surgical grade tubing (Figure 4.1). The
bioreactor, which has been developed through previous student projects, was imperative to
recreating a physiologic environment (81).

Figure 4.1. Model of the bioreactor setup for the BVM system. Closed loop containing:
Peristalitic pump (A), media reserivor (B), housing(C), and tubing(D). Top depicts the actual setup. Bottom is a solidworks generated image.
A variety of cell types were used to develop the recellularization process for a
decellularized scaffold. Preliminary work utilized 3T3 fibroblasts for information regarding the
ideal sodding density, the toxicity of the scaffold, the protocol for sodding, and the cell density
and distribution throughout the length of the scaffold. The 3T3 fibroblasts were ideal for this
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work because they are an immortalized cell type, making them relatively inexpensive for
preliminary work. For physiologically relevant work, human umbilical vein smooth muscle cells
(hUVSMCs) and human umbilical vein endothelial cells (hUVECs) were utilized. The
hUVSMCs comprise the main natural cell type in the media of an artery, while hUVECs make
up the endothelium. This chapter will describe the results of sodding the different cell types onto
the decellularized scaffold to effectively mimic a native artery.
4.2 Methods
4.2.1 Short-Term Cultivation – Trial 1
Initial work for recellularizing the scaffold began with determination of the optimal
cellular sodding density in order to create a continuous monolayer on the lumen of the scaffold.
The short term experiments, lasting 1-12 hours, examined the optimal sodding density for a
decellularized scaffold and subsequently the potential toxicity of the scaffold from the SDS
solution. The optimal sodding density will coat the lumen with a single layer of cells
consistently throughout the length of the vessel as well as around the circumference of the
lumen. Cells should be dispersed thinly and evenly throughout the scaffold limiting cell clumps
while promoting cell integration and adhesion. The preliminary work for a sodding density and
protocol was based on previous work done by Dr. Cardinal, where a similar sized scaffold and
BVM configuration was utilized (4).
Dr. Cardinal’s original protocol for sodding the scaffold in Appendix B: B.10, used a
scaffold approximately 3 to 4 mm inner diameter, 4.5cm in length, and sodded at a density of
5x105 cells per cm2. The previous work was modified for sodding the decellularized scaffold,
mainly regarding scaffold preparation and media used. Additional steps were also added to
account for the decellularization of the scaffold. These modifications are described in Appendix
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AB: B.11; note the scaffold dimensions as well as the sodding density did not change from the
previous work.
For initial experiments, 3T3 fibroblasts were expanded to obtain approximately 10
million cells per scaffold. The native porcine artery was decellularized following the methods
from Appendix B: B.3. The decellularized scaffold was cut to approximately 3 cm in length with
an inner diameter of 3 to 4 mm. The scaffold was sutured to the male barbs and luer locked into
the bioreactor. The scaffold was perfused, using a syringe, with culture media to remove all
bubbles from the scaffold. The 3T3 cells were tryspinsized to a cells into suspension, and the
cell solution, approximately 10 million cells, was perfused using transmural flow into the
proximal portion of the scaffold. Transmural pressure sodding ensures the cells are pushed into
the pores of the scaffold. An additional bolus of media was transmurally perfused through the
scaffold to push all cells remaining in the lumen into the scaffold wall. Transmural flow was
continued using an 8 roller (model 7519-25 Cole Parmer) peristaltic pump (Model 7523-60 Cole
Parmer Master Flex L/S) at a slow, steady rate of 10 rpm (0.5 ml/min) providing continuous
pressure on the scaffold wall. The transmural pressure pushes the cells into the scaffold
encouraging cell adhesion and a high yield of cellular attachment.
After 1 hour, the scaffold was carefully cut from the barbs in the bioreactor using a razor
blade. Extreme care was taken to not compress or jar the scaffold as to prevent accidental
removal of cells. Once removed, the scaffold was placed in histochoice for approximately 30
mintues to cross-link the structure. Scissors were then used to cut the scaffold longitudinally
creating 2 hemispheres and exposing the lumen for examination, again extreme care was taken to
keep the sodded cells intact (Figure 4.2). The scaffold was stained with bisbenzimide (BBI, a
Hoechst Stain Kit, St Louis, MO), which fluorescently labels the DNA in each cell to visualize
individual cells on the surface of the lumen (protocol Appendix B: B.12). Images were taken
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from the proximal side (where flow originates from) to the distal side on both the top and bottom
of the scaffold. Cell density and consistency was evaluated for each of the images by counting
the number of cells on the scaffold. The counting method used five 1 mm2 squares were drawn
on each image and then the cells within each square were counted. The average number of cells
on each image was used to determine if the sodding protocol and cell density effective created a
monolayer of cells. All scaffolds were imaged at 10x on an Olympus BX41 Fluorescence
Microscope.
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Figure 4.2. Longitudinal cut of the recellularized scaffold. Images were taken from
proximal to distal edges to visualize cell consistency.
4.2.2 Long-Term Cultivation – Trial 2
The BVM is intended to evaluate intravascular devices which require extended culture
duration. Thus, the scaffold must be tested for its ability to remain in culture for longer than 12
hours. Ideally, long term culture of the cells on a tubular scaffold should result in the production
of a nearly continious cellular monolayer and mimic a native artery. Therefore, in addition to a
long term culture, a more physiologic cell type was utilized to recreate the cellular layers of a
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native artery. hUVSMCs may be used to populate the media of the vessel, while hUVECs would
be better suited to create the endothelium.
Trial 2, Experiment A - Human Umbilical Vein Smooth Muscle Cell Sodding A
HUVSMCs were the first physiologically relevant cell type to be sodded into the
scaffold. In addition to the new cell type it was also the first time performing a long-term
cultivation. Although hUVSMCs are not the prime cell type for effectively mimicking the
endothelium, however they contribute to the vascular wall and would be acceptable for
preliminary testing. The set up for long term cultivation followed similar procedures as short
term; only the cell culture media was HUVSMC specific, and the flow rate was slowly increased
over time to ultimately reach a near-physiologic flow rate (Appendix B: B.14). Three individual
scaffolds/systems were set up. Once each scaffold was sutured into the BVM and the systems
were connected to the 8 roller peristaltic pump, scaffolds were pressure sodded with
approximately 3.4 million cells per cm2 each (estimated 10 million cells per scaffold) with
transmural flow at 7 rpm for 1 hour (Figure 4.3).

Figure 4.3. A setup of decellularized scaffold with the peristaltic pump and BVM.
After the 1 hour of transmural flow, the tubing was unclamped and flow was continued
luminally at 10 rpm for one additional hour, after which flow was increased to 15 rpm over night
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(approximately 12 hours). The next day, the flow rate was increased by 10 rpm every 30
minutes until reaching 90 rpm. Once the flow rate reached 90 rpm (approximately 5 mL/min),
the BVM was monitored daily. Two of the scaffolds were cultured for 1 day, about 24 hours,
and the third scaffold was cultured for 5 days. The culture media was kept fresh by exchanging
old media for fresh media via the reservoir every 3 days. As previously described, extra care
was taken when detaching the scaffold to prevent accidental removal of cells. Once excised
from the BVM, the scaffold was placed into histochoice for approximately 30 min. Then the
scaffold was cut longitudinally (Figure 4.2) and stained with BBI. Images were taken from
proximal to distal sides of the scaffold following the direction of flow. BBI images were
evaluated for cell density and consistency along the length of the scaffold by counting five 1
mm2 areas. Comparing these counts across the length of the scaffold determined if the sodded
cell density successfully created a cellular monolayer along the lumen of the scaffold. All
scaffolds were imaged on an Olympus BX41 Fluorescence Microscope.
To learn more about the scaffold and the sodding procedure on a decellularized scaffold it
was deemed prudent to analyze all 3 of the scaffolds via sectioning and staining. The experiment
was repeated exactly as before with hUVSMCs sodded onto a decellularized scaffold at 3.4
million cells per cm2. The scaffold was again removed from the BVM and preserved in
histochoice for embedding in paraffin wax for histological analysis via H and E staining.
Sections of the scaffold were imaged on an Olympus BX41 Microscope. Images of the sections
were only analyzed for the presence and location of the cells throughout the scaffold.
Trial 2, Experiment B – Human Umbilical Vein Endothelial Cell Sodding
To produce the most ideal scaffold, it must contain the endothelial cell monolayer
naturally found on the lumen of an artery. HUVECs have been utilized in previous work to
effectively mimic the endothelium on ePTFE scaffolds and should provide similar results on a
76

decellularized scaffold (4). The successful culture of hUVECs on a decellularized scaffold
provided the final proof of concept that this scaffold can house cells on the lumen of the scaffold,
thus providing the necessary results to implement a decellularized scaffold as part of the BVM
model.
The decellularized scaffold was sodded and cultured similarly to the hUVSMCs in
Appendix B: B.14, but again different cell types and medias were used (Appendix B: B.15).
First, two porcine arteries were decellularized following the protocol from Appendix B: B.3.
The hUVECs were labeled prior to sodding with Cell Tracker Green. The hUVECs were
cultured to 90% confluency. Cells were stained with a 15 μM concentration of Cell Tracker
Green following the manufacturer’s protocol, this protocol and optimization is further explained
below in section: 4.2.3 Dual sodding Proof of Principle – Trial 3 (see Appendix B: B.16 for
exact staining protocol). The cells were trypsinized and pressure sodded onto two grafts, at
approximately 1.5 million cells per cm2. The sodding density was less than previously used
because an unanticipated increase of vessel length. After sodding, vessels were placed on a
peristaltic pump with transmural flow at 10 rpm for 1 hour. Then, flow was averted lumenally at
10 rpm for 24 hours, no increase in flow rate over time occurred to reduce shear stress on the
cells. The vessels were taken down by cutting them from the barbs using a blade. To image the
vessels a longitudinal cut was made creating 2 semi circular halves. The endothelium was
exposed for imaging from proximal to distal, as seen in Figure 4.2.
4.2.3 Dual Sodding Proof of Principle – Trial 3
The overarching purpose of this experiment was to develop a method to pressure sod two
different cell types onto a scaffold for the BVM using two different fluorescent cell trackers.
The concept of the cell tracker is to visually monitor a cell type as it migrates, divides or
interacts with other cells types using a wide field fluorescent microscope. This protocol aims to
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provide successful dual sodding (i.e. pressure sodding two different cell types onto the
vessel). Ultimately, it would be desirable to use both hUVSMCs and hUVECs to dual-sod
BVMs, therefore the goal of these experiments was to develop and test two cell tracker dyes for
concurrent use to assess a dual-stained BVM
Staining Protocol
The cell tracker dye was made following the manufacturers instructions. Two cell
trackers were utilized in this methodology: Cell Tracker Green CMFDA (5- Chloromethyl
Fluorescin Diacetate; Invitrogen; Carlsbad, CA) catalog number C 7025 and Cell Tracker Red
CMPX (Invitrogen; Carlsbad, CA) catalog number C34522. The stock solution was created by
adding high-quality DMSO (D8418, St Luis, MO) to the lyophilized dye product. 10.8μL of
DMSO was added to the 50μg vial of cell tracker to produce a 10mM concentration of stock
solution. The stock solution was then diluted with serum free media to a concentration ranging
from 0.5 to 20μM (this work shows a 5μM concentration, but other concentrations are
characterized below in the graph), this was the working solution. Differences in concentration
depend upon the specific cell type and application of the cells. Higher concentrations are used
for cells which will go through several population doublings or for longer durations prior to
imaging. Lower concentrations of the working solutions can be utilized for less proliferative
cells or for short term experiments. Once the working solutions were made, the general dying
process was preformed as described below.
The cell culture media in a flask of cells was removed and the cell tracker working
solution was added in a volume to cover the total surface area of the cell culture flask. The Cell
Tracker Green working solution incubated for 30 minutes, while the Cell Tracker Red working
solution was incubated for 15 minutes, timing differences based on the lower range suggested by
the manufacturers protocol. Then the cell tracker working solution was aspirated from each of
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the culture flasks and replaced with the normal cell media for that culture. The cell culture
media was incubated on the dyed cells for at least 30 minutes cells prior to use. The cell culture
was then imaged on an Olympus BX41 microscope; the green dyed cells were excited at 488 nm
and with an emission at 520 nm (turret 4, S1, filter wheel one on 3, and filter wheel two on 2),
where red cells were excited at 587 nm and had an emission at 615 nm (turret 4, S1, filter wheel
one on 4, and filter wheel two on 3). The protocol for using cell tracker dyes to stain cells is
summarized in Appendix B: B.16.
Trial 3, Experiment 1 – Optimization of Cell Tracker Green Concentration
The purpose of experiment 1 was to determine the ideal concentration for the working
solution, with the goal of using moderately proliferative cells for one-week duration. The cell
type used in this experiment was 3T3 fibroblasts in order to gain a sufficient amount of
knowledge about the dye, while minimizing costs. The fibroblasts were cultured to 90%
confluency in a 6-well plate. Each well had a different concentration of the working solution of
Cell Tracker Green added; the concentrations were 0.5, 1.0, 5.0, 10.0, 15.0, and 20.0μM. The
previously mentioned staining methods were followed to dye the cells. These cells were
examined and imaged every other day for one week, assessing the changes in intensity.
Trial 3, Experiment 2 – Cell Tracker Green with Trypsin
The purpose of experiment 2 was to examine the effects of trypsin on the cell tracker dye.
Trypsin is a harsh enzyme that is necessary for cellular disassociation and the sodding process,
therefore it may affect the properties or intensity of the dye and needed to be evaluated prior to
use in a sodding experiment. 3T3 fibroblast cells were cultured to 90% confluency and stained
with a 5.0μM concentration of Cell Tracker Green in a T75 culture flask following the
previously mentioned staining methods. Once stained, the cells were trypsinized to make a cell
solution. Then approximately 0.5 million cells were placed in each well of a six-well plate.
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Cells were left in the six-well plate overnight (14 hours) to allow for cell adhesion. Cells were
then imaged and the intensity of the Cell Tracker Green was assessed.
Trial 3, Experiment 3 – Cell Tracker Green and Red in Co-Culture
The purpose of experiment 3 was to evaluate the ability of two different cell trackers to
be used together. This was a proof of concept for the potential use of two cell trackers for
analysis of a dual sodded vessel. Two T75 flasks of 3T3 fibroblasts were cultured to 90%
confluency. One T75 was dyed with Cell Tracker Red, and the other T75 was dyed with Cell
Tracker Green both at a concentration of 5μM, following the previously described staining
methods. Once dyed, the cell cultures were trypsinized and placed into a six-well plate. The
six-well plate contained two wells of Cell Tracker Green alone, two wells of Cell Tracker Red
alone, and two wells containing a combination of cells with both cell trackers, as seen in Figure
4.4. There was approximately 0.5 million cells per well, and the cells were left for 14 hours to
adhere for better imaging. Cells were imaged to analyze their interaction. The trials done
throughout this Chapter are summarized below in Table 4.1.
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Figure 4.4. This image represents the six-well plates used in experiment 3. The dyes are
represented by the colors, left is Cell Tracker Green, center is Cell Tracker Red, and right is the
combination of Cell Tracker Green and Red.
Table 4.1. Summary of Experiments From This Chapter.
Duration
1 hour

Analysis
BBI

Trial 2

Cell Type
3T3
HUVSMC and
HUVEC

1-3 Days

BBI and H/E

Trial 3

3T3

1 Day

Cell Tracker Green

Experiment A
Experiment B

HUVSMC
HUVEC

1-5 Days
1 Day

BBI and H/E
Cell Tracker Green

Trial 1

Experiment 1

3T3

1 week

Optimization of Cell
Tracker Green
Concentration

Experiment 2

3T3

1 hour

Cell Tracker Green
with Trypsin

Experiment 3

3T3

1 day

Cell Tracker Red and
Green Co-Culture
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Sub Experiments
None
Experiments A and
B
Experiments 1,2,
and 3

4.2.4 Analyzing Images
Counting the cells
To quickly count cell numbers, an imaging program was utilized (full detailed
instructions are in Appendix B: B.17). Images were opened and analyzed in the ‘Image J’
program. The image was made binary by going to Image, Color, split channels. This created
three images in grey scale labeled red, green, and blue. The green labeled images in grey scale
were selected. Next, by selecting Image, Adjust, and Threshold the image was changed to black
and white where black represents the most intense parts of the image (press dark background
making the highlighted cells black). To tabulate the average area of each cell and the number of
cells in the image select Analyze, Analyze Particles. A screen emerges asking for specificity of
the Size, Circularity. The size describes the range of pixels that must be found together to be
counted as a ‘cell’. The formula for circularity is given by equation 4.1.
 Area 
circularity  4π
2 
 Perimeter 

Equation 4.1

A value of 1.0 indicates a perfect circle. For green images the size should be “20Infinity” and circularity should be “0.00-1.00”. For red images the size should be “300-Infinity”
and circularity should be “0.50-1.00”. This effectively counts all the cells within the image. It is
important to note that the Cell Tracker Red dye was not optimized for the ideal concentration,
therefore the concentration used was saturated and the stains appeared spotted throughout the
cytoplasm of the cell. The lack of optimization for Cell Tracker Red explanations the change
required in analysis settings. In future experiments, Trial 3 - Experiment 1 should be repeated
for the Cell Tracker Red dye to determine the ideal concentration of dye that produces similar
visual results within the cell as the Cell Tracker Green Dye.
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To determine the cells per cm2 a Ronchi ruling was used to calibrate the pixels of the
image. An image of the calibration slide was taken at the same magnification where vertical
lines were the focal point of the image. By counting how many lines (through the use of cell
counter processing tool in Image J) span the width of the image, a ratio can be found to
determine the total surface area of the image. To calculate the size of one edge of an image is as
follows (Figure 4.5 for visual descriptions). In this case the numbers of pixels are seen in the top
left corner. The first number represents the number of pixels on the x-axis, which is 1392. 135
vertical lines were counted (Figure 4.5) and using equation 4.2, the x–length was calculated
using. Then equation 4.3 was used to calculate the y-length. These two numbers were then
multiplied together to calculate the area of the images.
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Figure 4.5. Top is a representative image of a Ronchi ruling. Bottom is the actual image of a
Ronchi ruling, although faint, the vertical lines are the incremental measurements.
Number of Vertical Lines
 the length of that side
Number of Pixels in the x direction
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Equation 4.2

Example 1: 135 vertical lines at 1392 pixles.
135
 0.9mm
1392

The ratio calculation can be seen as follows, where x is the length the other side:
Length of side 1
x

Pixels on side 1 Pixels on side 2

Equation 4.3

Example 2: Known side is 0.9mm on 1392, the other side has 1040 pixels.
.9mm
x

 x  0.67 mm
1392 pixels 1040 pixels
Once each side of the image has a calculated length, the sides can be multiplied together
to find the surface area of the image (detailed protocol for counting is in Appendix B: B.17). By
calculating the surface area of the image and count the number of cells within that image, the
cells per cm2 in the scaffold was determined.
Calculating the Intensity of the Image
The intensity of the image was calculated in order to compare the effectiveness of the dye
to remain in the cell through time and proliferation. The dye will photobleach and fade with time
and excess exposure to light, thus measuring the intensity describes any changes within the dyed
cells. Images were opened and analyzed in the ‘Image J’ program. The images were made
binary by selecting Image, Color, split channels. This created three images in grey scale labeled
red, green, and blue select and the color of the image was selected. Then, the circular button, on
the tool bar was clicked. This tool was used to circle a single cell on the image, allowing
analysis of the intensity for that part of a given cell. Once one cell was highlighted Analyze,
Histogram was selected. The histogram provided a mean number, which represented the mean
intensity of the area circled. This process was repeated for five cells in the image and the
numbers were averaged to get the relative intensity of all the cells (Appendix B: B.17). By
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determining the relative intensity, combined with the surface area, it was possible to count the
cells and examine the ability to retain the Cell Tracker Dye within the cells.
4.3 Results
4.3.1 Short-Term Cultivation – Trial 1
Short term cultivation provided a proof of concept regarding the sodding procedures,
specifically investigating the cellular density and consistency along the length of the scaffold.
Short term cultivation from Trial 1 included pressure sodding 3T3 fibroblasts followed by
transmural flow for 1 hour. Cell density and consistency were determined based on a square
counting method (Figure 4.6). The average number of cells from the 1 cm2 squares for each
image was used to compare the cell density throughout the length of the scaffold (Table 4.2 The
Quantitative Characterization of the 3T3 Fibroblasts on the Scaffold – Trial 1). After 1 hour of
cultivation about 1.6x105 cells/cm2 of the original 3.5 million cells/cm2. This remaining density
was consistent on top and bottom from proximal to distal and was assumed to be a monolayer of
cells on the scaffold as compared to densities found throughout literature, 2 x105 to 6 x 106
cells/cm2 was found to effectively create a monolayer of cells on several surface types (with
hUVECs) (82-86).
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Figure 4.6. Trial 1 with 3T3 fibroblasts sodded. The top of a sodded scaffold (A) and is the
bottom of the sodded scaffold (B). The boxes represent the 1 mm2 section of cells that were
counted.
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Table 4.2. The Quantitative Characterization of the 3T3 Fibroblasts on the Scaffold – Trial 1
Position
on the
Bottom Bottom Bottom Bottom Bottom
length
Box 1 Box 2 Box 3 Box 4 Box 5
of the
scaffold
25
16
26
8
19
A

Top Top Top Top Top
Avg Per Avg Per
Box Box Box Box Box
cm2
square
5
4
3
2
1
25

21

20

24

21

20.5

2.05x105

B

19

9

23

16

24

14

16

18

25

12

17.6

1.76x105

C

18

16

12

20

14

14

12

16

15

11

14.8

1.48x105

D

7

11

10

11

12

18

25

23

19

18

15.4

1.54x105

E

14

14

12

20

12

13

16

9

13

10

13.3

1.33x105

F

14

16

17

17

18

20

20

17

24

29

19.2

1.92x105

G

14

15

21

16

13

18

16

11

17

15

15.6

1.56x105

H

18

17

15

10

6

16

13

18

17

17

14.7

1.47x105

I

12

18

16

13

11

3

9

8

6

5

10.1

1.01x105

J

24

17

27

20

13

19

25

22

20

17

20.4

2.04x105

K

12

12

13

12

12

17

13

22

18

21

15.2

1.52x105

Average 1.60x105
4.3.2 Long-Term Cultivation – Trial 2
Trial 2, Experiment A - Human Umbilical Vein Smooth Muscle Cell Sodding
The scaffold sodded with hUVSMCs was taken down and stained with BBI following the
protocol from Appendix B: B11. No cells were visualized on the lumen of the scaffold, hence no
counting was performed (Figure 4.7).
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Figure 4.7. Trail 2, Experiment 1 with hUVSMC sodding. Top (A) and bottom (B).
After not visualizing any hUVSMCs using BBI staining, the experiment was redone and
the scaffold was embedded in paraffin wax for H and E staining. This basic staining enabled
easy visualization of the cell’s location post sodding. These images revealed that the hUVSMCs
migrated through the wall of the vessel and appeared to reside in the adventia (Figure 4.8).

Figure 4.8. Trial 2, Experiment A - H and E staining. Top (A) and bottom (B), the cells are
indicated by the arrows.
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Trial 2, Experiment B – Human Umbilical Vein Endothelial Cell Sodding
Experiment B assessed the ability of the Cell Tracker Green dye to remain within
hUVECs following pressure sodding onto a decellularized porcine artery. Fluorescent cells were
observed on each of the two vessels when viewed using the Olympus BX41 wide field
fluorescent microscope. However, vessel A (Figure 4.9 A) displayed more even distribution of
cells throughout the length of the scaffold than vessel B (Figure 4.9 B). Figure 4.9 was imaged
following a 24-hour incubation period with initial transmural flow for 1-hour at 10 rpm followed
by luminal flow for 24-hours at 10 rpm. The decellularized porcine vessel A had a strong
disbursement of cells throughout the length, each retaining some degree of fluorescence, while
vessel B had a sparse distribution of cells throughout the vessel. The number of cells on each
vessel was determined and the results are displayed in Table 4.3. The information in Table 4.3
shows a greater average number of cells per cm2 on vessel A compared to vessel B. Averages of
the cell counts from at the proximal and distal ends of the vessel were taken to obtain an overall
average across the entire vessel. Despite the difference in distribution, the presence of cells on
each vessel suggesting the cell tracker remains within the cells during the pressure sodding
process. The difference in distribution is likely due to external set-up factors, rather than the
ability of the cell tracker; i.e. transmural pressure sodding did not occur properly.
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Figure 4.9. Trial 2, Experiment B sodded with hUVECs. Vessel A (A) and vessel B (B).
Table 4.3. Average Number of hUVECs on Each Vessel per cm2.
Cells/cm^2
Avg Vessel A top

1,785.12

Avg Vessel A bottom

21,652.89

Avg Vessel B top

1,421.49

Avg Vessel B bottom

2,876.03

TOTAL
Avg Vessel A

11,719.01

Avg Vessel B

2,148.76

4.3.3 Dual Soodding Proof of Principle – Trial 3
To evaluate the potential to dual sod a scaffold, two cell trackers were utilized to identify
each cell type. The cell tracker dye incorporates into the cytoplasm of the cell and will remain
with it for a short duration as the cell proliferates and migrates. Thus, multiple cell types may be
dyed during the separate culturing process and the dye will remaining in the respective cells once
they have been combined in a given application.
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Trial 3, Experiment 1 - Optimization of Cell Tracker Green Concentration
Experiment 1 demonstrated the optimal dilution of Cell Tracker Green for a consistent
and bright stain on the cells. Over the duration of seven days, the intensity of Cell Tracker Green
changed substantially at each concentration until the seventh day when each of the dilutions
reached an intensity lower than that at the start of the experiment (Figure 4.11). Note these times
and respective concentrations are based on the moderately proliferating 3T3 fibroblasts, and the
intensity may vary when the dye is applied to other cell types. The intensity of the cell tracker
was assessed by averaging the intensity of five different cells from each image using ImageJ
analysis software. Table 4.4 summarizes most intense, or brightest, concentration of dye at each
time point; 15μM retained the greatest intensity both at time zero and day 7; 20μM fluoresced
most intensely following 24 hours; 10μM remained the most intense concentration following a
five day period. These numbers suggest smaller dilutions of the original working solution result
in longer retention of fluorescence intensity. 15 μM retained the average greatest intensity over a
seven day duration.
300

Cell Tracker Green Intensity

Intensity

250

[.5μM]

200

[1μM]
[5μM]

150

[10μM]

100

[15μM]
[20μM]

50
0
0 Hours

24 Hours

5 Days

7 Days

Time

Figure 4.11. Cell Tracker Green intensity at various concentrations over a 7-day
duration.
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Table 4.4. Concentration for the Brightest Fluorescent Intensity.
Concentration
0 Hours

15μM

24 Hours

20μM

5 Days

10μM

7 Days

15μM

Trial 3, Experiment 2 - Cell Tracker Green with Trypsin
Experiment 2 demonstrated the effects of trypsinization on the cells stained with Cell
Tracker Green, to show the treatments to the cells would not affect the dye properties. The
number of cells that remained dyed in culture were post trypsinization counted using Image J. If
trypsin affects the capacity for a cell to retain the Cell Tracker Green dye, the number of cells
visualized will change. The two treatments were sodded with the same number of cells and
imaged, then the number of cells present were counted using Image J (see Table 4.5). Using a
two-sample t-test, the number of cells for each treatment were compared and the p-value was
determined to be p = 0.418, which is not statistically different (Figure 4.12). Thus, Cell Tracker
Green is not affected by the trypsinization process of cell culture and the dyed cells should not be
altered as they are prepared for sodding.
Table 4.5. 3T3s Visualized Pre and Post Trypsinization.
With Trypsin Cells/cm^2
17355.37
A
33223.14
B
47438.02
C
38181.82
D
30743.80
E

Without Trypsin
A
B
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Cells/cm^2
127777.78
50000.00

F

60330.58

Comparison of 3T3s dyed With Trypsin vs Without Trypsin
140000
120000

Cells/cm^2

100000
80000
60000
40000
20000
Without Trypsin

With Trypsin

Figure 4.12. Dyed 3T3 cells with and without trypsinization, p-value = 0.418.
Trial 3, Experiment 3 - Cell Tracker Green and Red in Co-Culture
Experiment 3, looked at the use of two different cell trackers in conjunction with one
another. Cell Tracker Green and Red were used to stain two separate cultures, then dyed cells
were combined to observe their interaction. Following combination of the dyed 3T3 cells, the
cultures were examined using the Olympus BX41 wide field fluorescent microscope and the
results are displayed in Figure 4.13. Each cell tracker fluoresced at its respective
excitation/emission energy (Figure 4.13a, 4.13b) and using ImageJ the images were overlayed
such that the entire picture was shown (Figure 4.13c). The overlayed image exhibits the
potential of using two separate cell trackers to track the final location of the stained cells. The
Cell Tracker Red dye looks spotty because it was oversaturated and began to particulate within
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the cytoplasm of the cell, as confirmed by the manufacturer. The red dye worked to identify the
cell, but was not as well incorporated into the cytoplasm.

A

B

C

Figure 4.13. Staining using Cell Tracker Green and Red. Cell Tracker Red (A), Cell Tracker
Green (B), and merged (C).
4.4 Discussion
The work summarized in this chapter examined the decellularized scaffold’s ability house
cells on its lumen. This was shown through the development of a sodding protocol with various
cells types, and progressively showed the feasibility of sodding physiological cell types into a
scaffold. These experiments created a monolayer of cells on the lumen of the scaffold and
fulfilled the goal of the BVM.
4.4.1 Short-Term Cultivation – Trial 1
Work began with the 3T3 fibroblasts in Trial 1, ‘Short-Term Cultivation’, to develop
sodding techniques and optimize cell density for the recellularization of a decellularized scaffold.
Utilizing this particular cell type was advantageous because of its availability and low cost.
Through these experiments imaging techniques, transmural sodding procedures, and BVM setup
techniques were developed and established for future experiments. Trial 1 provided further
characterization of the decellularized scaffold. A successful culture indicated cell adhesion was
possible post decellularization.
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Prior to developing an appropriate sodding process, as described in Trial 1, several
preliminary trials (described below) were performed to optimize the final sodding protocol used
throughout all experimentation. Skills such as sodding procedures, bioreactor set up, and
analysis techniques were integral to the development and implementation of a scaffold into the
BVM. These trials provided the ideal opportunity to practice and improve the techniques needed
to successfully sod a scaffold in the BVM. These early trials were not discussed earlier in the
methods or results, but were imperative to the development of the sodding procedures and worth
mentioning. Attempts 1, 2, and 3 were performed prior to any experiments described previously
as a way to learn about the BVM set-up, several lessons were learned and are summarized below.
All of the set up and analysis procedures were performed as previously described in Appendix B:
B.11, but as the techniques improved so did the results.
Early Fibroblast Trials – Initial Lessons Learned
Attempt 1 was the first bioreactor set up done with a decellularized scaffold, as well as
my first experience with the BVM. Although several mistakes were made, the lessons learned
were by far the most helpful. Attempt 1 intended to have transmural flow, but due to
unsuccessful clamping of the tubing, luminal flow occurred, causing a reduced potential for any
cellular adhesion from occurring. The analysis techniques in this experiment were also were
very poor, in that the scaffold was not properly handled. The BBI stain is normally diluted and
mixed vigorously prior to staining. In Attempt 1, the scaffold was vigorously shaken while
attempting to mix the BBI dye; this excess force potentially dislodged cells from the scaffold.
Ultimately, when the scaffold was imaged there were very few cells on the lumen.
Attempt 2 had a better set up after adapting to techniques learned from Attempt 1;
although in this experiment, more unexpected problems arose. The shake table, which is an
essential part of the decellularization process, broke at some point during the 20 hour procedure.
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This equipment is imperative to successful decellularization and unfortunately there was no
method to quickly assess if the scaffold had been properly decellularized. Attempt 2 went
forward as planned in order to continue to develop techniques and to utilize all prepared
materials. It would have been prudent to isolate a portion of the scaffold to embed for
hematoxylin and eosin staining as confirmation of decellularization prior to recellularization.
However, no section was isolated, because the scaffold was specifically measured to fit into the
BVM. The analysis of the scaffold still proved to be difficult as the set up of the Olympus BX41
Fluorescence Microscope was not mastered and the inappropriate color filter was used, resulting
in a green images. From this, a protocol was developed to ensure the proper set up and usage of
the scope (Appendix B: B.13). Attempt 2 resulted in images with cells sodded on the lumen, but
could not be trusted because of the unclear decellularization.
Finally, Attempt 3, referred to in this chapter as ‘Trial 1’, went according to plan and
followed the methodology that was described in detail earlier in the methods section. The
techniques learned previously from Attempts 1 and 2 helped to successfully perform acute
sodding with about 3.5 million cells per cm2 of 3T3 fibroblasts onto 2 scaffolds, following the
protocol from Appendix B: B.13. Table 4.6 summarizes many of the lessons learned through
these initial experiments.
Table 4.6 Skills Developed Through Experimentation with 3T3 Fibroblasts.
Attempt

1
2
3

Cell Type

Duration Lessons Learned
Ensure transmural flow by clamping
Make the BBI solution prior to staining the
Fibroblasts
1 hour
scaffold
Proper Decellularization
Fibroblasts
1 hour
Understanding the Fluorescent Scope
Fibroblasts
1 hour
Successful Trial!
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An additional limitation of this work was the cell count methodology. As described, the
method involved using 5 side-by-side boxes to count cells. The five side-by-side 1mm2 boxes
caused the counts to occur in only one populated area. To better define the cell density
throughout the length. Where as the boxes should have been randomly distributed throughout
the image and remain in consistent positions for every image. This may reduce any biased that
may occur during the counting process.
4.4.2 Long-Term Cultivation – Trial 2
Once the decellularized scaffold was utilized in the BVM and a successful sodding
procedure was established, the cell type was then changed to a physiologically relevant cell.
Work started with the hUVSMCs because they were slightly less expensive and would still
provide a vascularly relevant cell type for recellularization. All sodding procedures were
performed as done with Trial 1, ensuring transmural pressure sodding for maximum cell
adhesion. Each of these trials will be discussed below.
Trial 2, Experiment A – Human Umbilical Vein Smooth Muscle Cells
The culture of hUVSMCs in Experiment A was extended to a longer duration and as such
required modifications to the flow rate. Flow was moved from a transmural direction to a
luminal direction and the flow rate was slowly ramped up. The changes in flow rate, although
novel for a decellularized scaffold, had been successfully done with hUVECs on ePTFE
scaffolds (4). The result of trial 2 was not as expected, as the BBI analysis showed little to no
cells on the lumen of the scaffold. Before assumptions were made about problems the sodding
process, the trial was repeated and scaffolds were embedded in paraffin for histological analysis.
Once stained with H and E, a few of the hUVSMCs were visible in the adventia of the scaffold.
The cells seen were most likely components of cells that were not fully removed during the
decellularization process. The decellularized scaffold is highly water proof and the hUVSMCs
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would not have migrated through the entire scaffold. While this result was not ideal, it also
proposed many questions about the sodding process and if this scaffold could still be utilized in
the BVM.
After looking into the literature regarding sodding hUVSMCs into a scaffold, it was
concluded that these cells are difficult to pressure sod (87, 88). Some successful sodding
procedures for SMCs incorporated have been performed by seeding cells on the exterior of the
scaffold and allowing them to migrate in towards the endothelium (87, 88). SMCs are attracted
to the highly collagenaous media of the decellularized scaffold and are not able to adher to the
lumen (87). This migration process occurs because of the great force used during pressure
sodding, resulting in cells residing in the adventia of the scaffold or beyond the wall rather than
the media. Successful pressure sodding of hUVSMCs has been done, but on a fibronectin
scaffold with no porosity and thus cells were did not migrate through the vessel wall (89). Other
successful SMC incorporation was done by creating a sheet out of the SMCs, then the sheet is
formed into a tube and used as a scaffold (28). Thus, other successful methodologies exist to
introduce SMCs into a scaffold, but pressure sodding is not ideal. Future SMC sodding should
investigate a external sedding methods as done by Williams et al (88). Externally seeding will
allow the SMCs to slowly migrate into the media of the scaffold.
Trial 2, Experiment B – Human Umbilical Vein Endothelial Cells
To further evaluate the potential for the decellularized scaffold to be used in the BVM
and to continue to use a pressure sodding method, hUVECs were introduced to mimic the native
cellular monolayer on the lumen of an artery. Dr. Cardinal had previously established a protocol
for pressure sodding hUVECs into an ePTFE scaffold to create a consistent monolayer of cells
on the lumen. The combination of Dr. Cardinal’s established methods and the skills learned in
this Chapter resulted in the successful sodding of a decellularized scaffold with hUVECs. This
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cell type remained in the endothelium as a consistent monolayer of cells throughout the length
and inner circumference of the scaffold. Utilizing hUVECs to create an endothelium effectively
mimics a native artery, fulfilling the goal of the BVM.
The longer durations cultures were somewhat unsuccessful because a contamination
would generally occur approximately 12 hours post sodding. Contaminations were identified by
a change in the culture media, from pink to orange. The media was also slightly cloudy and had
a distinct smell; indicating a change in pH or a bacterial contamination. There were several
instances when the setup could have been contaminated. Although the setup process uses all
sterile equipment and instruments, a contamination from poor sterile technique is still always
possible. However, the scaffold never underwent a sterilization process and could retain some
bacteria that could not be controlled by the 1% penstrep in the media. These results suggest that
hUVECs can be sodded into the scaffold to create a monolayer of cells on the lumen of the
scaffold to effectively mimic the endothelium. Also, assuming that decellularizing with penstrep
will lower the occurrence of a contamination, meaning longer culture duration and greater
potential to fulfill the goals of the BVM.
4.4.3 Dual Sodding Proof of Principle
All of the dual staining experiments led to a proof of concept for the use of cell tracker
dyes in dual sodding of decellularized porcine vessel to create a physiologically relevant
scaffold. Use of this dye will lead to a promising analysis tool for dual sodded scaffolds. Not
only was this powerful analysis tool identify multiple cell types, but it could also be utilized in
real time imaging because the dying process was complete prior to sodding. Samples can be
imaged while they grow because the dye has integrated with the cell, for a limited duration.
Future work will further optimize the Cell Tracker Red concentrations as well as use both cell
trackers on a dual sodded scaffold.
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Overall, the work in this chapter provided important results relevant to the use of
decellularized vessels as scaffolds in the BVM. Table 4.7 summarizes the progression of the
recellularization experiments and reasons for support of the decellularized scaffold’s use. In
conclusion, the decellularized scaffold was successfully sodded and cultured with both 3T3
fibroblasts and hUVECs. With improved sterile decellularization and analysis techniques, the
decellularized scaffold has the potential to become a unique scaffold type for the BVM.
Table 4.7. Summary of the Results from Recellularization the Decellularized Scaffold.
Sub
Experiments

Cell Type

Duration

Analysis

1 hour

Trial 2

3T3
HUVSMC
and HUVEC

1-5 days

BBI
BBI, H/E, Cell Tracker
Green

Trial 3

3T3

1 Day

Cell Tracker Green

None
Experiments
A and B
Experiments
1,2, and 3

Exp. A
Exp. B

HUSMC
HUVEC

1-5 Days
1 Day

BBI and H/E
Cell Tracker Green

None
none

Unsuccessful
Successful

None

Successful
Successful
Successful and
Plausible for dual
sodding

Trial 1

Exp. 1

3T3

1 week

Optimization of Cell
Tracker Green
Concentration

Exp. 2

3T3

1 hour

Cell Tracker Green with
Trypsin

None

Exp. 3

3T3

1 day

Cell Tracker Red and
Green Co-Culture

None
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Results
Successful
Monolayer
See experiments A
and B
Successful

Chapter 5 - Discussion and Conclusions
5.1 Overview and Summary
Cardiovascular disease affects one in three Americans and in 2006 claimed the lives of an
estimated 17.1 million individuals around the world (90, 91). These statistics demonstrate the
growing need for the use and development of effective therapies to treat cardiovascular disease.
The evaluation of a stent and its function requires both in-vitro as well as in vivo testing. Bench
testing provides a controlled environment to test specific aspects such as device fatigue, proper
expansion, or mechanical strength of the stent (29). In-vitro testing also provides initial
screening of biocompatibility and cell interaction. In-vivo testing examines the effectiveness,
biodegradation, inflammatory response, or elution profiles in a living organism (29). The
combination of these testing modalities affords a more complete analysis of the stent and its
physiological interactions within the body. This research seeks to bridge the gap between invitro and in-vivo testing through the development of an in-vitro BVM to test intravascular
devices such as stents. This system provides an in-vitro model that represents a physiologic
system, while permitting high-throughput and cost-effective testing. This allows for multidimensional analysis of stents and other intravascular devices because the mimic reproduces a
simplistic living vessel in an in-vitro environment.
Currently, the BVM utilizes an ePTFE scaffold, which has been shown to support a
monolayer of endothelial cells, therefore demonstrating the ability to mimic the intima of a
native artery (4). The model provides a quick and repeatable testing modality for new
intravascular devices. As a material, ePTFE is biocompatible and dependable, but has several
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physiologic limitations. The polymer scaffold has little compliance and is devoid of any
biological components, which will alter the interactions between the device and scaffold wall
when compared to responses in vivo. To address the physiological limitations of the current
BVM scaffold, the development and implementation of a completely biological scaffold was
evaluated.
One option for creating a biologic scaffold is to decellularize an existing vessel.
Decellularization is a promising technique that can be utilized to remove cells from a tissue.
Several groups have found a multitude of uses for the ECM from a decellularized tissue. Some
have focused on using the decellularized scaffold for use in-vivo, due to the lack of donors and/or
viable tissues. Ott et al. applied decellularization to remove the cells from an entire rat heart and
were able to recellularize the heart to regain function by stimulated electronic pulse (48).
Schaner et al. decellularized whole arteries to investigate their potential for use in bypass surgery
(49). Other groups such as Singelyn et al. have utilized decellularized tissues to isolate the
complex combination of proteins that comprise the native ECM (51). New decellularization
techniques will continue to develop to become a unique source of biologic materials for specific
applications.
To improve the capabilities of the BVM, this thesis examined the potential use of a
decellularized artery as a more physiologically relevant scaffold type, when compared to current
synthetic polymers. Utilizing a decellularized scaffold provides several potential advantages
including maintenance of structural integrity (mechanical strength and compliance) and
incorporation of natural binding sites for cells (40, 44). This type of scaffold would create a
more physiologic in vitro testing modality and further bridge the gap between bench tests and in
vivo studies. The following summarizes the work performed in this thesis to develop and
implement the decellularized scaffold into the BVM.
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The work from Schaner et al. supported the use of a decellularized porcine artery as a
vascular scaffold and provided the basic methods for the decellularization protocol (49). The
first step of this thesis developed a decellularization protocol, utilizing SDS as a detergent to
remove all cellular bonds from porcine arteries in order to produce an acellular scaffold. After
numerous trials, the final decellularization protocol included a 0.075% SDS solution perfused
through the lumen of the vessel, while concurrently being shaken at 30 rpm for 20 hours.
Decellularization was evaluated by staining with H and E dyes, to visualize the nuclei and
cellular material within the vessel. The complete decellularization of an artery, as determined by
a lack of hemotoxylin-stained nuclei, produced a biological-acellular scaffold type. Furthermore,
the structure of the scaffold remained intact through the harsh SDS washing. The perfusion of
the SDS solution during decellularization (as opposed to shaking alone) was vital to ensure the
lumen of the scaffold was kept open for use in future experiments, such as tensile testing or burst
pressure testing. Before implementation into the BVM, the scaffold was examined for the
maintenance of structural integrity and mechanical properties.
To ensure the scaffold maintained its native characteristics post-processing, the structural
and mechanical properties were evaluated. These experiments conducted as a side by side
comparison between the decellularized scaffold and a native artery. Visual inspections of the
wall thickness for decellularized scaffolds were similar to that of native controls, indicating no
drastic changes to the structure. Tensile testing and burst pressure tests were also performed on
the scaffold post-decellularization. The scaffold was stretched longitudinally until broken to
evaluate its elastic modulus and yield strength via tensile testing. The resulting elastic modulus
was not statistically different from that of a native artery at about 4 MPa; whereas the yield
strength of the scaffold (1.7MPa) was significantly lower than the native artery (2.6 MPa).
Radial strength was tested via burst pressure analysis, where the scaffold was filled with water
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until it burst. The burst pressure was determined to be similar to a native artery found in
literature at 1600 mmHg (71). Mechanical properties indicated that the decellularized scaffold is
not significantly different than a native artery, thus providing a physiologically relevant scaffold
for use in the BVM. This scaffold can be used in several ways; for its ideal compliance when
evaluating stents, investigating drug eluting stents effects on the vasculature, to explore new
imagine modalities and their ability to visualize several layers of an artery, and potentially to
model disease pathways such as restenosis.
Once the physical properties of the scaffold were evaluated, the scaffold’s capacity to
house cells was evaluated by pressure sodding cells into the lumen of the scaffold. Sodding 3T3
fibroblasts was a proof-of-concept to asses if cells could be distributed throughout the length of
the scaffold and were not harmed by the scaffold. Based on this success, more relevant cell
types were sodded to better mimic a native artery. Pressure sodding was not effective for
hUVSMC, as they prefer to adhere in a static environment where they slowly migrate into the
scaffold (87, 88). Whereas the hUVECs were pressure sodded and able to remain of the
scaffold. BBI and Cell Tracker Green staining were used to visualize the nuclei of the hUVECs
on the lumen of the scaffold post sodding. These results indicated that hUVECs were able to be
sodded to produce a monolayer of cells on the lumen of the scaffold, effectively mimicking a
native artery. In conclusion, the development of a decellularized scaffold created a biomemtic
material with the capacity to model and artery.
5.2 Challenges and Limitations
There are some key limitations to using a decellularized scaffold to model an artery.
Limitations include extensive contaminations, non-ideal mechanical testing methods, and poor
staining optimization. When the decellularized scaffold was used in the BVM for longer than 12
hours contaminations occurred. For example, in the first long term study with hUVSMCs, three
105

time points were to be examined (1, 3, and 5 days). After 12 hours of culture, two of the three
setups had to be stopped due to contaminations. After 36 hours of experimentation, the third set
up was taken down due to contamination once again. These losses severely altered the goal of
the experiment and resulted in a shorter evaluation time. Assuming this setup was performed
sterilely, the decellularized scaffolds were the only components that were not sterilized and
would be the source of contamination. If the BVM for the duration of the experiment, all longterm tests will be compromised, skewing the subsequent results.
The mechanical tests performed in this thesis did not evaluate the most relevant aspects
of the scaffold. Traditional tensile tests effectively examine elastic modulus and critical yield of
the material’s longitudinal strength; however this is not critical data. Although this test provided
useful background information, the decellularized scaffold is measured to fit within the BVM,
thus was not required to stretch longitudinally. In addition, the traditional methods require a
relatively flat material, two dimensional with only a small thickness. The scaffold is a tube and
needed to be cut longitudinally to fit the desired from. Altering the geometry, produces data that
doesn’t effectively mimic what occurs in the BVM. Ideally, more information about the radial
strength would provide more appropriate data. The radial strength is important during the
pressure sodding process as well as any interactions the scaffold with have with intravascular
devices.
Finally, to properly analyze a recellularized scaffold all dyes and analysis tools must be
optimized for proper identification of the structures within the culture. Specifically, the Cell
Tracker dyes utilized for the dual sodding proof of concept had to be optimized for the best use.
Cell Tracker Green was the main dye used and was properly optimized for the ideal
concentration. Once Cell Tracker Red was introduced, it was assumed it would function
similarly to the Green. However, the Cell Tracker Red dye resulted in spotty and inconsistent
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cell dying; although it had penetrated the cellular membrane, it was not evenly dispersed
throughout the cytoplasm. The dye was too concentrated, causing it to conglomerate; resulting
in a technically false representation of the cells. With further optimization of the Cell Tracker
Red, this crucial issue can be addressed and the stains will be consistent between the colors.

5.3 Future Work
Addition of Antibiotics: The primary isolation of the porcine arteries is not a sterile
process and the vessel was exposed to bacterial contaminants. Chapter 3 investigated the use of
antibiotics, penstrep, as a way to limit contamination. It was determined that one percent of
penstrep was sufficient to stop bacterial colonies from forming. This thesis utilized the antibiotic
only in culture media, during the final stages of the experiment. Theoretically if the scaffold is
exposed to antibiotics during multiple phases of experimentation, the exponential growth of
bacteria could be reduced. As seen in other work, the incorporation of 1% penstrep with 1%
SDS in the decellularization process may prevent contamination from occurring.(51).
Additionally, arteries are available for commercial purchase, and thus have a much smaller
amount of contamination with an increase in consistency (due to the high throughput more sterile
harvesting process).
Balloon Catheter for Burst Pressure: The burst pressure testing done in this thesis was
sufficient to provide a comparison between decellularized and native scaffolds. The burst
pressure was recorded at the moment before bursting at one point on the scaffold. This method
does not represent the overall radial compliance, but rather the critical strength of the scaffold.
To better investigate the radial compliance of the scaffold a balloon catheter can be inserted
inside the scaffold and filled to determine the pressure on the surface area of the lumen. The
resulting data will better represent the radial compliance throughout the scaffold. Evaluating the
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scaffold in this manner will not only improve the quality of the data, but also further demonstrate
the capacity of the BVM to test intravascular devices.
Radial Tensile Testing: The current tensile testing methods utilized in this thesis were
accurate to test the longitudinal strength of the scaffold, but were not relevant to the uses of the
scaffold in the BVM. The longitudinal strength is not imperative knowledge for use in the BVM
system, as the length of the scaffold was measured to fit rather than stretch. Modifying the
tensile testing apparatus could provide the elastic modulus and the critical yield in a radial
direction. Changing the ‘clamping’ mechanisms from a vice style to two rods, would allow the
scaffold to remain intact while still evaluating the elastic modulus and yield strength. The two
rods would be inserted into the lumen of the scaffold and pulled while remaining parallel to each
other. A modified tensile testing apparatus was suggested by Colby James, who also found
longitudinal elastic modulus relatively unhelpful. His thesis suggests the described
modifications to the tensile testing apparatus (92) – page 140, Figure 56. With a simple
modification of the current testing apparatus, more relevant data might be produced.
Optimize Cell Tracker Red: The optimal concentration of dye was determined for Cell
Tracker Green but not for Cell Tracker Red. Cell Tracker Red was too concentrated in the cell,
causing the dye to conglomerate and form spots within the cytoplasm rather than disperse evenly
throughout the cell. By investigating lower concentrations of Cell Tracker Red within the cells,
a concentration can be determined that will last during cell proliferation, while consistently dying
the cytoplasm of the cell. Investigating various concentrations of Cell Tracker Red can easily be
optimized to produce an accurate and consistent stain.
Dual Sodding the Scaffold: To develop the most physiologically relevant scaffold,
recellularizing the scaffold with two native cell types would better mimic the native artery. This
thesis sodded two cell types independently, but sodding two cell types together is plausible. The
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hUVSMCs should be externally sodded and given a chance to migrate into the media of the
scaffold, while hUVECs are luminaly pressure sodded. External sodding was used for
recellularization hUVSMCs and a potential method could be performed following the protocol
from Williams et al (88). Once the media of the scaffold has been recellularized with
hUVSMCs, the intima of the scaffold can be pressure sodded with hUVECs.
Translational Investigations: Although decellularizing an intact artery can produce a
scaffold to model an in vivo artery, the basic materials, or extracellular matrix, of the tissue can
be used to improve other scaffold models. Singelyn et al. decellularized tissues, then digested it
with pepsin and solubilized it to resulting in a temperature-responsive hydrogel (51). From this
research, it was found that collagens, laminin, and proteoglycans naturally found within a tissue
were retained throughout processing. Therefore, the solubilized decellularized material can be
used to coat a different scaffold type to improve the cellular adhesion properties and overall
culture. This theory was tested in Appendix D: Decellularized Coatings, where ePTFE scaffolds
were coated with solubilized decellularized porcine aorta ECM. The ability to use a
decellularized artery as a scaffold or as a coating to improve upon other scaffold types would
provide several potential uses for the decellularized material.
5.4 Conclusion
The in vitro BVM was developed to test intravascular devices and as such has a great
potential to be utilized for pre-clinical evaluations. Before this model is created, further
optimization of the current BVM system must be addressed. The current gold standard for the
BVM supports a polymer scaffold that is not physiologically representative of a native artery.
The development of a physiologically relevant tissue engineered blood vessel scaffold is critical
to the improvement of the BVM. A decellularized artery has the biomemtic properties necessary
to improve the physiological relevance of the BVM. In conclusion, this research provided the
109

documentation to support the potential for a decellularized porcine scaffold to be utilized as a
unique scaffold in the BVM.
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Appendix A – Abbreviations:
BAECs – Bovine Aortic Endothelial Cells
BVM – Blood Vessel Mimic
CABG – Coronary Artery Bypass Grafting
CAD – Coronary Artery Disease
CVD – Cardiovascular Disease
ECs – Endothelial Cells
ECM – Extracellular Matrix
ePTFE – Expanded Ploy(tetrafluroethylene)
HUMVECs – Human Umbilical Microvessel Endothelial Cells
HUVSMC – Human Umbilical Vein Smoot Muscle Cell
PGA – Polyglycolic Acid
PTFE – Polytetrafluorethylene
PAD – Peripheral Artery Disease
TEVG – Tissue Engineered Vascular Grafts
SEM – Scanning Election Microscope
SDS – Sodium doecyl Sulfate
SMCs – Smooth Muscle Cells
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Appendix B – Protocols and Experimental Details:
B.1 Determining the Optimal Concentration for Decellularizing Porcine Arteries:
Purpose:
To decellularize porcine arteries and optimize the decellularization process. Concentrations of
0%, 0.075%, 0.1%, and 0.125% SDS were evaluated for their ability to fully differentiate the
tissue.
Materials


Daigger orbital shake table (model SH 06050597)



10% liquid SDS



Several Clean 50 mL conicals



Razor blade



Milli-Q water



Sterile forceps



Histochoice

Decellularization Procedure:
1. Samples were removed from the -80°C freezer and placed in the 37°C water bath (make sure
the cap is screwed on tightly).
2. Once defrosted (in a malleable state), the vessel was cut with a razor blade. The vessel
sample was cut into 5 pieces about 5cm in length.
3. Samples were placed in individual 50mL tubes labeled with the proper corresponding sample
numbers.
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4. **Note: To mix the solution, all work should be done in the hood to keep all materials sterile.
Concentrations of 0%, 0.075%, 0.1%, and 0.125% sodium dodecyle sulfate (SDS)
deceullarization solution were measured.
a. A total volume of 20 mL of solution will be needed for the decellularization in a 50mL
tube. The SDS stock solution used is purchased as concentrated amount of 10% SDS in
Mill-Q. The various concentrations of SDS were calculated using the following
formulas:
Equation 1:
Final % SDS in solution (decimal form) * 20mL of total solution = The volume of a pure SDS solution

Equation 2:
The volume of pure SDS (from eqn 1)* 10 (dilution of SDS) = The volume of SDS to be used in the mix

Example calculation for .075% SDS in a 75mL of solution:
Equation1: 0.00075  20mL  0.015mL
Equation 2:

0.015mL/ 0.10  0.15mL of

10% SDS

For a 20mL SDS solution; 0.15mL of the SDS solution is added to 19.85mL of PBS water.
5. The tissues will remain on the bench top and not be placed in the hood.
6. 20mL of SDS solution at 0%, 0.075%, 0.1%, and 0.125% concentrations was poured into
their respective 50mL conical, along with the previously cut vessel sample.
7. The conicals were anchored to an orbital shake table.
8. The shake table was turned on to 100rpm to shake the tissues in solutions for 15 hours.
9. After 15 hours samples were removed from the shake table and the SDS solution was poured
down the drain.
10. The decellularized tissue was rinsed 5 times for 10 minutes with sterile PBS.
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a. Using sterile forceps, the decellularized tissue was transferred to a conical with 20 mL of
sterile PBS.
b. Samples were placed on the shake table for 10 minutes.
c. This process was repeated 5 times, for a total of 50 min and 5 rinse steps.
11. Decellularized tissues were transferred to a 15mL conical with 10-12mL of Histochoice. for
each sample. .
*Note: This is a dangerous material, be sure to use gloves and eye protection when pouring.
12. Samples were left in Histochoice overnight at room temperature allowing for fixation to
occur.
13. Fixed samples were embedded in paraffin wax blocks evaluated using hematoxylin and eosin
staining.
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B.2 Perfusion Decellularization:
Purpose:
To decellularize porcine vessels using a perfusion system to keep the lumen open.
Materials:


Daigger orbital shake table (model SH 06050597)



10% liquid SDS



Several Clean 50 mL conicals



Razor blade



Milli-Q water



Sterile forceps



Histochoice



Thermo Fisher Scientific Masterflex L/S 3 roller peristaltic pump (model 7519-05)



Male and Female luer lock barbs

Procedure:
Samples were kept in a -80°C freezer until you need to use them (no known time limit).
1. Samples were defrosted in a 37°C water bath. Samples were defrosted when the entire
sample was malleable and warm. If the sample is fresh, ignore this step.
2. Mix the .075% SDS deceullarization solution. The perfusion system uses a total of 75 mL of
solution. The SDS stock solution being used (Invitrogen Corporation’s catalog number
15553-027) is a concentrated amount of 10% SDS in PBS. The following formula will
obtain the volume of SDS in the solution:
Equation 1:
Desired % of SDS in the final solution (decimal form) * 75mL the total volume = the volume of a pure SDS solution

Equation 2:
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The volume of pure SDS (eqn1) / 0.10 (the percent dilution of SDS) = The volume of SDS needed to be used

Example calculation for 0.075% SDS in a 75mL of solution:
Equation1: 0 .00075  75mL  0.05625mL
Equation2: 0 .05625mL / 0.10  0.56mL of 10% SDS
For a 75mL solution, 0.56mL of the SDS solution is added to 74.4mL of PBS
water.
3. An end male lure lock barb that screws on to the 50mL tubes prepared with tubing was
located. The male lure lock barb was required to be the right size for the vessel lumen
diameter to fit over.
4. Samples were cut using a razor blade into sections approximately 5cm in length.
5. The proper lure lock barbs were then inserted into the lumen of the vessel and sutured tightly.
6. The barb and vessel were then screwed into place in the 50mL conical with tubing.
7. The tubing concial was placed on the peristaltic pump. The pump is set for fluid to be
pushed though the sample side of the tube.
8. The 50mL conical was filled with the 0.075% SDS solution.
9. The tubing was perfused to remove most of the bubbles. The sample needed to be
completely submerged in the SDS solution.
10. The pump was run at 140mL/min for 15 hours.
11. After 15 hours samples were removed from the shake table and the SDS solution was poured
down the drain.
12. The decellularized tissue was rinsed 5 times for 10 minutes with sterile PBS.


Using sterile forceps, the decellularized tissue was transferred to a conical with 20 mL of
sterile PBS.



Samples were placed on the shake table for 10 minutes.
125



This process was repeated 5 times, for a total of 50 min and 5 rinse steps.

13. Decellularized tissues were transferred to a 15mL conical with 10-12mL of Histochoice. for
each sample. .
*Note: This is a dangerous material, be sure to use gloves and eye protection when pouring.
14. Samples were left in Histochoice overnight at room temperature allowing for fixation to
occur.
15. Fixed samples were embedded in paraffin wax blocks evaluated using hematoxylin and eosin
staining.
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B.3 Final Perfusion Decellularization:
Purpose:
To decellularize porcine vessels using a perfusion system to keep the lumen open.
Materials:


Daigger orbital shake table (model SH 06050597)



10% liquid SDS



Several Clean 50 mL conicals



Razor blade



Milli-Q water



Sterile forceps



Histochoice



Thermo Fisher Scientific Masterflex L/S 3 roller peristaltic pump (model 7519-05)



Male and Female luer lock barbs

Procedure:
Samples were kept in a -80°C freezer until you need to use them (no time limit).
1. Samples were defrosted in a 37°C water bath. Samples were defrosted when the entire sample
was malleable and warm. If the sample is fresh, ignore this step.
2. Mix the .075% SDS deceullarization solution. The perfusion system uses a total of 75 mL of
solution. The SDS stock solution being used (Invitrogen Corporation’s catalog number
15553-027) is a concentrated amount of 10% SDS in PBS. The following formula will obtain
the volume of SDS in the solution:
Equation 1:
Desired % of SDS in the final solution (decimal form) * 75mL the total volume = the volume of a pure SDS solution

Equation 2:
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The volume of pure SDS (eqn1) / 0.10 (the percent dilution of SDS) = The volume of SDS needed to be used

Example calculation for 0.075% SDS in a 75mL of solution:
Equation1: 0 .00075  75mL  0.05625mL
Equation2: 0 .05625mL / 0.10  0.56mL of 10% SDS
For a 75mL solution, 0.56mL of the SDS solution is added to 74.4mL of PBS
water.
3. An end male lure lock barb that screws on to the 50mL tubes prepared with tubing was
located. The male lure lock barb was required to be the right size for the vessel lumen
diameter to fit over.
4. Samples were cut using a razor blade into sections approximately 5cm in length.
5. The proper lure lock barbs were then inserted into the lumen of the vessel and sutured tightly.
6. The barb and vessel were then screwed into place in the 50mL conical with tubing.
7. The tubing concial was placed on the peristaltic pump. The pump is set for fluid to be pushed
though the sample side of the tube.
8. The 50mL conical was filled with the 0.075% SDS solution.
9. The tubing was perfused to remove most of the bubbles. The sample needed to be completely
submerged in the SDS solution.
10. The pump was run at 20mL/min for 20 hours with the shake table at 30 rpm.
11. After 20 hours samples were removed from the shake table and the SDS solution was poured
down the drain.
12. The decellularized tissue was rinsed 5 times for 10 minutes with sterile PBS.
a. Using sterile forceps, the decellularized tissue was transferred to a conical with 20 mL of
sterile PBS.
b. Samples were placed on the shake table for 10 minutes.
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c. This process was repeated 5 times, for a total of 50 min and 5 rinse steps.
13. Decellularized tissues were transferred to a 15mL conical with 10-12mL of Histochoice. for
each sample. .
*Note: This is a dangerous material, be sure to use gloves and eye protection when pouring.
14. Samples were left in Histochoice overnight at room temperature allowing for fixation to
occur.
15. Fixed samples were embedded in paraffin wax blocks evaluated using hematoxylin and eosin
staining.
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B.4 Histological Staining:
Purpose:
To stain paraffin embedded section with hematoxylin and eosin for collagen and nuclei.
Methods:
Blocks were sectioned at 6μm and mounted on slides. Slides were placed in a slide rack and then
placed into glass dishes. Slides were dipped in the following order for the stated duration of
time.


3 min – xylene *Performed in fume hood*



3 min – xylene *Performed in fume hood*



3 min – xylene *Performed in fume hood*



2 min – 100% EtOH



2 min – 100% EtOH



2 min – 95% EtOH



1 min – air dry



4 min – Hematoxlin



1 min – Water Distilled



30 – 45 sec – Clearifier



1 min – Water Distilled



1 min – Bluing



1 min- Water Distilled



1 min – 95% ETOH



1 min 30 sec – Eosin



1 min - 100% EtOH



1 min - 100% EtOH
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1 min - 100% EtOH



3 min – xylene *Performed in fume hood*



3 min – xylene *Performed in fume hood*



3 min – xylene *Performed in fume hood*

While the slide rack remained in the last xylene dish, while each slide was individually pulled
out and cover slipped using mounting glue. Slides were left to dry for 48 hours.
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B.5 SEM Preparation:
Purpose:
To prepare the vessel scaffold for imaging with a scanning electron microscope.
Materials:


Gluteraldehyde



Distilled Water



Ethanol (at 25%, 50%, 70%, 95%, and 100%)

Methods:
1. Excise the sample from its given treatment
2. Place sample in the glutaraldehyde for at least 30 minutes
3. Rinse sample in distilled water 4 times
4. Place sample in 25% ethanol for 5 minutes
5. Place sample in 50% ethanol for 5 minutes
6. Place sample in 70% ethanol for 5 minutes
7. Place sample in 95% ethanol for 5 minutes
8. Place sample in 100% ethanol for 5 minutes
9. Let air dry
10. Mount the sample to a coverslip so that it as flat as possible. Double stick tape can be used
to adhere the sample to the coverslip.
11. Image with the SEM
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B.6 Tensile Testing Protocol:
Purpose:
To ensure all tensile tests are repeated in the same manner, in order to ensure reproducible results
Procedure:
1. Samples warm to room temp and not soaking wet.
2. Using the palm pilot tap on the “Inspect” icon
3. Prepare to load the sample:
a. Cut open the sample longitudinally
b. Measure the width of the sample (w)
c. Measure the thickness of the sample (t)
4. Load sample:
d. Place proximal end into the clamp that remains stationary.
e. Tighten the clamp on a small edge of the sample, clamp enough of the sample to hold it
in place
f. Repeat clamping process with the distal end into the movie clamp
i. Move the clamps into position, switch the machine into jog and in the direction
desired, until location is reached
5. Measure the gauge length. When the sample is taught (has some load), measure the gauge
length (the length between the two clamps) (lo).
6. Begin testing
g. Switch to toggle and the right direction
h. Push start on the palm pilot
i. Push the green button on the machine
7. Watch the palm pilot to reach a max load and look for the sample to break.
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8. Stop the palm pilot and push the green button on the machine.
9. A window to save will open on the palm pilot (save whatever name you wish.
10. Remove the sample by releasing the clamps and pulling the remains of the sample away.
11. Repeat for all samples.
12. To get the data off the palm pilot, first turn on the computer (password 4bmge).
13. On the palm pilot find the “Hot sync” icon, press on it. A new page will load, press the logo
in the center.
14. The computer will automatically begin to work (it will beep when done).
15. On the computer open the file “hand held” (this will covert the palm pilot data files into the
file type desired).
16. Make sure the Series XI is clicked on.
17. Open the file from the palm pilot.
18. Click on save as and determine a location that you want to save as. Save as a .txt file.
19. Then shut off the machine and put the palm pilot away.
20. Then use the tensile testing macro to determine the elastic modulus and the critical yield
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B.7 Burst Pressure Protocol:
Purpose:
To test the scaffold for its mechanical integrity post decellularization, with specific regard to the
radial compliance.
Materials:


Pressure Transducer



Data Acquisition software



Male and Female Barbs



Blood pressure arm cuff



Capped Male Luer

Procedure:
Calibration:
1. The blood pressure arm cuff was located
2. The pressure transducer was attached on either side of the tubing of the blood pressure cuff
3. The data acquisition software started recording (1)
4. The arrow just above the input for the data was clicked on and the bridge pod was selected.
5. The arm cuff was quickly pumped to the max pressure (remember this number)
6. Units was selected on the min and max screen
7. The lowest pressure seen was equal to zero
8. The highest pressure seen was equal to the max pressure from the arm cuff
9. ‘Ok’ was pressed several times for the calibration of the transducer
Set-up:
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Ordering: end piece => female piece that will to the sample => another fitting to the
sample and the male barb => transducer => fitting to transducer and tubing => tubing => stop
cock for syringe (seen in Figure B.1).
Testing:
1. Place the sample in between the fittings
2. Unlock the end cap
3. Connect the syringe and perfuse the lumen with fluid
4. Replace the end cap to the end
5. Begin recording
6. Slowly increase the pressure until the vessel bursts
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Figure B.1. Burst Pressure Images set up. Barbs and pressure transducer set up on a scaffold
(A). The syringe ready to apply force in the lumen of the scaffold (B). The connection with the
bridge pod and data acquisition connection (C). The completed set-up with all components (D).
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B.8 Bacterial Evaluation:
Purpose:
To test scaffold for bacterial content post harvesting and post decellularization. This will also
look at the potential for the Penicillin: Streptomycin, contained in cell culture media, to prevent
contamination
Materials:


Lysogeny Broth (LB)



Tryptic (Trypticase) Soy Agar plates



Glass beads



Penicillin:Streptomycin (Penstrep)



Sterile DCF-PBS

Methods:
1. Decellularize a vessel using the perfusion protocol in Appendix A.3
a. Cut the vessel sample in half: one part for decellularization and one part to be used as a
control
2. Place 1 mL of LB into test tube
3. Place sample into the test tube with LB
4. Vortex for 1 minute
5. Add penstrep to the desired plates to see if bacteria are resistant to the concentration of the
antibiotic used in the media.
a. Media contains 1% antibiotic
b. Agar is 15 mL volume
c. Add .15 mL of penstrep to the plate
6. Add glass beads
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7. Shake glass beads back and fourth in a crossing motion to move the penstrep solution around
the whole plate
8. Transfer the 0.1mL of the LB solution to the agar plate
9. Shake the beads again
10. Add 4 mL of brother to the LB tubes to increase the total volume to 5 mL (although 0.1 mL
was taken out for the agar plate, we assume the sample displaces about that much volume)
11. Add 0.05 mL (50 μL) of penstrep to the desired LB tubes to make a 1% solution of
antibiotics
Place samples (both agar plates and LB tubes) on an orbital shaker at 37°C for at least 12 hours.
Then evaluate the plates for the presence of bacterial colonies on the plate. For the broths,
evaluate the clarity of the liquids; where the more clear, the less bacteria.
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B.9 Tensile Test Evaluation:
Purpose:
To evaluate the raw date given by tensile testing
Methods – this is the Macro That is Run to Summarize the Tensile Testing Analysis:
‘Sub TensileTestMacro()’
'February 23, 2009'
k=0
d = InputBox ("How many tests would you like to analyze?")
If d > 3 Then
For k = 4 To d

'you didn't type in a number'

Worksheets.Add
Next
End If
For j = 1 To d
m=0
Max = 0
sumofx = 0
sumofy = 0
sumofxy = 0
sumofxx = 0
sumofxsquared = 0
Delta = 0
a=0
b=0
c=0
l=0
Filename = InputBox("Where is the location of the data file")
Name = InputBox("What test is this?")
a = InputBox("What is the gauge of the sample?")
b = InputBox("What is the width of the sample?")
c = InputBox("What is the thickness of the sample?")
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Worksheets(j).Name = Name

'you kept hitting cancel didn't you?'

Worksheets(Name).Cells(1, 1).Value = "Time"
Worksheets(Name).Cells(1, 2).Value = "Extension"
Worksheets(Name).Cells(1, 3).Value = "Load"
Worksheets(Name).Cells(1, 4).Value = "Strain"
Worksheets(Name).Cells(1, 5).Value = "Stress"
Worksheets(Name).Cells(1, 7).Value = "Linear Strain"
Worksheets(Name).Cells(1, 8).Value = "Linear Stress"
Worksheets(Name).Cells(1, 10).Value = "Critical/Yield Stress"
Worksheets(Name).Cells(1, 11).Value = "20% Yield Stress"
Worksheets(Name).Cells(1, 12).Value = "50% Yield Stress"
Worksheets(Name).Cells(1, 13).Value = "Slope"
Worksheets(Name).Cells(1, 14).Value = "y-intercept"

Open Filename For Input As #j 'Typed the filename wrong/file doesn't exist/you've already opened
it this session'
i=0
Do Until EOF(j)
Input #j, x, y
If i = 0 Or i = 1 Then
Worksheets(Name).Cells(i + 1, 1).Value = x
Worksheets(Name).Cells(i + 1, 1).Value = y
i=1+i
Else
If (x >= 0) And (y > 0) Then
i=i+1
Worksheets(Name).Cells(i - 1, 1).Value = (i - 2)

'need to delete the

Worksheets(Name).Cells(i - 1, 2).Value = y

'first two lines of

Worksheets(Name).Cells(i - 1, 3).Value = x

'the notepad file

Worksheets(Name).Cells(i - 1, 4).Value = y / a

'(only data points
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Worksheets(Name).Cells(i - 1, 5).Value = x / (b * c)
value into the size of the sample
t=y/a
u = x / (b * c)
If u > Max Then
Max = u
timestop = (i - 2)
End If
Worksheets(Name).Cells(2, 10).Value = Max
e = (0.2) * Max
f = (0.5) * Max
Worksheets(Name).Cells(2, 11).Value = e
Worksheets(Name).Cells(2, 12).Value = f
End If
End If
Loop
g=0
r=0
p=1
For m = 1 To (i - 2)
g=g+1
o = Worksheets(Name).Cells(g, 1).Value
h = Worksheets(Name).Cells(g, 5).Value
n = Worksheets(Name).Cells(g, 4).Value
If h >= e And h <= f And o <= timestop Then
p=p+1
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'no words) or you messed up typing a

Worksheets(Name).Select
Cells(g, 4).Select
Selection.Font.Bold = True
Cells(g, 5).Select
Selection.Font.Bold = True
Worksheets(Name).Cells(p, 7).Value = n
Worksheets(Name).Cells(p, 8).Value = h
End If
Next
Worksheets(Name).Cells(8, 1).Select
Charts.Add
With ActiveChart
.ChartType = xlXYScatterSmoothNoMarkers
.SetSourceData Source:=Sheets(Name).Range("D:E"), PlotBy:=xlColumns
.Location Where:=xlLocationAsObject, Name:=Name
End With
With ActiveChart
.HasTitle = True
.ChartTitle.Text = "Stress-Strain Curve"
.Axes(xlCategory, xlPrimary).HasTitle = True
.Axes(xlCategory, xlPrimary).AxisTitle.Characters.Text = "Strain"
.Axes(xlValue, xlPrimary).HasTitle = True
.Axes(xlValue, xlPrimary).AxisTitle.Characters.Text = "Stress"
.HasLegend = False
End With
Worksheets(Name).Cells(16, 6).Select
q=p-1
Charts.Add
With ActiveChart
.ChartType = xlXYScatter
.SetSourceData Source:=Sheets(Name).Range("G:H"), PlotBy:=xlColumns
.Location Where:=xlLocationAsObject, Name:=Name
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End With
With ActiveChart
.HasTitle = True
.ChartTitle.Text = "Linear Stress"
.Axes(xlCategory, xlPrimary).HasTitle = True
.Axes(xlCategory, xlPrimary).AxisTitle.Characters.Text = "Strain"
.Axes(xlValue, xlPrimary).HasTitle = True
.Axes(xlValue, xlPrimary).AxisTitle.Characters.Text = "Stress"
.HasLegend = False
End With
ActiveChart.SeriesCollection(1).Select
ActiveChart.SeriesCollection(1).Points(q).Select
ActiveChart.SeriesCollection(1).Trendlines.Add(Type:=xlLinear, Forward:=0, _
Backward:=0, DisplayEquation:=True, DisplayRSquared:=True).Select
Next
End Sub
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B.10 Original Sodding Protocol:
Purpose:
The purpose of this protocol was to sod an ePTFE scaffold with cells to create a
monolayer of cells throughout the length of the lumen.
Materials:


Blood Vessel Model setup



Cells to sod with



Conditioning, cell, and bioreactor Medias



Syringes



ePTFE scaffold

*** Please note, this work is based off of Dr. Cardinal’s original protocol for sodding a scaffold.
Some blanks are purposely left blank to be filled out and tailored to a specific experiment.
Procedure:
Prep 1 week prior
1. Gas sterilize biochambers and 2-port reservoirs
2. Determine target number of cells and passage schedule, then thaw cells
3. Cut grafts, mount on fittings, and suture
4. Autoclave grafts, flasks, and forceps
Prep the day before
5. Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
b. Conditioning Media (1:6 solution of FBS:M199 + antibiotics)
6. Denucleate grafts (using filtered EtOH)
a. 15 min 70% EtOH
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b. 15 min 100% EtOH
c. Leave in degassed Conditioning Media in incubator overnight
Set-up day: BVM conditioning
7. Warm up media (Bioreactor Media and Conditioning Media)
8. Fill chamber with media
9. Insert sterile grafts into biochambers
10. Using a syringe, flush lumen with Conditioning Media to prime graft
a. Clamp lumen and continue to prime graft
b. Repeat for all vessels
11. Place small WM pump in hood
12. Prime 2-port reservoirs with Conditioning Media
13. Attach primed biochamber to 2-port reservoir and condition graft for 10 min
a. Flow through lumen first to remove air, then clamp lumen and condition transmurally on
150rpm setting
14. Leave primed biochambers in large incubator until ready for sodding step
15. Prime 2-port reservoirs with Bioreactor Media
a. Prepare one for each vessel
b. Be sure that drip is visible and outlet is submerged
c. Clamp tubing and leave in big incubator
Set-up day: BVM sodding
16. Take corresponding number of primed biochambers and reservoirs to hood
17. Attach outlet of reservoir to inlet stopcock of biochamber
a. Leave reservoir inlet unattached and biochamber outlet facing trough
18. Record BVM numbers (or chamber ID):
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19. Harvest cells
a. Apply Trypsin, deactivate with media
b. Take 100uL from total _____mL cells
Counts:
20.

X=

x 2000 x (cell mL x .10)

total number of cells =
21. Pellet cell suspension (on 4 for 4 min)
22. Resuspend in _____mL Bioreactor Media
23. Sod each graft with ______mL cell solution
a. Cells per graft =
b. Sodding density =

cells/cm2

24. Chase with 1-3mL Bioreactor Media
25. Attach biochamber outlet to reservoir inlet
26. Bring BVMs to large incubator
27. Place on small WM pump - leave lumen clamped!!
28. Immediately begin transmural flow at 7rpm, and maintain for 1 hour
a. Started on pump at: ______ (time)
29. Unclamp lumen and maintain 7rpm luminal flow for 1 hour
30. Increase flow to 11rpm
31. Increase flow to 15rpm; leave overnight
The next day and beyond
32. Increase flow by 10-15rpm at a time to reach 90rpm by the end of the day
33. BVM maintenance: replace media reservoirs every 3rd day Check CO2!
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B.11 Acute 3T3 Sodding:
Procedure:
The purpose of this protocol was to develop a protocol for the sodding of a decellularized
scaffold with 3T3 fibroblasts.
Materials:


Blood Vessel Model setup



3T3 Fibroblasts



3T3 Fibroblast media



Syringes



Porcine scaffold

Procedure:
Prep 4 Days Prior
1. Set up cell passage schedule
a. Day 0: thaw the vial of fibroblasts (this case is with p8 cells) and put them into a T75
with 20 mL of fibroblast media
b. Day 1: Pass the fibroblasts 1:3 into a T225. The T225 is prepared with 36 ml of media.
To pass 3 mL of trypsin used to detach the cells and then 3 mL of fibroblast media.
c. Day 3: Will be time to isolate the cells. The cells will be centrifuged to make a pellet and
be used in sodding
2. Start the cells passage (day 0)
3. Pass the cells (day 1) into a T225
Prep the day before
4. Start decellularization (day 2), use the normal perfusion decellularization system
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a. Prior to the start of decellularization, suture the fittings to each end of the vessel
corresponding to how they need to fit into the BVM
Prep the day of
5. Stop decellularization and continue with the rinse process (day 3)
a. On the 4th rise start to warm up the fibroblast media
Harvest Cells
6. During the 5th rise (day 3)
a. Tryspinize cells with 9 mL of trypsin
b. Deactivate the trypsin with 9mL of fibroblast media
c. With the 18 mL, put it in a 50 mL conical
d. Put the conical into the centrifuge, and spin down for 4 min (on setting 4)
e. Fill the biochamber with Fibroblast media
f. Stop the rinse cycle
g. Put the vessel in the bioreactor, trying to keep it straight and fairly tight
h. Perfuse the system with fibroblast media (lumenally and transmurally)
i. Prime the media reservoir and the tubing with fibroblast media
j. Remove conical from centrifuge and pipette off all the media except the cell pellet
i. About 6 million cells were cultured
ii. Cells/cm2 = Total Number of Cells/Surface Area
k. Then add 4 mL of fibroblast media per scaffold to the conical
l. Mix the conical to break up the pellet and create a mixed, homogenous cell solution
m. Get two 10 mL syringes (one with 4 mL of fibroblast media and one with the 4 mL of the
cell solution)
n. Put a trough at the distal portion of the bioreactor
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o. Close off the distal luminal stop cock
p. Put the syringe of the cell solution on the proximal side- inserting into stopcock
q. Then inject cell solution through syringe
r. Then attach the syringe with the 4mL of media and flush transmurally as a chaser to force
the cells into the lumen of the vessel
7. Then attach the media reservoir tubing in line with the bioreactor
8. Put the bioreactor on the 8-roller pump
9. Set the flow at 10 rpm for 1 hour transmurally
10. To take down – cut the vessel out of the chamber, keeping track of proximal and distal ends
11. Put the vessel in the histochoice
12. Wait one day before cutting and getting ready for BBI
The next day and beyond
13. Cut a middle of the vessel into a thin cross-section
14. Cut the proximal and distal portions longitudinally into top and bottom
15. Put the samples into the BBI previously wrapped in foil because of its the light sensitivity
16. Image 3 sections on each part of the vessel along the lengths and around the cross-section
17. Count the number of cells per image
18. Process and embed the sample for histology
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B.12 Making the BBI Stain:
Purpose:
To image the cells after they have been sodded to quickly and easily identify the cell
density and consistency throughout the scaffold.
Materials:


Histochoice



Milli-Q



Bisbenzimide (BBI, a Hoechst Stain Kit 33258)

Procedure:
1) Put portions of scaffold in histochoice for 24 hours
a. ** Be careful to leave this as steady as possible as to not disrupt the cell adhesion
2) Make a solution of BBI (1:1000):
a. 30μL of BBI with 15 mL of Milli-Q
b. Mix well
c. Cover in Foil
3) Carefully move scaffold from histochoice to BBI solution
4) Incubate at room temperature for 30 min
5) Image
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B.13 Procedure for (BBI) Evaluation of Cell-Sodded Scaffolds:
Purpose:
To visualize cells on a scaffold
Methods:
1. Put on safety glasses. Cut samples with blade or scissors, being careful to not disrupt cell
lining inside lumen (squeezing, touching, and scraping can all disrupt lining and ruin
experiment).
2. Use washed forceps to place samples in corresponding 15-mL conicals that contain BBI
solution. Carefully keep track of samples. Leave foil on conicals.
a. Let samples soak for at least 15 minutes (longer is better).
3. Put away extra stock solution. Clean up preparation area.
4. With permission or help from Dr. Cardinal, use fluorescent microscope to obtain en face
images. Take forceps to use at microscope. See Figure A.2 for pictures of steps below.
a. Log into notebook (fluorescence; initials; date; time and lamp hours).
b. Turn turret to setting 4.
c. Turn on Olympus lamp (green switch).
d. Turn on Optiscan wheels (black switch).
e. Turn on camera (black switch).
f. Set filter wheel 1 to 1, and set filter wheel 2 to 1.
g. Open shutter:
h. Set Prior keypad to shutter S1.
i. Dial objectives to desired magnification (typically 4x and 10x for BBI images).
j. Set thin bar to icon of eye and camera.
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k. Sign into computer by clicking Kristen’s account (password can be obtained from
Kristen).
l. Click QCapture Pro (on desktop).
m. Click camera icon at top of QCapture Pro window:
n. Place slide on microscope. Place sample on slide.
o. See Figure A.3.
p. Manually adjust microscope to clarify image.
q. If scaffold is too wet, carefully blot end of scaffold on Kim wipe.
r. Take pictures. Save pictures if desired (labeled with sample info, initials, and
magnification).
s. Shut down system by switching off Olympus lamp, Optiscan wheels, and camera (on top
of microscope).
t. Log out of notebook.

e
a, t

j

g
d
c
b

i
p
f, h

Figure B.2. Microscope anatomy. Letters correspond to step 6 in protocol.
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First click Auto Set.
Type larger
number in mmm
blank for lighter
image and smaller
number for darker
image.
Click + to increase
size of image
window and – to
decrease size of
image window.

Figure B.3. QCapture Pro control panel.
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B.14 Long-Term Testing of Decellularized Vessels with hUVSMCs:
Purpose:
To test to see if the decellularized scaffold can house SMCs for a longer time frame. The
decellularized vessel will be sodded with SMCs for 1, 3, and 7 day time points. Hopefully the
vessel house the SMCs as the start to integrate with the scaffold wall and form as unique layer.
Materials:


Blood Vessel Model setup



Human Umbilical Vein Smooth Muscle Cells (hUVSMCs)



HUVSMC media



Syringes



Porcine scaffold



Vessel A: Length = 3.4 cm, Inner Diameter = 0.322 cm



Vessel B: Length = 3.4 cm, Inner Diameter = 0.429 cm



Vessel C = Length = 3.4 cm, Inner Diameter = 0.49 cm

Protocol:
Prep 1 week prior
1. Gas sterilize biochambers and 2-port reservoirs
2. Determine target number of cells and passage schedule, then thaw cells
3. Autoclave grafts, flasks, and forceps
Prep the day before
4. Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
b. SMC Media
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5. Decellularize grafts
a. 0.1% SDS with PBS
b. Place in reservoir chamber
c. Perfuse at 20mL/min for 20 hours with the shake table at 33 rpm
d. Have both ends sutured to respective barb
Set-up day: BVM conditioning
6. Rinse the grafts with sterile Milli-Q 5X 10 min
7. Warm up media (Bioreactor Media and SMC Media)
8. Fill chamber with BR media
9. Insert rinsed grafts into biochambers
10. Using a syringe, flush lumen with SMC Media to prime graft
a. Clamp lumen and continue to prime graft
b. Repeat for all vessels
11. Prime 2-port reservoirs with SMC Media
12. Attach primed biochamber to 2-port reservoir and condition graft for 10 min
a. Flow through lumen first to remove air, then clamp lumen and condition transmurally on
150rpm setting
13. Leave primed biochambers in large incubator until ready for sodding step
Set-up day: BVM sodding
14. Take corresponding number of primed biochambers and reservoirs to hood
15. Leave reservoir inlet unattached and biochamber outlet facing trough
16. Record BVM numbers (or chamber ID):
17. Harvest cells
a. Apply Trypsin, deactivate with media
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b. Record confluency of flasks and number/size of flasks used for each vessel:
18. Pellet cell suspension (on 4 for 4 min)
19. Resuspend in 12 mL Bioreactor Media
20. Sod each graft with 4 mL cell solution
a. Cells per graft = 6 million
b. Sodding density = 1.5million cells/cm2 (average)
21. Chase with 1-3mL SMC Media
22. Attach biochamber outlet to reservoir inlet
23. Bring BVMs to large incubator
24. Place on pump - leave lumen clamped!!
25. Immediately begin transmural flow at 7rpm, and maintain for 1 hour
a. Started on pump at: ______ (time)
26. Unclamp lumen and maintain 7rpm luminal flow for 1 hour
27. Increase flow to 11rpm for 1 hour
28. Increase flow to 15rpm; leave overnight
The next day and beyond
29. Increase flow by 10-15rpm every 30 min until reaching 90rpm
30. BVM maintenance: replace media reservoirs every 3rd day
a. Check CO2!
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B.15 Long-Term Testing of Decellularized Vessels with hUVECs:
Purpose:
To look at the potential hUVECs have for creating an endothelial lining on decellularized
porcine arteries. Pressure Sodding hUVECs should suffice for a monolayer of endothelial cells
to create a physiologic model of a native blood vessel. Also cell tracker will be used to identify
the hUVECs with in the vessel. Using the cell tracker in the case provides a proof of concept
that the cell tracker is a simple dye that can be used for dual Sodding on vessels, to monitor any
cell types placed in the scaffold.
Materials:


Blood Vessel Model setup



Human Umbilical Vein Smooth Muscle Cells (hUVECs)



HUVEC media



Syringes



Porcine scaffold



Vessel A: Length = 3.89 cm, Inner Diameter = 0.59 cm



Vessel B: Length = 4.3 cm, Inner Diameter = 0.48 cm

Protocol:
Prep 1 week prior
1. Gas sterilize biochambers and 2-port reservoirs
2. Determine target number of cells and passage schedule, then thaw cells
3. Autoclave grafts, flasks, and forceps
Prep the day before
4. Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
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b. HUVEC Media
5. Decellularize grafts
a. 0.1% SDS with PBS
b. Place in reservoir chamber
c. Perfuse at 20mL/min for 20 hours with the shake table at 33 rpmHave both ends sutured
to respective barb
Set up Day: Applying Cell Tracker
6. Make Stock Solution: Add 1.8μm of DMSO to the 50μg of cell tracker,
7. Add 9.5μl of Stock solution and 19mL of serum free media
8. Vortex the working solution
9. Remove media on the cells
10. Rinse with DCF-PBS
11. Add working cell tracker solution to the flask of 3T3’s
12. Incubate for 30 min
13. Remove working solution
14. Rinse with DCF-PBS
15. Fill with normal cell media
16. Incubate for 30 min
Set up Day: Static Culture
17. Rinse the grafts with sterile Milli-Q 5X 10 min
18. Warm up media (HUVEC Media)
19. Place stop-cocks on both ends of the vessel
20. Put 10 mL of HUVEC media in a trough
21. Using a syringe, flush lumen with HUVEC Media to prime graft
159

a. Clamp lumen and continue to prime graft
b. Repeat for all vessels
22. Leave vessels in the trough for sodding
Set-up day: BVM Culture
23. Rinse the grafts with sterile Milli-Q 5X 10 min
24. Warm up media (Bioreactor Media and HUVEC Media)
25. Fill chamber with BR media
26. Insert rinsed grafts into biochambers
27. Using a syringe, flush lumen with HUVEC Media to prime graft
a. Clamp lumen and continue to prime graft
b. Repeat for all vessels
28. Prime 2-port reservoirs with HUVEC Media
29. Attach primed biochamber to 2-port reservoir and condition graft for 10 min
a. Flow through lumen first to remove air, then clamp lumen and condition transmurally on
150rpm setting
30. Leave primed biochambers in large incubator until ready for sodding step
Set-up day: BVM sodding
31. Pellet cell suspension (on 4 for 4 min)
32. Resuspend in 8 mL HUVEC Media
33. Sod each graft with 4 mL cell solution
c. Cells per graft = 6 million cells
d. Sodding density = 0.91 million cells/cm2 (average)
Static set up:
34. Rotate the vessel 45° ever 15 min for 1 hour
160

35. Take down vessel after 1 hour and evaluate
BVM set up:
36. Chase with 1-3mL HUVEC Media Attach biochamber outlet to reservoir inlet
37. Bring BVMs to large incubator
38. Place on pump - leave lumen clamped!!
39. Immediately begin transmural flow at 7rpm, and maintain for 1 hour
a. Started on pump
b. Rotating 45° every 15 min for an hour
40. Unclamp lumen and maintain 7rpm luminal flow for 1 hour
41. Increase flow to 11rpm; leave overnight
The next day and beyond
31. Take down the vessel after 3 days
BVM Analysis
34. To view the cells, the cell tracker can be highlighted via setting on the fluorescence
microscope
a. Green: Turret-4, S1, FW1–3, FW2-2
b. Red: Turret-4, S1, FW1–4, FW2-3

161

B.16 Cell Tracker Staining:
Purpose:
To stain cells Multiple colors for dual sodding
Materials:


5-20 μL pipette and sterile head (usually in the hood in 209)



3 ml Syringe with Needle tip



DMSO 100mL bottle from the corner cupboard (Sigma-Aldrich ) catalog number 276855
(anhydrous)



Cell tracker Red CMPX (Invitrogen; Carlsbad, CA) catalog number C34522



Cell Tracker Green CMFDA (5- Chloromethyl Fluorescin Diacetate; Invitrogen; Carlsbad,
CA) catalog number C 7025



Sterile Serum-free Media (for whatever cell type you are using)



1 – 25 ml pipettes (the regular ones we use)

Procedure:
7) Warm media in the water bath
8) Use a needle tip and syringe to pull out 1 mL of DMSO and placed in a 15mL conical
9) Use micropipette to pull out 10.8μL of DMSO from the 15mL conical
10) Add the DMSO to the vial of Cell Tracker – attempt to get most of the powder cell tracker
dye in with the DMSO. This is a 10mM concentration of stock solution, via the following
equations:
moles
g
.05 g
mole  
 1.08 x10 4 moles
L
w 464.86
4
1.08 x10 moles
0.01M 
L  1.08 x10 2 L  10.8mL
L
M 
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11) Dilute to the desired concentration for the cell tracker dye to create the working solution
Use the equation c1v1  c2 v2 (where c1 = 10mM – from the stock solution, v1 = is unknown,
c2 = the desired concentration – in this case 5μM, and v2 = the final volume needed)
10mM ( x)  5M (19mL)

a. 10000 M ( x)  5M (19mL)
x  .0095mL  9.5L of Stock solution
12) Votex the working solution for use
a. Solution can be stored in the fridge for up to one week
13) Remove the media from the cell culture
14) Add your working solution of the Cell Tracker Dye to the cell culture
a. Cell Tracker Green should be incubated on the cells for 30 min
b. Cell Tracker Red should be incubated on the cells for 15 min
15) Remove the Cell Tracker Dye working solution from the cell culture
16) Add cell media back onto the cell culture
17) Incubate for at least 30 minutes
18) Cells are now dyed (‘dyed cells’) and able to be used as you wish – i.e. pressure sodding
described below
a. The dyed cells can be used for about 1 week (different concentrations will produce
different intensities, as characterized by the graph below) as the dyed cells proliferate
either through passages or sodding.
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B.17 Analyzing Cell Tracker Images:
Purpose:
To easily, consistently, and quickly count cells that had been successfully stained with
fluorescent dyes.
Materials:


Images of the cells



ImageJ analysis program

Procedure:
Counting the cells
Images were opened and analyzed in the ‘Image J’ program. The image was made binary
by going to Image, Color, split channels. This created three images in grey scale of red, green,
and blue.

The grey scale of the green image was selected. Next Image, Adjust, and Threshold were
selected to change the image to black and white where black represents the most intense parts of
the image (be sure to press dark background to make the cells highlighted in black).
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To tabulate the average area of each cell and the number of cells in the image Analyze, Analyze
Particles was selected.
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A screen emerges asking for specificity of the Size, Circularity. For green images the size
should be “20-Infinity” and circularity should be “0.00-1.00”. The results will pop up in a new
window.

The previously mentioned parameters are sufficient for analyzing images that were taken with
Cell Tracker Red as well. For red images the size should be “300-Infinity” and circularity
should be “0.50-1.00”. This will produce similar results as the green images.
To determine the amount of cells per mm2 a Ronchi ruling was used to calibrate the view
(by pixels) of the microscope. An image of the calibration slide was taken at the desired
magnification where vertical lines were the focal point of the image.
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By counting how many lines (through the use of cell counter processing tool in Image J) span the
width of the image, a ratio can be found to determine the total surface area of the image. To use
cell counter: initialize and press type one, then click each line seen across the width of the image
(it will be marked and counted).

To calculate the size of one edge of an image is as follows:

Number of Lines Spanning the Image
 the length of that side
Number of Pixels in the x direction

Example 1: 135 lines on the width of the image.
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Equation. 1

135
 .9mm
1392

The ratio calculation can be seen as follows, where x is the length the other side:
Length of side 1
x

Pixels on side 1 Pixels on side 2

Equation. 2

Example 2: Known side is .9mm on 1392, the other side has 1040 pixels.
.9mm
x

 x  .67 mm
1392 pixels 1040 pixels

Once each side of the image has a calculated length, the sides can be multiplied together to find
the surface area of the image (.9mm x .67mm = .603mm).

Combination of the Green and Red Images
Using Image J the individual combination images can be overlaid to produce an image
which best represents the cells present on the vessel. Open both green and red images in Image
J. Then combine by selecting Image, Color, Merge channels. A screen with pop up to select the
image that represents the color channels (i.e. the title of the red image should be displayed on the
red option and the green title should be under green). Finally, ensure create a composite image is
checked at the bottom and push ok. This will produce a new composite image titled RGB 50%.
Intensities may be adjusted to produce the most vivid picture via selecting Image, Adjust, Color
Balance. Then save this image as a new composite for later use and evaluation.
Calculating the Intensity of the Image
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Images were opened and analyzed in the ‘Image J’ program. The images were made
binary, by selecting Image, Color, split channels. This created three images in grey scale of red,
green, and blue select and the color of the image can be selected. Then click on the circular
button:

This tool was used to circle a single cell on the image and then Analyze, Histogram was selected.
The histogram will have a mean number, which is the mean intensity of the area circled. This
process was repeated for five cells in the image and the numbers were averaged to get the
relative intensity of all the cells.
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Appendix C - Extra Data
C.1 Higher Magnification Decellularization Pictures

Figure C.1. Higher magnification of decellularization. Native (A), 0% SDS (B), 0.075% SDS
(C), 0.01% SDS (D), and 0.0125% SDS (E). Most degradation in (E) with the most amount of
SDS.
170

C.2 Sample Tensile Testing Data:
The original parameters are recorded then the stress and strain curve and linear elastic modulus
graphs are shown directly below.
1. Por5-a (decellularized)
a. Lo= 13.42mm
b. W= 11.43mm
c. T =0.79mm
d. Do=4.11mm
Stress-Strain Curve
3.5
3

Stress

2.5
2
1.5
1
0.5
0
-0.5 0

0.2

0.4

0.6

0.8

1

1.2

Strain

Stress

Linear Stress
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0

y = 4.957x - 1.3706
R2 = 0.9603

0

0.1

0.2

0.3
Strain

171

0.4

0.5

0.6

Youngs: 4.957 Mpa
Critical: 3.147311 Mpa
2. Por5-b (control)
e. Lo= 8.94mm
f. W= 8.14mm
g. T =0.81mm
h. Do=4.14mm
Stress-Strain Curve
2.5

Stress

2
1.5
1
0.5
0
0

0.2

0.4

0.6

0.8

1

1.2

Strain

Linear Stress
1.2
y = 4.5817x - 2.7618
R2 = 0.9755

1

Stress

0.8
0.6
0.4
0.2
0
0.66

0.68

0.7

0.72

0.74
Strain

Youngs: 4.5817 Mpa
Crictical: 2.05595
3. Por5-c (decellularized)
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0.76

0.78

0.8

0.82

0.84

i. Lo=11.564mm
j. W= 11.43mm
k. T =0.88mm
l. Do=5.2mm
Stress-Strain Curve
2.5

Stress

2
1.5
1
0.5
0
0

0.2

0.4

0.6

0.8

1

1.2

Strain

Linear Stress
1.2
y = 4.2417x - 1.4641
R2 = 0.9971

1

Stress

0.8
0.6
0.4
0.2
0
0

0.1

0.2

0.3

0.4

0.5

Strain

Youngs: 4.2417Mpa
Critical: 1.937376Mpa
4. Por5-d.1(control) ** Not sure if it worked on this one, was tested twice
m. Lo=10.17mm
n. W= 9.1mm
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0.6

0.7

o. T =0.71mm
p. Do=4.0mm
Stress-Strain Curve
1.2
1

Stress

0.8
0.6
0.4
0.2
0
-0.2

0

0.2

0.4

0.6

0.8

1

1.2

1.4

1.6

Strain

Linear Stress
0.6
y = 1.3407x - 0.7469
R2 = 0.9756

0.5

Stress

0.4
0.3
0.2
0.1
0
0

0.1

0.2

0.3

0.4

0.5
Strain

Youngs: 1.3407Mpa
Critical: 1.031347Mpa
5. Por5-d.2 (control) **This was tested as well
q. Lo=11.67mm
r. W= 9.1mm
s. T =0.71mm
t. Do=4.0mm
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0.6

0.7

0.8

0.9

1

Stress-Strain Curve
3.5
3

Stress

2.5
2
1.5
1
0.5
0
0

0.2

0.4

0.6

0.8

1

1.2

1.4

Strain

Linear Stress
1.6

y = 8.0713x - 5.9794
R2 = 0.9936

1.4

Stress

1.2
1
0.8
0.6
0.4
0.2
0
0.8

0.82

0.84

0.86

0.88
Strain

Youngs: 8.0713 MPa
Critical: 2.961121 MPa
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0.9

0.92

0.94

C.3 Summary Table of Raw Tensile Testing Data:
Table C.1. Summary of Young’s Modulus and Critical Yield for Tensile Tests
Size

Treatment

Critical Yeild (Mpa)

Youngs (Mpa)

Small

Native

2.22

3.4

Small

Native

2.22

3.41

Small

Native

3.855

8.5395

Small

Native

4.5199

8.9296

Medium

Native

2.05595

4.5817

Medium

Native

1.27

8.0713

Small

decell

3.02

7.868

Small

decell

1.27

2.352

Small

decell

2.36

5.4421

Small

decell

1.23

5.1969

Small

decell

0.9814

3.262

Medium

decell

1.937376

4.957
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C.4 Images and Average Cell Counts for 3T3 Sodding:
Pictures of BBI were all taken at 4x, the later the letter in the alphabet, the further distal the
picture was take. Also note, that top and bottom were not specifically noted at the time of
removal of the vessel.

Figure C.2. Bottom A: These two pictures had the most cells, but you can clearly see that there
are ridges displaying more cells
Bottom A

A
B
C
D
E
F
G
H
I
J
K

1
5
5
3
9
6
14
10
9
13
3
15

2
13
9
4
14
5
14
9
18
13
4
19

3
17
10
1
32
9
10
5
12
8
3
11

4
13
9
3
15
9
17
11
12
12
3
13
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5
17
10
3
20
8
13
8
12
16
4
11

Avg Per
square
13
8.6
2.8
18
7.4
13.6
8.6
12.6
12.4
3.4
13.8

Avg Per
mm^2
1300
860
280
1800
740
1360
860
1260
1240
340
1380

Average

1038.18182

Figure C.3. Top A: These pictures were the ones with the most visable cells, the ridges are
again visible with the highlighted cells.
Top A

A
B
C
D
E
F
G

1
4
15
10
15
10
14
9

2
7
18
13
17
10
15
4

3
10
15
12
12
10
9
10

4
6
19
12
10
10
20
13

5
8
7
10
10
6
12
5

Avg Per
square
7
14.8
11.4
12.8
9.2
14
8.2

Avg Per
mm^2
700
1480
1140
1280
920
1400
820

Average

1105.71429

Figure C.4. Bottom B: Much more of a visible cell lining, random cell orientation
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Bottom
B

A
B
C
D
E
F
G
H
I
J
K
J

1
25
19
18
7
14
14
14
18
12
24
12
12

2
16
9
16
11
14
16
15
17
18
17
12
9

3
26
23
12
10
12
17
21
15
16
27
13
10

4
8
16
20
11
20
17
16
10
13
20
12
7

5
19
24
14
12
12
18
13
6
11
13
12
9

Avg Per
square
18.8
18.2
16
10.2
14.4
16.4
15.8
13.2
14
20.2
12.2
9.4

Avg Per
mm^2
1880
1820
1600
1020
1440
1640
1580
1320
1400
2020
1220
940

Average

1490

Figure C.5. Top B: Again lots of cells more randomly dispersed
Top B

A
B
C
D
E
F
G
H
I
J
K

1
25
14
14
18
13
20
18
16
3
19
17

2
21
16
12
25
16
20
16
13
9
25
13

3
20
18
16
23
9
17
11
18
8
22
22

4
24
25
15
19
13
24
17
17
6
20
18
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5
21
12
11
18
10
29
15
17
5
17
21

Avg Per
square
22.2
17
13.6
20.6
12.2
22
15.4
16.2
6.2
20.6
18.2

Avg Per
mm^2
2220
1700
1360
2060
1220
2200
1540
1620
620
2060
1820

Average

1674.54545

Appendix D – CIRM Translational Project
Development of a Decellularized Aorta Coating to Improve ePTFE Polymer-Cell Interface
Aubrey Smith, Chris Miracle, and Dr. Kristen Cardinal
D1.1 Introduction
The current BVM system can utilize both polymer (ePTFE or PLGA) and biologic
scaffolds, however none of which present the ideal model. The polymer scaffolds do not mimic
the natural compliances and lack native biological components to encourage cell adhesion.
Biologic scaffolds, such as the decellularized construct described here, cannot be consistently
reproduced and limits the capacity for a high throughput system. The ideal scaffold would
contain the best of each scaffold; one that is consistent in size and strength, has the capacity to
mimic native compliances, and has biologic components. Several of these improvements are
possible by using the decellularized material as a complex tissue specific biological coating on a
polymer scaffold. This combination utilizes the polymer scaffold as a high throughput model
and when coated with the extracellular matrix (ECM) from a decellularized artery, the unique
biological components to aid in cell adhesion.
As a California Institute of Regenerative Medicine (CIRM) intern, the opportunity arose
to be immersed in cutting edge stem cell research. Dr. Christman’s lab at the University of
California, San Diego is focused on designing scaffolds for cardiac tissue engineering. The lab
has a particular interest in decellularized tissues as a naturally derived matrix for cell cultivation.
These decellularized tissues contain the appropriate chemical and biological components to
mimic the native environment and incorporate a diverse range of proteins. Dr. Christman’s lab
has shown preliminary results for the matrix’s ability to naturally differentiate stem cells using a
decellularized tissue matrix as an extracellular matrix coating for cell culture substrates. The
ultimate goal of the research during the internship was to enhance stem cell differentiation into
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cardiac lineages using decellularized tissue matrices. Dr. Chrisman et al. have done several
experiments and published on numerous uses for the decellularize materials. It is from the work
done in this internship that the coating method can be used as a translation project with the BVM
system.
Most recently, DeQuach et al. were able to see cell maturation of committed skeletal
myoblast progenitors when cultured on muscle-specific ECM (1). The decellularized composed
of a complex mixture of peptides from a variety of collagens and proteoglycans such as decorin,
dermatopontin, heparan sulfate, and lumican. In addition, a Blyscan assay for glycosaminoglycan
(GAG) content measured 16.8 ± 0.1 μg of GAG/mg of ECM. Proteoglycans and GAGs are
known to play an important role in binding growth factors in-vivo. Preliminary data
demonstrates that the decellularized skeletal muscle can be processed into an soulable, and
retains a complex mixture of ECM components (1). In-vitro, skeletal muscle matrix has shown
to enhance differentiation of C2C12 skeletal myoblasts compared to the standard collagen
coating (Figure D.1). Skeletal myoblasts were also shown to preferentially migrate towards the
skeletal matrix compared to controls of collagen alone, fetal bovine serum (FBS, a known
chemo-attractant), and pepsin using a trans-well migration assay. Migration towards the matrix
was also tissue specific, with myoblasts migrating towards skeletal versus the similarly
processed cardiac and brain matrix. This in-vitro data demonstrates that this soluable form of
skeletal matrix can both attract and enhance differentiation of skeletal muscle progenitors (2).
This complex composition varies between tissue types thus, providing a unique advantage over
other more simple coatings.
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Figure D.1. The improvement of Skeletal Myoblasts on Decellularized Skeletal Matrix. A
shows myoblasts on collagen and B are myoblasts on Skeletal Muscle Matrix, labeled by myosin
heavy chain (red) and Hoechst (blue). C. is the percent differentiation, D is the change in width
of the myotube, and E is the number of nuclei per myotube (2).
The work done by DeQuach et al., provided the motivation of this proof-of-principle
experiment, to evaluate coating the decellularized ECM from pig aortas on polymer scaffold to
improve the polymer-cell interface. To assess the effectiveness and potential benefits of applying
a porcine ECM coating onto the scaffold, sodding efficiency and cell viability assays were
performed. The efficiency assay determined the number of cells incorporated into the scaffold as
a percentage of the total initial cell-sodding count. The viability assay used a live and dead stain
analysis to calculate the percentage of live cells remaining on the scaffold after three days.
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D.2 Methods
D.2.1 Decellularization Coating
Aorta ECM was isolated by decellularizing porcine aorta. The vascular tissue was
decellularized (see Figure D.2) using a techniques modified from the originally published
methods from Singeliyn et al. for myocardial matrix (3). Briefly, the freshly excised tissue was
chopped into 2 mm pieces; then the tissue was washed in millipore water. The tissue was then
agitated in 1% sodium dodecyl sulfate (SDS) and 1% penstrep in phosphate buffered saline
(PBS) solution at 100 mg per 1000 mL for 20 hours (Figure D.2). Finally, decellularized
vascular tissue was rinsed in millipore water to remove the SDS for 10 minutes 5 times. The
decellularized ECM was desiccated (Figure D.2) and then milled to create a powder, followed by
enzymatic digestion using pepsin, creating a solubilized vascular matrix (Figure D.2). Pepsin
(SIGMA, St. Louis, MO) was dissolved in 0.01 M hydrochloric acid (HCl) to make a
concentration of 1 mg/mL. Approximately 10 mg of the ECM was digested in 1 mL of pepsin
solution under constant stirring. After approximately 56 hours, the matrix was diluted using
0.1 M acetic acid to make a 1–2.5 mg/ml concentration of decellularized aorta coating. This
solution was used to the coat ePTFE scaffold for 1 h at 37°C, followed by rinsing with PBS (2).
Each scaffold was denucleated and sterilized with EtOH prior to ECM coating. Each scaffold was placed
in 70% EtOH for 15 min and then in 100% EtOH for 15.
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Figure D.2. The procedure for creating the decellularized coating matrix. 1) Harvest the muscle
and removed the excess connective tissue. 2) Rinse with deionized water to remove blood and
debris. 3) Decellularize with SDS solution for 20 hours. 4) Remove detergent by rinishing with
deionized water. 5) Lyophilize the decellularized tissue. 6) Mill the decellularized tissue to
create a white powder. 7) Aliqout the ECM powder was stored at -80 °C for later use. 8) The
ECM power digested in pepsin for 48 hours (with agiation at 60 rpm). 9) Dilute the ECM/pepsin
solution in 1.0 M acetic acid to 1 mg/ml. 10) Coat the culture surface for culture for 1 hour at
37°C. 11) The surface is now ready for culture.
D.2.2 Sodding Scaffolds
A total of two BVM systems were set up with the following conditions: (1) an ePTFE
scaffold that was conditioned with media, and (2) an ePTFE scaffold with the decellularized
aorta coating. The denucleated scaffold (BVM setup 1) was placed in a 15ml conical with
Conditioning Media (M199 and 10% Fetal Bovine Serum) in the incubator at 37 °C overnight.
BVM setup 2 was coated with the decellularized coating for 1 hour at 37 °C and was then rinsed
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several times with PBS. After each scaffold was prepared, they were inserted into the BVM
system. The bioreactor was filled with Bioreactor Media, approximately 200-300 mL. A
syringe was used to flush the lumen with Conditioning Media to prime the scaffold. The 2-port
media reservoir was also primed with Conditioning Media. The assembled BVM system was
attached to a peristalitic pump and primed with transmural flow at 150 rpm.
One week prior to set up, 10 million hUVECs were cultured for each scaffold, about one
T225 flask at 80% confluency. Cells were trypsinized to detach from the culture plate and the
cell suspension was spun down. The supernatant was aspirated from the cell pellet. The cells
were resupsended in 4 mL of Bioreactor Media and were pressure sodding into the lumen of the
scaffold. This was done by clamping the distal end of the scaffold and using a syringe, the cells
were slow injected with transmural flow into the lumen. After the cells were sodded, 4 mL of
Bioreactor Media was injected in a similar fashion to ensure the scaffold was pressure sodded.
The BVM system was then connected with the peristaltic pump at 7 rpm with the distal
end of the scaffold clamped for transmural flow. After one hour of transmural flow, flow was
redirected for luminal flow at a low flow rate. One hour post luminal flow, the media reservoir
was replaced with a new conical containing HUVEC media. The bioreactor media in the original
reservoir was saved for analysis in the sodding efficiency assay. The rpm of the pump was then
slowly ramped up to 90 rpm in increments of 10-15 rpm every hour and was left running at 90
rpm until day 3.
D.2.3 Analysis
A sodding efficiency assay was developed to investigate the capacity for a coated
scaffold increase cell adhesion during the pressure-sodding process. The sodding efficiency
analysis was done using a Trypan Blue stain and a hemocytometer. Trypan Blue is a common
staining agent used to calculate the number of live and dead cells in suspension. The cell counts
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were taken from various solutions at three points during the experimentation: (a) the cell solution
prior to sodding {Ci}, (b) the reservoir media after being switched one hour post luminal flow
{Cr}, and (c) all of the media within the system at the point of take down {Ct}. The efficiency
assay takes a 150 μl sample of the cell suspension and transfers it to a microcentrifuge tube
containing 50 μl of Trypan Blue. 10 μl of this Trypan Blue-cell solution was pipetted onto a
hemoytometer. Cell counts were taken from at least 5 squares, the following equation is used to
calculate the approximate number of cells in the solution:


Total Cells Counted
  Dilution Factor  10 4  Cell Suspension Volume
Total Cell Count  
 Number of Squares Counted 

 

To determine the sodding efficiency, the following equation is used:
Sodding Efficiency 

Ci  Ct  Cr 
 100
Ci

Once the culture was complete, the scaffolds were carefully removed from the BVM
system. Using a blade, each end of the scaffold was cut from the barbs. Extra care was taken to
ensure the scaffold was not compressed and the cell monolayer was altered. Once excised from
the BVM, the scaffolds were cut into 4 sections (Figure D.3). Sections A and C were analyzed
with bisbenzimide nuclear stain to identify cell consistency and distribution on the lumen of the scaffold.
Then the sections were embedded for H&E analysis of the cellular monolayer as a cross section. Sections
B and D were assessed using a live and dead staining on the scaffold wall as a viability assay. The assay
was performed on Sections B and D to evaluate the viability of the cell population remaining on the
scaffold post culturing.
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Figure D.3. Scaffold sections. A and C were imbedded for H&E analysis. B and D were assessed using
a live/dead stain.

Staining Methods
The BBI stain, is a nuclear die that attaches within the chromosomes of the cell. This is a
very quick stain that is used here to simply identify the presence of cells. Sections A and C of
the scaffold were fixed in 10% formalin for at least 24 hours. The scaffolds were dipped in a
1:1000 concentration of the BBI dye, diluted in Millipore water. The scaffolds were left in the
solution for 15 minutes, in the dark. After staining, the scaffold was place in covered Millipore
water until imaged. After sections A and C were imaged with the BBI stain, they were processed
and embedded in paraffin wax. The blocks were then cut into 6 μm sections and stained with H
and E to identify the cellular lining on the scaffold.
The viability assay was developed by using a live and dead stain as a means of identifying
the cell population remaining on the scaffold post culturing. The scaffold portions were fixed in
histochoice for at least 30 minutes. Then the scaffolds were gently dunked into a PBS solution to
rinse prior to staining. A 2μM solution of Calcein AM and a 1μM solution of EthD-1 was
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prepared for the live and dead stain. The sections were incubated in the solution for 30 minutes
in dark conditions. Once again the scaffolds were placed into PBS for imaging. The BBI and
live and dead stains were preformed as whole mount stains on the lumen of sections from the
scaffold. Scaffolds were imaged using an Olympus BX41 microscope at 100 times
magnification.
Statistical Analysis
Statistical analysis was performed using 2-sample T-tests. The difference between the
original cell counts were determined by comparing the number of cells/ cm2 from the coated and
uncoated scaffold. Difference in sodding efficiency was determined for the coated and control
groups by comparing the final sodding density (cells/cm2) based off of the results from the
efficiency assay. Any difference in cell viability between the coated and control group was
determined by comparing the percentage of live cells on the BVM calculated in the cell viability
assay.
D.3 Results
The efficiency of the pressure sodding HUVEC into the lumen of a ePTFE scaffold was
determined using the Trypan Blue stain and a hemocytometer. The cells were counted: (a) prior to being
pressure sodded, (b) post luminal flow, (c) at the time of take down. The efficiency was calculated as
previously mentioned. The percentage of cells remaining adhered to the scaffold post sodding and
culturing was significantly increased on the coated scaffold (p-value = 0.002). The non-coated scaffold
had a 35% efficiency, where as the coated scaffold had a 78% percent efficiency (Figure D.4)
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Figure D.4 Pressure sodding effiencey of HUVECs on ePTFE. The coated scaffold had a
significantly greater ability to retain cells on the lumen of the scaffold (p-value = 0.002).
Sections A and C from each treatment was embedded in paraffin wax for further analysis. The
sacffolds were sectioned and stained with H&E (Figure D.5). A pink lining was visualized on both
scaffold, indicated cell matrix or the decellularied ECM coating remained on the lumen of the scaffod.
However, there are very few identifiable purple nucli on the lumen of the scaffold. Although, as seen by
the efficency assay and confirmed with BBI staining, cells must be maintained within the scaffold. From
qualitative analysis, the lining of the scaffold does not appear altered between the two treatments. To
further verify the ability of the coated scaffold to increase cell adhesion, BBI stains were analyzed. The
BBI stain identifies the cells and their relative location on the surface of the lumen (Figure D.6 and D.7).
The primary function was to evaluate the cell consistancy and disribution throughout the length of the
scaffold. Figure D.6 and D.7 displays a consistent monolayer throughtout the length of both coated and
non-coated ePTFE scaffolds. Additionally, these images were used to count cell density on the scaffold,
as a means to quantiatively compare the treatments. There was a significant increase in the number of
cells remaining on the lumen of a coated scaffold compared to the non-coated (control) scaffold (p-value

= 9.54 E-5). Figure D.8 illustrates the difference in cells/cm2 between each treatment.
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Figure D.5. H and E images of the cellularized ePTFE scaffold. Left is the control (A) and
Right is the coated scaffold (B).

Figure D.6. BBI images of the non-coated scaffold; proximal (A) and distal (B)

Figure D.7. BBI images of the coated scaffold; proximal (A) and distal (B)
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Figure D.8. BBI cell counting. Significant increase in cell numbers on the coated ePTFE
scaffold (p-value = 9.54 E-5).
The live and dead stain was the last analysis preformed on the scaffolds. Calcein AM
and EthD-1 were used to identify the live and dead cells. Live cells were identified with Calcein
AM and a green fluorophores, while EthD-1 identified dead cells with a red fluorphores. Figure
D.9 are sample images from the whole mount live dead stains. With qualitative analysis, the
uncoated scaffold has an increased number of red cells on the lumen of the scaffold, indicating a
higher instance of cell death, compared to the coated scaffold. Additionally, these live and dead
cells in these images were used to quantitatively identify the differences in cell numbers visually
seen. Figure D.10 quantitatively compares the amount of live and dead cells between each the
coated and non-coated ePTFE scaffolds. On both sections B and D of the scaffold, there was a
significant increase in the number of live cells on the lumen of the scaffold (p-value section B =
0.041 and section D = 0.045).
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Figure D.9. Live and dead stains on the ePTFE scaffolds. Calcein AM indicatd a live cell with a
green fluorophor, EthD-1 identified dead cells with a red fluorphor; uncoated scaffold (A) and
coated scaffold (B)

*

*

Figure D.10. Viability comparison of live HUVECs on ePTFE. P-value for section B = 0.041
and section D = 0.045.
D.4 Discussion
The BVM has been developed to bridge the gap between in-vitro and in-vivo preclinical
testing of intravascular devices. To mimic a native artery, a polymer scaffold has been utilized
and to recreate an endothelium, a monolayer of cells coats the lumen of the scaffold. The
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polymers used in the BVM are ePTFE and PGLA; both are biocompatible and have a consistent
structure. However, the scaffolds are composed of polymers and lack any biological
components; which impedes with cellular adhesion properties. To improve the polymer-cell
interface, protein coatings have been introduced to the polymer-cell interface. As seen from this
work, a decellularized coating can be used to provide a complex combination of tissue specific
proteins to the polymer. The addition of the decellularized coating was found to improve the
sodding efficiency of the pressure sodding process, increase the number of cells on the lumen of
the scaffold, and improve the viability of the cells which remained on the ePTFE. Indicating, the
addition of the decellularized aorta coating stands to improve the polymer-cell interface of the
BVM model
The sodding efficiency was assessed using Typan Blue and counting the number of cells
at specific time point throughout the culture. The decellularized coating allowed more cells to be
retained during the pressure sodding procedure as well as throughout the culture. There was a
two fold increase in the percentage of cell remaining on the scaffold after 3 days of culture. The
non-coated scaffold had approximately 38% of its original cells on the lumen; while the
decellularized aorta coated scaffold retained approximately 75% of the cells. This trend was
confirmed using the standard counting method of BBI staining. Rather than evaluating the
percentage of cells lost during culture, the number of cells which remained on the lumen of the
scaffolds was counted. Again a significant increase in the number of cells was seen on the
coated scaffold with approximately 37,000 cells/cm2 verses 26,000 cells/cm2 observed on the
non-coated scaffold. These results indicated the use of a decellularized coating on ePTFE
scaffolds improves cellular adhesion.
Additionally, a viability assay was developed to asses if the decellularized coating altered
the amount of live and dead cells seen on the scaffold. To create the decellularized coating,
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pepsin, HCL, and acetic acid were used. The use of these harsh chemicals may have negatively
affected the polymer-cell interface, by leaving residual chemicals on the scaffold. Any
chemically residue would have a poor interaction with the cells, causing a decrease in cell
viability. In order to prevent this from occur, after the scaffold was coating, it was rinsed several
times in sterile PBS to ensure only the proteins of the decellularized matrix remained adhered to
the scaffold. Live and dead staining was preformed of the cells which remained on the lumen of
the scaffold after three days of culture. The staining revealed there was a significant increase in
the percentage of live cells on the decellularized coating. The non-coated scaffold had
approximately 43% viability, while the decellularized coating improved the viability to about
65%.
The previously discussed results are very promising however there are some limitations
to the work. This was a very short proof-of-principle work that should be expanded to
investigate the repeatability of the procedure and results. Additionally, this procedure should be
modified to incorporate the use of PLGA scaffolds. This experimentation intended to use PLGA
scaffolds in addition to the ePTFE scaffolds; however the PLGA did not interact with the
decellularized coating well. As mentioned, the decellularized coating was created with the use of
several harsh chemicals and the interaction with the PLGA cause the immediate dissolving of the
scaffold. Thus, the PLGA scaffold was not included in this experimentation. However, the
solution can be neutralized to attempt this coating experiment once more and to further
investigate the utility of the decellularized coating.
These experiments have demonstrated the use of a decellularized aorta coating has the
ability to improve cellular adhesion and viability on an ePTFE scaffold. The tissue specific,
complex combination of proteins, proteoglycans, and glycosaminoglycans found in the
decellularized aorta coating has improved the polymer surface to encourage cellular adhesion.
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The increased number of cells found on the lumen improves the development of a consistent
monolayer of cells on the lumen of the scaffold, thus mimicking the native endothelium.
Additionally, by enhancing the polymers ability to maintain more viable cells the ability to have
a functional endothelium will be improved. In conclusion, the use of a decellularized coating has
the potential to vastly improve the polymer-cell interface of the scaffolds used in the BVM
system.
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